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resumo 
 
 
A aquisição e manutenção da mobilidade do espermatozoide é fundamental 
para a fertilização do oócito e consequentemente conceção. Durante décadas, 
as vias de sinalização necessárias à aquisição de mobilidade por parte do 
espermatozoide foram alvo de intensos estudos. Contudo, este processo ainda 
não é inteiramente conhecido. Ademais, as limitadas opções disponíveis para 
contraceção masculina (preservativo, vasectomia e coito interrompido) refletem 
a necessidade de desenvolver um contracetivo masculino baseado na 
modulação da mobilidade do espermatozoide. A via de sinalização 
GSK3/PPP1R2/PPP1 está envolvida na aquisição de mobilidade do 
espermatozoide ao longo do transito do epidídimo. O objetivo principal deste 
trabalho é enriquecer o conhecimento dos eventos celulares necessários na 
mobilidade do espermatozoide através da caracterização e modulação da via 
de sinalização GSK3/PPP1R2/PPP1 em espermatozoides humanos. 
Desenhámos, sintetizámos e caracterizámos um bioportide que quebra 
interações proteicas baseado em tecnologia de cell penetrating peptides. 
Estudos in vitro revelaram que o bioportide de ruptura interfere com a interação 
PPP1R2/PPP1CC2 e é capaz de restabelecer a atividade da PPP1CC2. 
Também demonstramos que o bioportide reduz significativamente a mobilidade 
do espermatozoide. Com o objetivo de identificar interacções proteína-proteína 
adequadas à intervenção farmacológica, focámos a nossa atenção na proteína 
GSK3, um modulador da interação PPP1R2/PPP1CC2 em espermatozoides. 
Descrevemos pela primeira vez o interactoma da GSK3 no testículo e 
espermatozoide humanos e reportamos um papel específico da isoforma 
GSK3 na mobilidade do espermatozoide. Uma análise in silico revelou 
interatores da GSK3 e GSK3 que estão envolvidos na mobilidade do 
espermatozoide e potencialmente poderão ser alvos de intervenção 
farmacológica para um novo contraceptivo masculino. Em conclusão, 
demonstramos que é possível provocar a quebra de interações proteína-
proteína e modular a mobilidade do espermatozoide usando de bioportides. 
Também identificamos potenciais novas interações proteicas envolvidas na 
mobilidade do espermatozoide. Finalmente, mostramos que é possível 
idealizar um novo tipo de contracepção masculina baseado na inibição da 
mobilidade do espermatozoide.  
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abstract 
 
Sperm motility acquisition and maintenance is a fundamental process for 
oocyte fertilization and consequently conception. The signaling events 
underling sperm motility acquisition have been studied for decades. However, 
many questions are still unanswered. Also, the limited options currently 
available for male contraception (condom, vasectomy and withdrawal) reflect 
the necessity of a new group of male contraceptives based on sperm motility 
modulation. GSK3/PPP1R2/PPP1 signaling pathway is involved in sperm 
motility acquisition during epididymis transit. The main goal for this work was to 
deepen the knowledge on the signaling events involved in human sperm 
motility by focusing on the characterization and modulation of the signaling 
pathway GSK3/PPP1R2/PPP1. We first designed, synthetized and 
characterized a disruptive bioportide based on cell penetrating peptide 
technology. In vitro studies revealed that the disruptive bioportide interferes 
with PPP1R2/PPP1CC2 interaction and restores PPP1CC2 activity. We also 
demonstrated that when exposed to the disruptive bioportide, sperm motility is 
significantly reduced. Aiming to identify sperm protein-protein interactions 
suitable for pharmacological intervention, we turn our attention to GSK3, a 
modulator of PPP1R2/PPP1CC2 interactions in sperm. We provide for the first 
time GSK3 human testis and sperm interactomes. We reported an isoforms 
specific role for GSK3 in human sperm motility and an in silico analysis 
revealed GSK3 and GSK3 interactions involved in sperm motility and 
potential targets for pharmacological intervention. In conclusion, we 
demonstrated that it is possible to target protein-protein interactions and 
modulate sperm complexes involved in motility using bioportides. Moreover, we 
identified new potential protein interactions involved in sperm motility and 
showed that the development of new type of male contraceptive based on 
inhibiting sperm motility is now achievable.  
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A. Introduction and Aims 
 

A1. Male Reproductive System 
A1. Male reproductive System  
The male reproductive system has the purpose of producing, maturate and deliver the male 
gametes to the female reproductive tract. Anatomically, the male reproductive system is composed 
of two testes, a system of genital ducts (tubuli recti; efferent ducts; epididymis, deferent ducts; 
ejaculatory ducts and urethra), accessory glands (seminal vesicle, prostate and bulbourethral 
glands) and the penis. Functionally, spermatozoa or sperm must be produced (spermatogenesis) in 
the testis, matured in the epididymis and delivered to the female reproductive system by the penis. 
Moreover, the production of sexual hormones, specifically testosterone, occurs in the testis. In the 
next section, the morphological and functional characteristics of the Homo sapiens male 
reproductive system will be briefly described [1]. In Figure A1.1 an overview of the male 
reproductive system is presented.  
 
A1.1. Testis – Where everything begins 
Human testes are ovoid shape organs, localized outside the abdominal cavity and accommodated 
within the scrotum. This localization maintains the testes at an average temperature of 32ºC, 
optimal for its function. Within each lobule, there are 1 to 3 seminiferous tubules, the functional 
unit of the testis, and Leydig cells, which are responsible for the production of testosterone [2,3]. 
Seminal vesicle
Ductus deferens
Epididymis
Testis
Bladder
Ureter
Penis
Bulbourethral glands
Prostate
Seminiferous 
tubule
Sertoli cell
Germ cells
Blood vessel
Leydig cell
Sertoli cell nucleus
A B
Figure A1.1. Overview of the male reproductive system. A. Components of the male reproductive system. The 
bladder and the ureter are not part of the male reproductive system. B. Schematic cross-section of a testicular tubule, 
showing germ cells inserted in Sertoli cells. In the interstitium there are Leydig cells and blood vessels. Figures were 
produced using Servier Medical Art. 
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The seminiferous tubules are composed of germ cells line and Sertoli cells. Figure A1.1, describes 
the morphological structure of the seminiferous tubule. Germ cells will originate mature sperm 
through spermatogenesis. In Homo sapiens more than 200 million sperm are produced every day. 
Spermatogenesis can be divided in two distinct phases: (i) proliferative and meiotic phase; and (ii) 
haploid phase. The proliferative phase ensures the continuum of sperm production through a 
constant renewal of spermatogonia (the least mature germ cells). Consequently, spermatogonia 
can either undergo mitosis and duplicate itself or enter meiosis. By mitosis, spermatogonia yields 
primary spermatocytes and the latter, divides meiotically into two secondary spermatocytes. 
Finally, secondary spermatocytes divide into spermatids. Meiosis will reduce the chromosomal 
information into half. The haploid phase is characterized by the acquisition of crucial morphological 
structures necessary for fertilizing potential. It is divided in two sub-phases: spermiogenesis and 
spermiation. Spermiogenesis is defined as the process of transforming a round haploid spermatid 
into a highly specialized spermatozoon. At the organelle level, the Golgi complex will originate the 
acrosome [4]; the spermatid cytosol is merged into sperm head skeleton and, sperm axoneme is 
formed by outer dense fibers and fibrous sheath [5–9]. To accomplish such metamorphosis, 
transcription, translational and prost-translational modification increase drastically. Yet, by the end 
of spermiogenesis, transcription is ceased due to replacement of histones for protamines in sperm 
DNA, which results in highly packed DNA [10]. From this point on, sperm must rely on existing 
proteins to control its function. Spermiation refers to the detachment of fully differentiated sperm 
from the seminiferous epithelium and the journey through the lumen of the seminiferous tubules 
[11]. Also, during spermiation, the remnants of germ cells cytoplasm are rejected.  
Sertoli cells provide structural support and nourishment of germ cells; perform phagocytosis of 
degenerating germ cells; allow spermiation of fully mature sperm, control germ cell proliferation 
and differentiation by paracrine secretion of regulatory proteins and create a unique 
microenvironment for the germ cell line (blood-testis barrier) [12–14]. Morphologically, Sertoli cells 
are pyrimid-like cells that involve partially the germ cell line. Around 18% of the seminiferous tubule 
is composed of Sertoli cells and the number of Sertoli cells positively correlates with sperm output. 
Adjacent Sertoli cells form tights junctions, creating a unique environment, isolating germ cells from 
the rest of the body. This is particularly important to isolate germ cells form the immune system 
[13]. 
The last type of cells present in testis are the Leydig cells. These cells lay between seminiferous 
tubules and contact directly with blood vessels. Beginning in puberty, Leydig cells increase the 
production of testosterone, in response to luteinizing hormone [15]. This stimulates the beginning 
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of spermatogenesis, through Sertoli cell signaling. Through the entire adulthood, spermatogenesis 
is controlled by constant feedback with the nervous system (hypothalamus and pituitary) [16].  
 
A1.2. Epididymis – where everything starts to function 
By the end of spermatogenesis, sperm is morphological complete but functionally immature. To be 
able to fertilize an oocyte, sperm must journey through the epididymis [17]. Epididymis is a highly-
convoluted duct that connects the efferent ducts to the deferent ducts. It is localized in the 
posterior surface of the testis and in primates can have a length range from 1-7 meters [18]. 
Estimates of the time necessary for sperm to migrate through human epididymis are inconsistent. 
Rowley et al suggested a range of 1 to 21 days and Amann and Howards between 3-4 days [19,20]. 
The epididymis has five main roles: (i) transport of testicular sperm out of the testis; (ii) create a 
suitable environment for sperm maturation; (iii) promote progressive spermatozoa motility; (iv) 
prepare sperm for fertilization; (v) and sperm storage. Sperm goes through morphological and 
functional maturation in the epididymis.  
Since testicular sperm are transcriptionally silent cells, the maturation of sperm through the 
epididymis depends on post-translational modification of pre-existing proteins and protein 
exchanges between the epididymal lumen and the sperm. Phosphorylation, glycosylation and 
proteolysis of sperm proteins are among the most common post-translational modification. Most 
proteins that suffer this process are linked to interaction between sperm and oocyte (zona pellucida 
and oocyte membrane) and acrosome reaction [21–23]. The role of phosphorylation on sperm 
maturation, particularly motility acquisition, is discussed further on section A2. 
Epididymosomes, small extracellular vesicles secreted by the epididymis´s epithelial cells are the 
major players in the interchange of proteins between sperm and epididymal lumen. It was 
suggested by Cornwall that epididymosomes allow the safe delivery of proteins to sperm, escaping 
the proteolytic activity in the epididymal fluid [17]. Within the proteins delivered by 
epididymosomes, proteins involved in sperm motility, immunological protection and inhibition of 
capacitation are the more abundant [23].  
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A1.3. The spermatozoa – the final result 
Sperm can be divided in two main structures: head and flagellum. These structures are surrounded 
by a unique plasma membrane. In the next section, we will focus on the morphological features of 
sperm head, connecting piece and plasma membrane composition (Figure A1.2). An extensive 
description of sperm flagellum can be consulted in section A2. 
 
 
 
 
 
 
 
 
 
 
 
The human sperm head is spatula-shaped and its main components are the nucleus and the 
acrosome. These two structures are surrounded by a small amount of cytoplasm and cytoskeleton 
structures [24]. The acrosome lies anteriorly to the nucleus, and the cytoplasm lies in the narrow 
space between both structures and the plasma membrane. Within the nucleus, the DNA is highly 
compacted and its volume is considerably less than in somatic cells [24]. These results from: 
protamines highly compacted DNA and sperm only having half the genetic information of somatic 
cells. Still, approximately 4% of DNA is  bound to histones and has been proved that the expression 
of such DNA is essential for early embryo development [25]. Surrounding the nucleus is the nuclear 
envelope. The unique feature of sperm nuclear envelope is that, contrary to somatic cells, it does 
not present nuclear pore complex [26]. Furthermore, the sperm nucleus is protected by a rigid 
structure formed by bonding of structural proteins, the perinuclear theca [5]. These features result 
in an optimal shaped nucleus for mobility and better protection of the genetic information. The 
acrosome covers half to two thirds of the sperm head. This organelle is derived from the Golgi 
Figure A1.2. Schematic representation of the human sperm head and connecting piece. Human sperm head contains 
anteriorly the acrosome and posteriorly the nucleus. The nucleus is surrounded by the nuclear envelope and the 
perinuclear theca. The connecting piece is composed by the capitulum and the segmented columns and connects the 
head to the flagellum. 
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complex and presents an inner acrosomal membrane adjacent to the nucleus and an outer 
acrosomal membrane adjacent to the plasma membrane. The acrosome houses several proteases, 
hidroglycolases and esterases, some which are sperm-specific (e.g acrosin), that upon specific zona 
pellucida signaling are released by exocytosis (acrosome reaction). These proteases will create a 
path for sperm penetration into the zona pellucida [27]. After acrosome reaction, the equatorial 
region of these organelle is exposed and is involved in the initial interaction between sperm and 
oocyte membrane [28].  
Immediately behind the sperm head is the connecting piece. This structure functions as an anchor 
between the head and the tail. Consequently, it must be somewhat flexible. The connecting piece 
is formed by two main structures: the capitulum and the segmented columns. The capitulum inserts 
into the head and distally interacts with the segmented columns. Distally, the segment columns 
fuse with the other dense fibers of the flagellum [29,30]. 
In general, the sperm plasma membrane contains 70% phospholipids, 25% neutral lipids and 5% 
glycolipids [31]. The most abundant phospholipid of the plasma membrane is sphingomyelin. This 
lipid confers rigidity to bilayer membranes. Regarding neutral lipids, human sperm membrane 
contains very high amounts of cholesterol. Cholesterol is a plasma membrane stabilizer with the 
particularity of maintaining membrane fluidity [32]. Consequently, cholesterol is a key lipid for 
sperm permeability and motility. In human sperm plasma membrane, the only glycolipid is 
seminolipid [33], which is present only in mammalian sperm and Schwann cells [34]. It is believed 
that this molecule participates in maintenance of lipid diffusion barriers (see bellow) [33]. After 
epididymis transit, plasma membrane presents high cholesterol/phospholipid ratio. This results in 
plasma membrane stabilization which is beneficial to the journey in the female reproductive 
system.  
Mammalian sperm plasma membrane is divided into five macrodomains: acrosome; postacrosome, 
equatorial segment; midpiece and principal piece. Each domain appears to have a unique 
composition and organization which reflects different properties and functions [35,36]. For 
example, the acrosomal macrodomain is highly fusogenic compared with the post acrosomal 
macrodomain. One hypothesis for this is that the acrosomal macrodomain is rich in phospholipids 
that form “cone shape holes” into the membrane, resulting in an unstable membrane [33]. Another 
question that arises is how these macrodomains are confined to a specific part of the sperm. Lipid 
diffusing barriers have been described in sperm, specifically in the posterior ring and annulus. The 
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posterior ring segregates the content of sperm plasma membrane of the head and tail and the 
annulus between the midpiece and principal piece [36].  
 
A1.4. Accessory glands  
After epididymal transit, sperm are pushed to the deferent ducts, ejaculatory ducts and finally 
urethra, upon stimulation. During this journey, the accessory glands (Figure A1.1) secret several 
fluids that will form the seminal plasma. Please note that the epididymal fluid and sperm cells 
represent around 3-5% of all semen volume [37]. Altogether, sperm and seminal plasma form the 
semen.  
Secretion from the seminal vesicle is responsible for around 50% of the seminal plasma content and 
is alkaline and very rich in fructose. Fructose will be consumed by sperm cells producing energy and 
the alkaline environment will balance the acidic female reproductive tract fluids.  This will result in 
stimulation of sperm motility. Fructose quantification is widely used as a marker for seminal vesicle 
function. However, some question have arisen regarding the fidelity of such marker. Since fructose 
is consumed by sperm, fructose concentration also depends on the rate of fructose consumption 
sperm and not exclusively on seminal vesicle function. Several roles for seminal vesicle secretion 
have been described. Promotion of sperm motility; increase stability of sperm DNA and suppression 
the immune system activity in the female reproductive system are some [38]. 
The next contribution to the seminal plasma are the secretions from the prostate which represent  
around 20-30% [37]. Prostatic fluid is rich in zinc (Zn2+), citric acid and prostate specific antigen 
(PSA). Moreover, it presents a slightly acidic pH [39]. It appears that Zn2+ stabilizes spermatic DNA 
and prevents DNA fragmentation, specifically by stabilizing chromatin [40] It  further presents anti-
microbial activity [39,41]. Citric acid maintains an acidic environment and since it is 100x more 
secreted by the prostate than by other accessory glands, it may be used as a prostate activity 
function biomarker. Finally, the PSA promotes liquefaction of semen and consequently stimulates 
sperm motility [39,42]. Similarly, to the epididymis, the prostate also secretes small vesicles, the 
prosteosomes, which may fuse with the sperm cell. Theses vesicles are rich in proteins and will 
transfer such proteins to sperm, by membrane fusing.  
The last accessory glands are the bulbourethral glands which, upon sexual stimulation, secrete, to 
the urethra, an alkaline mucus-like fluid rich in glycoproteins. This fluid neutralizes the acidity of 
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pre-existing urine residues and provides lubrication for the penis during intercourse [43]. The 
bulbourethral contribution to the seminal plasma is very small (around 1%)[37].  
Finally, the last step to accomplish fertilization is releasing the semen into the female reproductive 
system by ejaculation. Ejaculation is defined by the expulsion of the semen through the penis. Upon 
stimulation, the sympathetic nervous system activates the contraction of muscle in the epididymis, 
seminal vesicle, prostate and deferent ducts. Consequently, the semen is released to the urethra. 
The accumulation of semen in the urethra stimulates the contraction of muscles within the penis 
(bulbospongiosus and ischiocavernosus muscles) resulting in the release of semen [44].  
 
A1.5. Male Fertility: infertility and contraceptives 
Infertility is defined as the incapability of conceive after 12 months of unprotected intercourse [45]. 
In a recent study, Agarwal estimated that 15% couple’s worldwide are infertile, from which 50% 
have a male contribution and 20-30% are exclusively due to male factors [46]. Furthermore, 
idiopathic male infertility predominates as the major cause of infertility (50% of all male infertility 
cases) [47]. The fact that key mechanisms responsible for several sperm processes, such motility, 
are still not fully understood, may be the key to understand idiopathic cases of male infertility. 
Understanding sperm physiology is a step towards unveil and more important diagnose and treat 
idiopathic male infertility.  
On the other hand, male contraceptives have not evolved as much as female contraceptives in the 
last decades. They fall in three main categories: vasectomy, male condom and withdrawal. In 2015, 
all together, male contraceptives represented 21% of contraceptive practice worldwide [48]. 
Vasectomy, is the blockage of the vas deferens and consequently passage of sperm. It is an invasive 
procedure that until recently was irreversible and has a very high effectiveness (97%-98%). Male 
condom is a physical barrier that prevents sperm cells to meet the oocyte. Most men refer 
discomfort using a condom. However, it is the only contraceptive that prevents sexual transmitted 
diseases and has an effectiveness of 85%. Finally, withdrawal, the pulling out of the penis from the 
vagina prior to ejaculation,  is the least effective contraceptive (73%) [49]. 
Considering that the period of male contraceptive usage is increasing (earlier sexual initiation and 
latter fatherhood) and the choices available for men are limited, we believe that a new male 
contraceptive is necessary. Targeting the signaling pathways involved in sperm motility acquisition 
may be the future of male contraceptives. Using this approach, spermatogenesis is not disturbed, 
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ensuring that it is reversible, but keeps sperm from encountering the oocyte. Therefore, 
understanding the mechanism involved in sperm motility acquisition is key. 
A2. Signaling mechanisms in mammalian sperm motility 
A2. Signaling mechanisms in mammalian sperm motilitya 
Human spermatozoon is one of the most differentiated cell types and must leave the male body 
where is produced and achieve its goal in the female reproductive system [50]. In order to fertilize 
an egg, the sperm is formed in the testes, in a process called spermatogenesis. At the end of 
spermatogenesis, sperm are morphologically complete but functionally immature and incapable of 
fertilizing an egg. To be functional, sperm cells must undergo: (i) maturation in the epididymis; (ii) 
capacitation and (iii) acrosome reaction in the female reproductive system [51]. These events are 
co-dependent, since acrosome reaction does not occur if capacitation is impaired and capacitation 
depends on functional maturation of sperm in the epididymis. Motility acquisition is essential for 
human sperm function and ultimately male fertility. In 2011, Paoli defined sperm motility as a 
propagation of transverse waves along the flagellum in a proximal- distal direction producing an 
impulse that pushes the spermatozoon through the female genital tract [52]. 
Severe asthenozoospermia is one of the causes of male infertility which arises from the inability of 
the sperm cell to reach the oocyte [53]. Primary or activated motility is acquired throughout the 
journey in the epididymis. Although the exact mechanism behind motility acquisition is still far from 
being fully understood, specific signaling events are described in the literature as essential for this 
process [51,54]. Low-amplitude symmetrical tail movements characterize sperm activated motility 
and drive sperm in a straight line in a non-viscous media (seminal plasma) [55]. However, in 
fallopian tubes, sperm must acquire a specific type of motility, hyperactivated motility, which is 
characterized by high amplitude and asymmetric flagellar bends. Only this type of flagellar 
movement allows sperm to overcome dense mucus, detach from the oviductal epithelium and 
penetrate the egg’s protective vestments [56]. Curiously, in the viscous media hyperactivated 
sperm swim in a circular or figure-8 pattern [55,57]. Alterations in pH, specific molecules, and ion 
concentration changes are a few of the crucial events for stimulation of hyperactivated motility 
[58,59]. However, the cellular mechanism and signaling pathways responsible for this type of 
motility are not fully described.  
To be motile, human sperm need a morphologically complete flagellum; be able to produce energy 
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to power flagellar movement; and functional signaling pathways (to transduce external signals into 
internal signals). This review will discuss these three topics, but will mainly focus on the signaling 
pathways involved in human sperm motility regulation. For an in-depth review on sperm 
bioenergetics please see du Plessis et al. [60] 
 
A2.1. Sperm flagellum - structure and function 
The human sperm are composed of two main structures: head and flagellum (Figure A2.1). The 
head comprises the nucleus and the acrosome. The nucleus houses the genetic information to be 
delivered to the oocyte. Upon acrosome reaction, the acrosome integrity is disrupted and its 
content is released digesting the oocyte’s zona pelucida [61]. The flagellum contains the motile 
apparatus necessary for sperm motility [55,62] and is divided into four ultrastructures: connecting 
piece; midpiece; principal piece and end piece [55]. The connecting piece attaches the flagellum to 
the sperm head; the midpiece contains the sperm mitochondria; the principal piece and the end 
piece generate the flagellar waveform pattern motility [55,62,63]. The main structure of the 
flagellum is the axoneme, which is the sperm motility motor. This structure is well conserved 
throughout evolution, present in flagella from protozoans to humans [50,62]. The axoneme 
originates in the connecting piece and terminates in the end piece. Typically, the axoneme is 
composed of nine microtubules doublets and a central pair, designated a 9+2 structure. The nine 
microtubules doublets connect to each other by nexin links and connect to the central pair by 
projections, the radial spokes. The latter are responsible for positioning and spacing the 
microtubules doublets in a perfect circle around the central pair microtubule. Projecting from the 
microtubules doublets are the inner and outer axonemal dynein arms (classified according to their 
position in relation to the doublet microtubule). These proteins are key for motility, by promoting 
sliding of a microtubule doublet in relation to the adjacent. The flagellar beating pattern begins 
with a dynein from one doublet transiently interacting with the following doublet. In the presence 
of ATP, axonemal dynein “walks” towards the base of the flagellum, forcing the adjacent 
microtubule doublet to slide down. Since microtubules are attached to the connecting piece, this 
movement encounters resistance, leading to the bending of the flagellum. At the end, the dynein 
detaches from the adjacent microtubule. To obtain a flagellum waveform movement and 
consequently motility, this process has to occur on one side of the axoneme and be inactive on the 
opposite site. Hence, the flagellar beat appears to be based on an “on-and-off” switch of the 
axonemal dynein arms, in specific points in the axoneme [50,55,62,63].  
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Figure A2.1. Schematic representation of human spermatozoon and flagellum structure. Human sperm is divided into 
two parts: head and flagellum. The flagellum is further divided into four structures: connecting piece; midpiece; principal 
piece and endpiece. A cross-section shows that the flagellum structure differs between midpiece and principal piece. In 
midpiece, plasma membrane and mitochondrial sheath surround the outer dense fibers. Within outer dense fibers, is the 
axoneme, composed of the microtubule doublets associated with the dyneins arms (inner and outer), radial spoke and 
microtubule central pair. Nexin connects adjacent microtubule doublet. In the principal piece, plasma membrane and 
fibrous sheath surround the outer dense fibers. In two opposing microtubule doublets, the outer dense fibers are replaced 
by to longitudinal columns of fibrous sheath. 
 
In mammalian sperm, between the axoneme and the plasma membrane there are several accessory 
structures, such as the mitochondrial sheath, outer dense fibers and fibrous sheath [50,55]. In the 
midpiece, the axoneme is surrounded by outer dense fibers and the mitochondrial sheath, while in 
the principal piece the axoneme is surrounded by outer dense fibers and fibrous sheath. The end 
piece has no accessory structures between the axoneme and the plasma membrane [62]. The 
mitochondrial sheath is composed of individual mitochondria coiled helically around the axoneme. 
In humans, the midpiece length is about a dozen mitochondrial turns [64]. The outer dense fibers 
have a petal-like shape, are directly above the axoneme microtubules doublets and diminish in 
diameter from base to tip of the principal piece [65]. The outer dense fibers appear to be 
responsible for maintaining the passive elastic structure and recoil of the flagellum and to protect 
the axoneme against shearing forces [66]. In the principal piece, the fibrous sheath confers 
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flexibility, shape and plane to the flagellar beat [67]. It also supports and ensures 
compartmentalization of signaling proteins that regulate motility, capacitation, and 
hyperactivation. In the principal piece, two opposing outer dense fibers are replaced by fibrous 
sheath projections [65] (Figure A2.1).  
The regulation and propagation of this “on-and-off” signal and the conversion into flagellar bending 
appears to reside in the control of the ATPase activity of axonemal dynein arms. Although this 
process is not fully understood, alterations in pH, ATP availability, calcium concentration and 
phosphorylation of key proteins appears to modulate axonemal dynein arms activity and 
consequently sperm motility. The process of ATP production and the signal pathways that control 
axonemal dynein activity will be discussed in the next topics [68].  
 
A2.2. Energy for motility - Oxidative phosphorylation vs glycolysis 
One of the key requirements for sperm motility is energy availability. ATP is the fuel used by 
axonemal dynein ATPases within the flagellum [69], and active protein modifications, such as 
phosphorylation, also depend on ATP. Thus, it is not surprising that sperm requires exceptionally 
high amounts of ATP when compared to somatic cells [70]. Consequently, a constant and adequate 
supply of ATP is crucial [69]. In spite of the efforts [69,71,72], a long-standing debate exists on the 
metabolic pathway responsible for sperm motility bioenergetics: oxidative phosphorylation in 
mitochondria, glycolysis in the flagellum and head, or both.  
In mammalian sperm, oxidative phosphorylation occurs in mitochondria, which are exclusively 
located in the midpiece. A mature mammalian spermatozoon contains approximately 72-80 
mitochondria [73] and in theory can produce more than 30 ATP molecules per glucose molecule 
[74]. Since midpiece is localized at the anterior end of the flagellum the transport of ATP to the all 
length of the flagellum must be efficient. Ford et al believe that the model of flux transfer chains 
proposed by Dzeja and Terzic in 2003, is able to transport the ATP produced in mitochondria 
through the entire flagellum [72,75].  It was indeed shown that an increase in human sperm motility 
requires a parallel increase in mitochondrial activity [52,71,76]. Also, the use of specific inhibitors 
for the mitochondrial electron transport chain and ATP synthase decreases drastically human 
sperm motility [74]. Moreover, high mitochondrial activity levels increase the success of in vitro 
fertilization rate [69]. These studies suggest that human sperm motility correlates with 
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mitochondrial functional status. Further, mitochondrial activity is negatively correlated with 
morphological alterations in the midpiece, which appears to reinforce the role of mitochondrial ATP 
production in sperm motility [71]. 
In spite of the reports supporting the role of mitochondria in sperm motility, its contribution to 
flagellar beat can be questioned. Since mitochondria are localized in the midpiece, it has been 
argued if ATP diffusion and carrier systems are able to supply ATP throughout the entire length of 
the flagellum (about 50µm in humans) [72,74]. Also, some authors argued that if ATP produced in 
the mitochondria fuels motility, the levels of reactive oxygen species produced during the electron 
transport chain would be harmful to DNA integrity [77]. However, both enzymatic (e.g. superoxide 
dismutase and glutathione peroxidases) and non-enzymatic antioxidants (e.g. glutathione and 
ascorbic acid) present in human sperm and seminal plasma appear to control the levels of ROS 
activity [77–79]. 
A growing hypothesis for the source of ATP (or at least part of the ATP) in sperm is the glycolytic 
pathway. Glycolysis is the process by which glucose is converted into pyruvate. During this process, 
energy is released in the form of ATP and NADH, with a rate of 2 ATP molecules per glucose. When 
human sperm are deprived of glucose (the starting unit of glycolysis) or when glycolysis is blocked, 
ATP content and protein tyrosine phosphorylation decreases. Consequently, sperm exhibits 
decreased motility [74,80–83]. Mukai and Okuno proved that even when mitochondria function is 
conserved, mouse sperm motility decreases when glycolysis is impaired. Moreover, a sperm-
specific lactate dehydrogenase (LDHC) accounts for 80-100% of the LDHC activity in human sperm 
and is anchored to the fibrous sheath along the length of the flagellum, representing a local ATP 
production closer to the site of ATP consumption [83]. Also, Odet et al showed that a disruption in 
mouse sperm-specific Ldhc resulted in impaired fertility due to immotile sperm [84]. Furthermore, 
sperm-specific LDHC presents a low Km for pyruvate and a high Km for lactate, suggesting a higher 
affinity of LDHC for pyruvate and consequently a preference for the glycolytic energy pathway. It is 
noteworthy to mention that although most mammals rely, at least partially, on glycolysis for 
motility, the bull seems to be an exception. Oxidative phosphorylation in bull sperm appears to be 
the only source of ATP [85].  
A third possibility for ATP availability in human sperm is a cooperation and dependence between 
oxidative phosphorylation in mitochondria and glycolysis in the flagellum. This hypothesis is 
supported by the different energetic subtracts of the reproductive tract fluids [60,70]. It appears 
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that mammalian sperm switch between metabolic pathways depending on oxygen availability and 
glucose, pyruvate, lactate, sorbitol, glycerol, and fructose concentration in the fluid [74,81,86–89].  
For example, in the human female reproductive tract, glucose, pyruvate and lactate are found in 
the range of 0.5-3.2mM, 0.1-0.2-mM and 4.9-10.5mM, respectively. Sperm must adapt its 
bioenergetic metabolism according to the metabolites available from the epididymis until the 
fallopian tubes [90]. 
 
A2.3. Signaling pathways in sperm motility 
Sperm leaving the testes are immotile and acquire motility throughout the epididymis journey. 
Sperm is virtually devoid of transcription and translation due to highly condensed DNA and lack of 
endoplasmatic reticulum [91]. Since gene expression cannot be accounted for functional alterations 
in sperm, activation or inhibition of specific signaling pathways and protein post-translational 
modifications must be involved. The interaction between sperm and the environment created by 
the epididymis and the female reproductive tract are essential to trigger sperm motility.  
Several signaling pathways have been described as having a role in mammalian sperm motility. In 
the next section, the most relevant signaling pathways and messengers involved in sperm motility 
acquisition in the epididymis and hyperactivated motility in the female reproductive tract will be 
described. 
A2.3.1. Sperm motility in the male reproductive system – A journey through the epididymis  
After spermatogenesis, sperm is morphologically complete but functionally immature. When 
entering the epididymis, a long convoluted tubule that connects the testis to the vas deferens, 
human sperm is incapable of fertilizing an oocyte. The epididymis is roughly divided into three 
regions: caput, corpus, and cauda. The caput is adjacent to the testis and the caudal portion 
adjacent to the vas deferens [12]. Only during the journey through the epididymis the sperm 
acquire fertilization ability. Epididymal maturation involves the interaction of sperm with proteins 
that are synthesized and secreted into the epididymis in a region-dependent manner [17]. Most of 
studies concerning epididymis function are carried out in rodent models, due to the limited 
availability of human epididymal tissues at reproductive ages, the impossibility of mimicking the 
epididymis environment in vitro and the difficulty to manipulate the human epididymis 
experimentally. The exact mechanism behind sperm motility acquisition in the epididymis is still 
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unknown [55].  
One of the first described signaling events responsible for sperm motility acquisition within the 
epididymis is the control of Phosphoprotein Phosphatase 1 (PPP1, also known as PP1) activity in 
sperm (Figure A2.2). PPP1CC2 (also known as PP12), a testis-enriched sperm-specific PPP1 isoform 
is distributed throughout the flagellum, midpiece and posterior region of the head [92] suggesting 
a role in motility and acrosome reaction [93,94]. In 1996 Smith et al described, for the first time, 
the association between PPP1 activity and sperm motility. In caput sperm PPP1 activity is high and 
sperm is immotile. Conversely, in caudal sperm PPP1 is inactive and sperm are motile [95,96]. In 
the following years, several studies attempted to unveil the signaling pathways responsible for PPP1 
activity modulation in sperm, through the epididymis journey. PPP1 regulatory subunit 2, PPP1R2 
(also known as Inhibitor-2) is a PPP1 inhibitor [97]. In sperm, PPP1R2 localizes throughout the 
principal piece, midpiece and posterior and equatorial regions of the head. Former studies 
described PPP1R2 activity in human sperm and that some of the sperm PPP1 population is bound 
to PPP1R2 and therefore inactive [98]. When phosphorylated at threonine 73, human PPP1R2 is 
unable to bind to PPP1, rendering its activity [99]. Glycogen synthase kinase 3 (GSK3) is the kinase 
responsible for PPP1R2 phosphorylation. Interestingly, GSK3 activity has been extensible correlated 
with sperm motility regulation both in cauda and caput (bovine, mouse and macaque models) [100–
102]. GSK3 is 6 times more active in caput than in caudal sperm and its activity is correlated 
negatively with sperm motility [100,102]. Moreover, GSK3 appears to have an isoform-specific 
function on sperm motility. When GSK3alpha is knockout there is a decrease in sperm motility and 
metabolism, while GSK3beta conditional knockout is fertile [103].  
Recently, Koch et al showed that the Wnt signaling can be partially responsible for GSK3 activity 
regulation in epididymal sperm. In corpus and caudal epididymis, Wnt signaling proteins are 
released in epididymosomes from epididymal principal cells. In the epididymis lumen Wnt proteins 
bind to Low-density lipoprotein receptor-related protein 6 receptor (LRP6), activating it. In turn, 
LRP6 induces GSK3 inhibition, which leads to decreased PPP1R2 phosphorylation [104]. 
Synergistically, GSK3 activity can be modulated by Phosphoprotein phosphatase 2A (PPP2 also 
known as PP2A). Dudiki et al demonstrated that in caput sperm demethylated and phosphorylated 
PPP2 isoform alpha (PPP2CA) is active. Consequently, it dephosphorylates GSK3 in serine residues 
rendering active. Subsequently, PPP1R2 threonine 73 is phosphorylated and the inhibitor becomes 
inactive, resulting in active PPP1 and immotile sperm. On, caput sperm, methylation of PPP2CA 
increases due to a decrease in Protein phosphatase methylesterase 1 (PPME1) activity. In these 
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conditions, PPP2CA becomes inactive resulting in increased GSK3 serine phosphorylation and thus, 
its inactivation. Subsequently, PPP1R2 is active and inhibits PPP1, leading to motile sperm [105] 
(Figure A2.2).   
 
Figure A2.2. Schematic representation of the signaling events required for sperm motility acquisition in the epididymis. 
In caput epididymis, PPP2CA is phosphorylated and consequently active, which in turn dephosphorylates GSK3 at serine 
residues, rendering it active. GSK3 phosphorylates PPP1R2 at thr73 which inhibits the interaction between PPP1R2 and 
PPP1 resulting in active PPP1. PPP1R7 is bound to p17, which leads to free and active PPP1. Active PPP1 results in 
dephosphorylation of key residues and consequently immotile sperm. In cauda epididymis, PPME1 activity decreases 
increasing PPP2CA methylation, resulting in inhibition of PPP2CA. Consequently, GSK3 serine phosphorylation increases 
leading to GSK3 inhibition. Also, Wnt binds to LRP6 receptor which promotes GSK3 inhibition by an unknown mechanism. 
Moreover, ATP binds to purinergic receptors (PR), resulting in calcium influx. Calcium activates sAC, which produces cAMP 
activating Rap guanine nucleotide exchange factor (RAPGEFs). The latter activates AKT that phosphorylates GSK3 at serine 
residues inactivating it[106]. GSK3 is inhibited, which leads to decrease Thr73 PPP1R2 phosphorylation (the phosphatase 
responsible is unknown). Consequently, PPP1R2 binds PPP1. Also, PPP1 is bound to PPPP1R2P3 and in a complex with 
PPP1R7, actin and PPP1R11. Thus, PPP1 activity is inhibited and ser/thr phosphorylation of key residues increases leading 
to motile sperm. P: Phosphorylation; M: Methylation. Green arrows: activation. Red arrows: inhibition. Yellow arrows: 
phosphorylation. In yellow: phosphorylated proteins. In pink: methylated proteins.  
 
Moreover, in 2013, Korrodi-Gregório et al identified a new PPP1R2 isoform in human sperm,  
PPP1R2P3 (also known as inhibitor 2-like) [98]. This isoform has the unique feature of threonine 73 
being replaced by proline avoiding GSK3 phosphorylation. Korrodi-Gregório et al hypothesized that 
PPP1R2P3 is only present in caudal motile sperm, representing a constitutively inhibitor of PPP1, 
and therefore responsible for the process of sperm motility acquisition along the epididymis 
journey [98] (Figure A2.2). 
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Besides PPP1R2, PPP1 regulatory subunit 7 (PPP1R7) and PPP1 regulatory subunit 11 (PPP1R11), 
other two PPP1 inhibitors are present in sperm, suggesting a synergetic mechanism for PPP1 activity 
control [107]. PPP1R11 (also known as I3) is a human homolog of the mouse Tctex5, a protein 
associated with male infertility due to impaired sperm motility. On mouse sperm, PPP1R11 is 
localized in the head and principal piece of the flagellum, the same subcellular localization of PPP1 
[108]. In rat liver cells, PPP1R7 (also known as sds22) inhibits PPP1, and in rat testis, it associates 
with PPP1CC2. In caput, bovine sperm PPP1R7 and PPP1CC2 do not interact. Instead, PPP1R7 is 
associated with a 17kDa protein (p17) [109], resulting in active PPP1. Conversely, in mouse caudal 
sperm, PPP1R7, PPP1R11, actin and PPP1 form a complex catalytically inactive [107] (Figure A2.2). 
Although PPP1 plays a crucial role in keeping motility at check in caput sperm, its substrates are still 
unknown. Besides PPP1, a sperm-specific isoform of calcineurin (PPP3CC) appears to be involved in 
epididymal maturation. Upon ablation of PPP3 and regulatory subunit PPP3R2, male mice are 
infertile due to impaired hyperactivation and penetration of zona pelucida. Phenotypically, sperm 
without PPP3CC presents an inflexible midpiece. When sperm is hyperactivated, the bending 
capacity of the midpiece increases, however, PPP3CC null sperm are incapable of exhibiting this 
increase.  Interestingly, inhibition of PPP3CC with specific inhibitors, results in a quick phenotype (5 
days) alteration from normal to inflexible midpieces. After one week of halting drug administration, 
the sperm are completely recovered and fertility is restored [110]. 
Since for sperm motility dephosphorylation must be shut down, it is not surprising that 
phosphorylation must increase. It is well known that the soluble adenylyl cyclase/Cyclic adenosine 
monophosphate/cAMP-dependent protein kinase (sAC/cAMP/PRKA; cAC/cAMP/PKA) signaling 
pathway affects positively sperm motility. Although the sAC/cAMP/PRKA signaling is mostly 
associated with hyperactivated motility [58], its involvement in sperm motility acquisition is 
unquestionable (see below) [111,112].  In 2013, Vadnais et al, proposed a cross talk between the 
GSK3/PPP1R2/PPP1 and sAC/cAMP/PRKA pathways during motility acquisition in the epididymis 
[106] (Figure A2.2). In Figure A.2. the main signaling pathways involved in motility acquisition in the 
epididymis are represented.  
A2.3.2. Sperm motility in the female reproductive system 
During unprotected intercourse, millions of sperm are deposited in the female reproductive tract, 
more specifically in the vagina. From there on sperm must swim until they reach the oocyte in the 
fallopian tube. Although sperm is already motile when ejaculated, hyperactivated motility must be 
acquired to overcome all the filters and traps imposed by the female reproductive tract. 
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Interestingly, it is the unique female enviroment that triggers the signaling pathways essential for 
sperm hyperactivated motility [113]. In the past years, many efforts have been made to unravel the 
role of key messengers and signaling pathways involved in hyperactivated motility.  
Firsts messengers -  Calcium, bicarbonate, and progesterone 
In sperm, calcium (Ca2+) plays a central role in events preceding fertilization, specifically, motility, 
chemotaxis and acrosome reaction. The relevance of Ca2+ on eukaryotic cell physiology is reflected 
in the several Ca2+-depended enzymes, intracellular Ca2+ stores and Ca2+ channels [114] . Human 
sperm is no exception. The most described role of Ca2+ in human sperm motility is the activation of 
the soluble adenylyl cyclase (sAC). Moreover, inhibition of Ca2+ signaling is associated with male 
subfertility [115] 
In human sperm, mean basal Ca2+ is kept around 100nM-200nM, while in the extracellular medium 
varies between 1-2mM [116]. This gradient concentration is accomplished by a Ca2+-ATPase pump, 
which promotes Ca2+ efflux with ATP consumption [117,118]. A low resting Ca2+ concentration is 
what keeps human sperm in a basal motility state in the caudal portion of the epididymis and vas 
deferens. However, in the female reproductive tract, Ca2+ concentration must increase to induce 
hyperactivated motility. The female reproductive system controls the increase in Ca2+ concentration 
in the sperm through clues in specific places, and menstrual cycle phase [119]. 
 The influx of Ca2+ into human sperm is promoted by several mechanisms: increase in membrane 
permeability [120]; depolarization [121]; inhibition of the Ca2+-ATPase pump; activation of voltage-
dependent calcium channel (VOCCs). Yet the main known mechanism for Ca2+ influx into sperm is 
the CatSper (cation channel of sperm), identified in 2001 by Ren et al [122]. This channel, located 
at the principal piece of the flagellum, is the only constitutively active Ca2+ conductance present in 
human sperm, responds weakly to voltage alterations and is pH-sensitive [122,123]. Moreover, null 
mice for CatSper1 are infertile [122]. Human CatSper activation is triggered mainly by extracellular 
progesterone (see below), prostaglandins [124] and an alkaline environment (created by increasing 
HCO3- concentrations) [125]. Curiously, mouse CatSper is activated by neither progesterone nor 
prostaglandins. This suggests a species-specific Ca2+ influx process, possibly to avoid cross-species 
fertilization [124]. Although it is not located to the sperm’s head, CatSper appears also to be 
involved in the acrosome reaction by increasing Ca2+ concentration [126]. Further, Brenker et al 
concluded that a range of small odorant molecules present in the female reproductive tract 
activates CatSper, resulting in chemotaxis of the sperm towards the oocyte [127].  
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Although the process of Ca2+ influx is essential for sperm motility, it is established that the human 
sperm has Ca2+ stores. The most promising candidates for Ca2+ stores in human sperm are the 
acrosome, the nuclear membrane and the cytoplasmic droplet [128]. Interestingly, it appears that 
in the sperm flagellum there are no Ca2+ stores, suggesting that the stores are important on 
processes such as acrosome reaction, rather than in motility. Moreover, the presence in human 
sperm of sarcoplasmic/endoplasmic reticulum calcium ATPases (SERCAs), channels that transport 
Ca2+ from the intracellular medium to Ca2+ stores in somatic cells, further reinforces the presence 
and functional importance of Ca2+ stores [128,129].  
Progesterone is probably the most potent activator of capacitation of human sperm [130]. It is 
produced by the cumulus oophorus cells that surround the oocyte. At nanomolar concentration 
range, progesterone induces Ca2+ influx and promotes extensive phosphorylation through the 
activation of several kinases, such as PRKA [131], Protein kinase C (PRKC), Mitogen-activated 
protein kinases (MAPKs) and Phosphatidylinositol 4,5-bisphosphate 3-kinase (PIK3C, PI3K) 
[132,133]. Phenotypically, progesterone increases the number of motile sperm, induces 
hyperactivated motility and acrosome reaction, and appears to be involved in sperm chemotaxis 
towards the oocyte [133–138]. 
In somatic cells, progesterone acts through classic nuclear progesterone receptor and regulates 
gene expression. Conversely, sperm is transcriptionally silent and the effect of progesterone on 
sperm physiology is far too quick to be explained by gene expression [139]. In 2011, Strünker et al 
and Lishko and et al concluded that progesterone activates the CatSper channel [124,125]. As sperm 
leave the epididymis and mixes with the prostatic seminal vesicle fluid, the bicarbonate (HCO3-) 
content increases [140]. Reaching the female reproductive system, sperm encounters an acidic 
environment, which should reduce motility.  Yet, the basic pH of the seminal plasma neutralizes the 
acidic pH and allows sperm motility [141] and the semen is deposited closely to the uterus cervix 
so that sperm can quickly move out of the vagina [56,142]. Within the uterus, the rich HCO3– alkaline 
environment is essential for sperm hyperactivated motility [143]. Curiously, throughout the 
menstrual cycle, HCO3– concentrations vary from 35nM at the follicular phase to at least 90nM at 
ovulation, potentiating fecundation [142]. Sperm-specific Na+/ HCO3- co-transporters mediate the 
influx of HCO3- and, as a result, there is an increase on sperm pH and depolarization [144]. Though, 
to achieve complete depolarization, there must be a Na+ and K+ influx, Na+ is transported by the 
Na+/ HCO3- co-transporters and K+ influx is mediated by Calcium-activated potassium channels and 
the ion transporter Na,K-ATPase. Calcium-activated potassium channels are regulated by 
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intracellular alkalinization and cAMP, which hints a HCO3- indirect regulation of K+ [141]. Within the 
sperm, HCO3- activates factors that exchange phospholipids within the bilayer plasma membrane. 
Consequently, cholesterol is vulnerable to albumin, which is the most abundant protein on the 
female reproductive system, and the main cholesterol acceptor. Albumin can decrease up to 40% 
of the sperm cholesterol content and this leads to an increase on membrane fluidity [145,146]. 
Depolarization, intracellular alkalinization and increased membrane fluidity promote influx of Ca2+.  
The Na,K-ATPase pump is a membrane protein found in all eukaryotes [147]. By using the energy 
released from ATP hydrolysis the Na, K-ATPase pump promotes the efflux of three molecules of Na+ 
and influx of two molecules of K+ [148]. Two subunits compose the Na,K-ATPase protein, the alpha 
and beta subunits. In several species, including human, the alpha4 sbunit presents the most 
restricted expression. It is present in sperm principal piece only in mature sperm of males in sexual 
maturity. Besides the Na,K-ATPase alpha4 subunit, only subunit alpha1 is present in sperm [147]. 
Knockout studies revealed that the Na,K-ATPase alpha4 subunit is crucial for sperm physiology, 
since alpha4 subunit KO is completely sterile. Knockout sperm presents reduced primary and 
hyperactivated motility, bent flagellum, increased intracellular Na+ and cell plasma membrane 
depolarization [149]). Mcdermott et al reinforce the role of Na,K-ATPase alpha4 subunit on human 
male fertility by showing that an overexpression of this protein in mouse testis results in an 
increased total motility (among other parameters of sperm movement) [150]. Although the exact 
mechanism underlying the role of Na,K-ATPase in sperm physiology is not fully characterized, Na,K-
ATPase alpha4 isoform appears to  regulate intracellular H+. Since is unlikely that the Na,K-ATPase 
transports H+, its ability to regulate intracellular H+ arises from its effect on the activity of a Na+/H+ 
exchanger (NHE). NHE uses the Na+ gradient established by the Na,K-ATPase to extrude H+ in 
exchange for the influx of Na+ [151] and, consequently there is an increase in the intracellular pH 
[151] (Figure A2.3). In bovine sperm, Jimenez et al demonstrate that Na,K-ATPase activity is up-
regulated during capacitation. Also, when Na,K-ATPase activity is impaired, the intracellular 
decrease in Na+ and plasma membrane depolarization that typically accompany sperm capacitation 
are inhibited [152]. Ouabain, a cardiac glycoside produced in adrenal glands, is a Na,K-ATPase 
inhibitor which may have a physiological role in fertilization.[153–155]. 
Signaling pathways in hyperactivated motility 
It appears that all the processes that occur in the female reproductive system increase the Ca2+ and 
HCO3- concentrations in the sperm. This raises the question: within the sperm, what signaling 
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pathways Ca2+ and HCO3- modulate in order to promote hyperactivated motility? 
The most well-known pathway that controls hyperactivity and is highly dependent on Ca2+ and 
HCO3- concentrations is the sAC/cAMP/PRKA pathway.  The sAC is specific to sperm, does not 
interact with Guanosine-5'-triphosphate and for its activation, it needs to bind to HCO3- and Ca2+ 
[144]. Upon activation, sAC converts adenosine monophosphate into 3´.5´- Cyclic adenosine 
monophosphate (cAMP). The increase of cAMP activates PRKA, a serine/threonine kinase that is 
dependent on cAMP [54,156]. The fact that when sAC or Calpha2 sperm-specific PRKA subunit are 
knockout, sperm does not acquire motility reinforcing the necessity of such signaling pathway in 
sperm motility [157,158]. PRKA appears to target and activate tyrosine kinases since inhibition of 
PRKA is correlated with a decrease in tyrosine phosphorylation [159].  
 
Figure A2.3. Schematic representation of the signaling events required for sperm hyperactivated motility in the female 
reproductive system. Several mechanisms are responsible for intracelullar Ca2+ increase in sperm. Progesterone binding 
to CatSper; activate VOCCs and inhibition of Ca2+-ATPase pump promote Ca2+ influx. In sperm, HCO3-  and Na+ increase 
due to activation of Na+/HCO3- co-transporter. Potassium enters through a calcium-activated potassium channels (CAPC) 
and Na,K-ATPase. The Na+ gradient created by the Na,K-ATPase, activates the Na+/H+ exchanger that promotes the influx 
of Na+ and de efflux of H+. HCO3- activates exchange factors (EF) that promote cholesterol externalization, becoming 
vulnerable to albumin.  HCO3- and Ca2+ activate sAC, which converts AMP to cAMP and activates PRKA. PRKA activates 
tyrosine kinases, by phosphorylation. Also, Ca2+ activates PIK3C, which forms PIP3, that in turn activates PDPK1 and PDPK1 
and PDPK2 activate AKT by phosphorylation. AKT activates tyrosine kinases by phosphorylation. At the same time, DAG 
activates PRKC which phosphorylates RAF-1; RAF-1 activates MAP2K2 and MAP2K2 activates MAPK3/1. Again, MAPK3/1 
activates tyrosine kinases by phosphorylation. MAPK3/1 phosphorylates ARHGAP6 which may be involved in 
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hyperactivated motility. MAPK14/11/12/13 inhibits hyperactivated motility.  Src inhibits PPP1, which allows an increase 
of tyrosine kinases phosphorylation. Tyrosines kinases phosphorylate key proteins inducing hyperactivated motility. P: 
Phosphorylation; Prg: Progesterone. Green arrows: activation. Red arrows: inhibition. Dashed arrow: predicted function. 
In yellow: phosphorylated proteins. 
PRKA activity control and its subcellular localization are crucial for compartmentalization of its 
effect. In sperm, PRKA is typically tethered to A-kinase anchor proteins (AKAPs), which in turn 
targets PRKA to specific subcellular sites and provides a mechanism for defining its substrates [131]. 
Besides anchoring PRKA, it has been showed that AKAPs can also scaffold phosphatases and other 
kinases from macromolecular complexes essential for signaling cascades within the sperm [131]. In 
flagellum sperm, AKAPs have a prominent role and AKAP4 is the main component of the fibrous 
sheath. Moreover, when AKAP4 is knockout sperm numbers are normal but sperm is incapable of 
progressive motility and proteins usually associated with the fibrous sheath, such as PRKA, are 
absent or significantly reduced [117].   
Besides increasing PRKA activity, Battistone et. al proved that serine/threonine phosphatases must 
be inactivated to allow the increase in serine/threonine phosphorylation. Members of the Src family 
kinase (SFK) inactivate members of the serine/threonine phosphatases family possible by tyrosine 
phosphorylation.  In human sperm, PPP1CC2 is the most promising candidate since it exhibits 
predicted tyrosine phosphorylation sites and only high okadaic acid concentrations overcome the 
SKI606 effect (an SFK inhibitor) [160]. Nevertheless, the involvement of other serine/threonine 
phosphatases, such PPP2CA or PPP4C cannot be ruled out [160]. 
Although sAC/cAMP/PRKA plays a central role in hyperactivated motility, it is not the only signaling 
pathway involved in this process. The involvement of the PIK3C-AKT pathway in sperm 
hyperactivated motility was described by Sagare-Patil et al.  Progesterone promotes the influx of 
Ca2+ through the CatSper channel. Within the sperm, Ca2+ activates PIK3C (unknown mechanism) 
converting PIP2 into PIP3. The latter binds and activates 3-phosphoinositide-dependent protein 
kinase 1 (PDPK1), which phosphorylates RAC-alpha serine/threonine-protein kinase (AKT or PKB) in 
threonine 308. Consequently, AKT serine 473 becomes exposed and vulnerable to phosphorylation 
by PDPK2. Both phosphorylations render an active AKT, that phosphorylates serine residues on key 
proteins in sperm motility [133]. 
The Mitogen-activated protein kinase (MAPK) signaling is also involved in human sperm 
hyperactivated motility, although its role is controversial. In 2005, a study in human sperm stated 
that tryptase, a product of mast cells in the female reproductive system, activates MAPK3/1 (also 
known as ERK1/2), which in turn inhibits motility [161]. However, in 2008, Almog et al 
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demonstrated the existence of the MAPK cascade elements, more specifically, MAPK3/1, SOS, RAF-
1, MAP2K1 and MAPK14/11/12/13 (also know as p38 proteins) in the tail of mature ejaculated 
human sperm and revealed a positive correlation between MAPK3/1 and motility. Upon activation 
by diacylglycerol (DAG), Protein kinase C (PRKC, PKC) becomes active and phosphorylates RAF-1, 
which in turn phosphorylates and activates MAP2K1. MAP2K1 activates MAPK3/1 by 
phosphorylation. One of the identified substrates of MAPK3/1 was Rho GTPase-activating protein 
6 (ARHGAP6). This protein may control the active slide of microtubules in sperm flagellum since it 
has already been described as being involved in cell motility and actin remodeling [162]. On the 
other hand, active MAPK14/11/12/13 inhibits sperm motility [163]. Again in 2015, Silva et al also 
showed a negative correlation between MAPK14/11/12/13  activation and human sperm motility 
[164]. In Figure A2.3 the signaling pathways involved in sperm hyperactivated motility in the female 
reproductive system are represented.  
A2.3.3. Correlation between sperm motility and tyrosine phosphorylation 
In 1989, Leyton and Saling described for the first time the presence of tyrosine phosphorylation in 
mammalian sperm (mouse) [165]. Twenty-six years later, the importance of tyrosine 
phosphorylation in capacitation and motility is unquestionable. The increase of proteins tyrosine 
phosphorylated in the human sperm is a hallmark of capacitation and has been positively associated 
with acquired and hyperactivated motility [159,166,167]. Most of the signaling pathways involved 
in human motility, including the ones described previously, culminate in activation of tyrosine 
kinases. The identity of most tyrosine kinases is  unknown, still, the tyrosine kinases Scr [168],  
FGFR1 [169] and ABL1 [170] are already associated with tyrosine phosphorylation in mammalian 
sperm.  
Several studies proved that dozens of proteins undergo tyrosine phosphorylation during 
capacitation in the sperm, mainly proteins localized in the flagellum [102,171–174]. In fact, human 
AKAP4 (see above), was one of the first proteins to be identified as a substrate for tyrosine 
phosphorylation[175]. Fibrous sheath protein of 95 kDa [176]; CABYR [177] and HSP90 [178] are 
other targets of tyrosine kinases [144]. Also, it has been hypothesized that dyneins are tyrosine 
phosphorylated and that this post translation modification controls the sliding of microtubules and 
therefore motility. The challenge for the next years is to identify new tyrosine phosphorylation 
targets and their relationship with sperm motility [159]. 
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A2.4. Concluding remarks 
This review attempts to summarize the current knowledge on the signaling pathways involved in 
sperm motility regulation.  Since the first observation of the sperm by Anton van Leeuwenhoek´s in 
1677, the knowledge concerning the sperm cell grew exponentially. The sperm structure, energy 
metabolism, epididymal maturation, and capacitation are indispensable for fertilization. 
Nevertheless, the road to unraveling the molecular players involved in the regulation of this 
processes is still long. Specifically, the molecular basis of sperm motility is not fully understood. 
Nowadays, we believe that the major setback to fully comprehend the molecular basis of human 
sperm motility is a technical one. Animal models and in vitro experiments are the only options to 
study epididymal maturation and capacitation.  Understanding the mechanism responsible for 
human sperm motility is of great value. Sperm motility is the perfect target for male contraception 
since it does not disturb spermatogenesis and hormone production. Also, decreased sperm motility 
is increasing in developed countries, resulting in an escalation in male infertility rates. 
Understanding the signaling pathways behind sperm motility can help pinpoint the cause of male 
infertility and contribute to the development of new therapies. 
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A3. Interactomics and Bioinformatics: making sense of a big 
mess 
Proteins are the “working force” of cells, having roles that go from structural support, enzymatic 
activity, production of other proteins, extracellular signals reception, etc. Protein-protein 
interactions (PPIs) control all biological processes within a cell and sperm cells are not an exception. 
After spermiogenesis, human sperm cells are virtually transcriptionally silent. This implies that 
sperm cannot rely on production of new proteins to respond to environment changes and 
orchestrate cellular processes. For that reason, two questions arise: what proteins are present in 
the human sperm and what interactions they stablish? Two scientific fields try to answer these 
questions, Proteomics and Interactomics. Proteome is the entire set of proteins being expressed in 
a given cell at a given time. Interactomics is the entire set of interactions occurring in a given cell at 
a given time [179]. Note that interactions can occur between every molecule within a cell, for 
example protein-protein; protein-DNA, Protein-RNA, DNA-RNA, etc. In the next section, we will 
focus on PPIs and those will be referred as the interactome, for simplification.  
How big is the sperm proteome? In 2009, Baker estimated that the human sperm proteome would 
comprise around 2000-2500 proteins [180]. Several attempts have been made to decipher human 
sperm proteome. These studies not only aimed to establish the normospermic human proteome 
[181–185], but also depicted the proteomes of different stages of sperm maturation (e.g. ejaculated 
and capacitated) [186–189]; specific fertility/infertility conditions (asthenozoospermic; normal but 
IVF failure) [190–197]; specific subcellular compartments of spermatozoa (head or flagellum) 
[198,199]; post-translational protein modifications (phosphoproteome, nitrosylations, 
glycosilation) [186,200,201] and associated pathologies (diabetes, obesity, epididymitis) [202–204]. 
As far as our knowledge goes, more than 50 studies unveil a small portion of the human sperm 
proteome. The disparities between normospermic and asthenozoospermic samples have been 
extensively analyzed. This reflects the merging need to understand sperm motility mechanisms. 
Regarding human testis proteome, much has already been revealed. In 2015, the Human Protein 
Atlas project released the human tissues proteome, which included the testis-specific proteome. 
Eighty-two percent of all human transcripts analyzed are expressed in testis and around 11% 
present an elevated/restricted expression in testis. As expected, the elevated/restricted proteins 
are mainly involved in spermatogenesis [205]. Previously, Guo and colleagues and Djureinovic and 
colleagues characterized the human testis proteome [206,207].  
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By contrast, there are few interactomic studies on both testis and sperm, but none aimed to unveil 
the complete interactome of testis and sperm. Still, specific protein interactomes have been 
characterized in human testis. In 2011, Fardilha et al identified the interactome of PPP1CC1 and 
PPP1CC2 in human testis [92]. Among others, the testis interactome of APP, TCTEX1D4 and BRAP2 
have been identified and characterized [208–210]. In human sperm, interactomes appear to be 
restricted to sperm-egg interactions [211]. Still, several PPIs have been identified in both testis and 
human sperm, but not resorting to an “Omic” approach.  
Taking this into account, revealing the interactome of already known proteins involved in sperm 
motility will deepen our knowledge on motility mechanisms and may contribute to the 
identification of potential targets for a new male contraceptive. 
 
A3.1. All or nothing: high-throughput techniques for protein-protein 
interactions identification 
The term “Interactome” was first created by Sanchez in 1999 and intended to describe all binary 
PPIs in an organism [212]. Since the human genome was sequenced in 2001 [213], revealing the 
proteome and interactome of Homo Sapiens has been set as the next goal. However, it has been 
estimated that the human interactome contains a range of 130,000–650,000 binary interactions, 
far too complex to currently map [214,215].  
Interactomes can be identified using two approaches: in silico through prediction algorithms or 
experimentally via high-throughput techniques [216]. In silico techniques will not be discussed 
further. The biggest attraction of high-throughput techniques is that in a single experiment 
hundreds of PPIs can be identified. There are several high-throughput techniques available that 
allow PPIs identification. However, we consider that two stand out: Yeast two-hybrid (YTH) and Co-
immunoprecipitation followed by Mass spectrometry (co-IP/MS). In the next section, both 
techniques will be briefly described as well as their advantages and disadvantages. 
A3.1.1. Yeast two-hybrid 
Yeast two-hybrid was the father of all high-throughput techniques for PPIs identification. In 1989, 
Fields and Song, idealized the YTH system by taking advantage of two properties of eukaryotic 
transcription factors: (i) gene transcription only occurs in the presence of the DNA binding domain 
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(DBD) and the activation domain (AD) of a transcription factor; (ii) the two domains only need to be 
in close proximity and no covalent bond is necessary. In the original YTH, one protein of interest 
(bait) was fused into the DBD of GAL4 transcription factor and another protein to the AD (prey). If 
both proteins interact, the GAL4 transcription factor was resembled and the LacZ reporter gene 
was transcribed. This resulted in yeast colonies turning-blue in the presence of the substrate X-gal 
[217]. Quickly the YTH gained popularity mainly because it offered significant advantages compared 
to biochemical methods of PPIs identification (for example in vivo vs in vitro) [215]. Figure A3.1 is a 
schematic representation of the YTH principle.  
 
 
 
 
 
 
 
 
In its almost 30 years of existence, YTH has evolved, modified and improved. One of the biggest 
modification of this method is the possibility of high-throughput screening. The usage of cDNA 
libraries as preys, allows the identification of complete interactomes of a specific protein in one 
single experiment [218,219]. To further improve the method, several modifications were 
introduced to increase the number of interactions identified; decrease the rate of false positives; 
perform the screen in mammalian cells; identify protein-DNA and protein-RNA interactions and in 
different subcellular compartments [220,221]. 
The contribution of YTH to unveil interactomes is indisputable. In fact, the YTH became one of the 
most popular tools in molecular biology and thousands of PPIs have been identified with this 
method. Several interactomes have been characterized by YTH, ranging from complete organisms 
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Figure A3.1. Schematic representation of YTH principle. The cDNA of a protein of interest (bait) is cloned into a vector 
with the DNA binding domain (DBD) of a transcription factor. A cDNA library or a cDNA of a protein (bait) is cloned 
into a vector with an activating domain (AD) of a transcription factor. Both vectors are transformed into yeast. Within 
the yeast, two hybrid proteins are produced and if bait and prey protein interact the DBD and AD come into close 
proximity in the nucleus and transcription of reporter genes is activated. 
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to disease-specific interactomes [222–224]. The significant contribution of YTH to PPIs databases 
reflects the utmost importance of this technique. Around 50% of the interactions reported in 
PubMed resulted from YTH screenings and from 1990 to 2007 the number of high confidence binary 
interaction described by YTH increased exponentially [223,225]. We believe that even 30 years 
later, the YTH is probably the most commonly used technique for the detection of PPIs [215,226]. 
In 2005, two separated YTH experiments tried to characterize the human interactome. Rual et al 
identified around 2800 interactions (300 new) and Stelzl et al identified 3186 interactions (mostly 
new ones) [227,228]. Although both interactomes were obtained using the YTH, the experimental 
procedures were distinct. This may explain the low percentage overlap between both interactomes 
datasets (16% of common proteins and from those only 15% of the interactions were common) 
[229]. 
A3.1.2. Co-immunoprecipitation and Mass spectrometry 
Co-immunoprecipitation was first coupled with Western blot allowing small-scale PPI identification. 
Yet, coupling co-IP with mass spectrometry (co-IP/MS), transformed this technique in a high-
throughput approach for detection and identification of PPIs [230,231]. As the name suggests, co-
IP isolates PPIs from cells or tissues by using an antibody that specifically recognizes a protein. Since 
it is typically performed in non-denaturing conditions, the antibody will not only “pull-down” its 
antigen but all proteins bond to it [232–234]. The biggest advantages of co-IP are that physiological 
conditions are kept (protein concentration, protein tridimensional structure, post-translational 
modifications, etc) and it is very specific and compatible with several downstream applications. 
Mass spectrometry is capable of identifying thousands of proteins in a single experiment. Thus, it 
seems wise to use mass spectrometry as the technique to identify PPIs after a co-IP in a high 
throughput manner (Figure A3.2 shows a schematic representation of co-IP/MS). Still, co-IP does 
not prove a direct interaction, since, protein complexes are often identified by co-
immunoprecipitation. 
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Mass spectrometry measures the mass-to-charge ration of ions, originated by breaking a complex 
mixture of proteins. The major advantages of mass spectrometry it is sensitivity; quantity of 
information obtained and its ability to identify the peptide sequence of the interactors. Still, the 
high cost, challenging optimization, not only of the mass spectrometry itself, but also for the 
combination of this technique with for example co-immunoprecipitation, and the complex analysis 
of the results can be discouraging to the researchers [235]. In sperm, co-immunoprecipitation is 
particularly significant, since it is one of the only techniques that allows interactome identification. 
Any technique for PPI identification that relies on expression of exogenous DNA (e.g. tag based pull-
down) or construction of a sperm cDNA library (e.g. yeast two-hybrid) cannot be employed to unveil 
the sperm interactome.  
A key aspect that must be considered when choosing and analyzing results from high-throughput 
PPIs techniques is the type of interactions detected. PPIs can be classified as transient or stable, 
according to the temporal range of interaction. Transient PPIs have a higher probability of complex 
dissociation while stable PPIs have a higher temporal stability. Note that, a transient interaction can 
have high values of affinity and consequently be a strong interaction that last short period of time 
[236,237]. Focusing on YTH and Co-IP/MS, the PPIs identified are from distinct nature. YTH is able 
to detect transient and stable interactions due to the genetic reporter gene approach (amplifies the 
signal). Consequently, YTH must be used when, for example, signaling interactions are the goal of 
the study [233,238]. Co-IP/MS often detects stable and strong interactions. These result in the 
enrichment of PPIs from protein complexes such, the proteasome and cytoskeleton structures, or 
Figure A3.2. Schematic representation of a co-immunoprecipitation followed by mass spectrometry. Protein-
protein interactions are isolated by using antibody specific to a protein of interest and eluted for Mass spectrometry 
analysis. For mass spectrometry, isolated proteins are cleaved and analyzed according to their mass to charge ratio. 
The peptide mass fingerprint is compared with repositories of mass fingerprints in publicly available databases. 
Finally, interactors of a protein of interest are identified. 
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strong interactions, such PPIs from anchoring proteins. The use of strong detergent in the lysis 
buffer and the multiple washing steps is the main reason for the loss of transient and weak 
interactions [216].  
 
A3.2. And now what? In silico analysis of interactomes 
High-throughput techniques for PPIs detection are the best option for interatomes identification. 
Yet, the fact that these techniques provide a great amount of information can be overwhelming. 
What are the key binary interactions in testis and sperm? Have these interactions already been 
described elsewhere? What is the biological meaning of such interaction? The challenge is to extract 
meaningful information from an immense amount of data and ultimately provide answer to one 
biological question. In silico analysis of interactome data can help answer such questions and 
decipher the biological relevance of the identified interactome.  
Typically, bioinformatics analysis is based on extracting information from databases, enrichment 
and information visualization tools. In the next section, we provide a rough guide on how to perform 
an in silico analysis of interactomics data. To a more detailed guide please consult [242]. 
A3.2.1. Protein-protein interactions databases 
To complement data obtained by experimental approaches, PPIs from public accessible databases 
can be retrieved. Currently, there are more than 200 PPIs publicly accessible databases [243]. Thus, 
it can be very difficult to choose the best option to retrieved PPIs data. Databases can range from 
PPIs, gene expression patterns, protein subcellular localization, among many others. There are two 
main types of databases: primary or secondary. Primary databases are repositories of experimental 
results submitted directly into the database. These data can be curated by database-associated 
researchers to ensure accuracy of the information. Secondary databases collect information from 
primary, other secondary databases and scientific literature and manually or computationally 
analyze this data to create new knowledge [239] 
First, it is crucial to understand the origin of PPIs data in each database. PPIs can either be 
experimentally proved by small-scale or high-throughput techniques or predicted by extrapolation 
based on genomic context, structural information, network topology, text mining or machine 
learning algorithms. Although predict PPIs information can be suitable for an initial approach on a 
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specific protein interaction, high confident experimentally PPIs data must be used in an in silico 
analysis approach. To achieve high confident PPIs, each database classifies PPIs using quantitative 
or qualitative scores and different levels of curation. Typically, scores take into account the type of 
interaction, the number and quality of the experimental techniques used, the number of times the 
PPI is described in the literature and if the interaction is described in several non-human organisms 
[244]. Curation relates to constant update and confirmation of PPIs by a great human effort. 
Specifically, curators review publications and extract PPIs information. The type of information is 
vast, from identity of the interactions partners; experimental technology used; organism where 
PPIs was detected, among others [245]. Each PPIs database has a different curation policy (deep or 
shallow), which results in low overlap between repositories. Consequently, a choice must be made 
between recovering only PPIs information (shallow) or recovering as much detail about PPIs as 
possible (deep) [179,246].  
In 2012, the International Molecular Exchange (IMEx) consortium established common curation 
rules and a central registry to manage article incorporation into databases [247]. Several PPIs 
databases were encouraged to incorporate the IMEx curation rules and became members of the 
IMEx consortium. The consortium aims to coordinate curation to avoid redundant work, increase 
curation coverage by pre-establishing scientific publication to each database and synchronize 
curation to ensure data consistency across all IMEx databases. Table A3.1 lists the publicly available 
PPIs databases that present human PPI data (data obtained on 18 July 2017). 
Besides the quality and origin of the PPIs data in each database, the way PPIs information is 
reported must be considered. Due to the individual data report formats of each database, merging 
and comparing information could be challenging. In 2004, several databases united efforts and 
created the PSI-MI XML format which has been supplemented by a tabular format (PSI-MITAB). 
Currently, these table puts together 15 types of information from each binary and uses a controlled 
vocabulary (standardization of terms). These allows an easiest way to interchange, download, 
combine, visualize and analyze data in a single format from multiple resources [247,248]. 
A3.2.2. Adding biological meaning to protein-protein interactions 
High-throughput PPIs identification techniques pushed the interactomic area forward. However, 
PPI biological context is partial lost when using high-throughput techniques. To circumvent this 
problem, biological information can be added to PPIs. Biological enrichment tools are defined as 
bioinformatics methods that take advantage of biological knowledge accumulated in databases and 
A3. Interactomics and Bioinformatics: making sense of a big mess 
apply these knowledge into raw data. [240]. Enriching PPIs with information such as tissue 
expression, gene ontology, cell signaling involvement and association with mammalian phenotypes, 
will allow to pinpoint biological important interactions in the overwhelming number of PPIs 
identified. In the next section, we will describe how to add biological context to PPIs. 
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Table A3.1. Protein-protein interactions databases. Publicly PPIs available that present human PPIs information. Name, type of database, curation level, latest update, reference and some 
features are described. Data retrieved on 18 July 2017. 
Database Type of database Curation level Features Last Update Reference 
IntAct Primary (self-curation) and 
secondary (data curated by 
other platforms) 
Only experimental data 
IMEx (manually 
curated) 
Around 750 000 interactions  
Scoring system relies on type of interaction 
and interaction detection method 
Binary interactions (protein-protein and 
protein-other molecules) data for several 
organisms besides Homo Sapiens 
February 2016 [245,249] 
 
DIP Primary  IMEx (manually and 
computer approaches 
curated) 
More than 81.000 binary interactions for 10 
different organisms 
It is possible to search PPIs by interactions 
motifs or protein domains. 
February 2017 [250] 
 
HPIDB Primary (self-curation) and 
secondary (curation of 12 
external databases) 
 
IMEx (manually 
curated) 
Host-pathogen PPIs 
More than 55.000 interactions between 55 
host (animal and plant) and 523 pathogen 
species (virus, bacteria, fungi, etc) 
March 2017 [251,252] 
  
MINT Primary  IMEx (manually 
curated) 
Around 125.000 binary interactions (PPIs and 
proteins-other molecules) in more than 600 
organisms or in vitro assays. 
Association with human disease is stablished 
Currently being 
update by IntAct 
[245,253,254]  
MatrixDB Primary (experimental only) IMEX (manually 
curated) 
Binary interactions established by 
extracellular matrix proteins, proteoglycans 
and polysaccharides 
More than 15.000 molecular interactions 
(IMEx extended). However, the core of 
MatrixDB is composed by 789 interactions 
2015 [245,255] 
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I2D Secondary (experimental and 
predicted) 
IMEx PPIs for five model organisms and Homo 
Sapiens 
More than 1 million PPIs 
October 2015 [256,257] 
 
InnateDB Primary (experimental) and 
secondary 
IMEX (manually) Genes and proteins interactions and signaling 
pathways involved in the immune system of 
humans, mice and bovine to microbial 
infection. 
18,780 described interactions. 
Junes 2017  [258] 
 
UniProt Secondary IMEx Data drives from multiple databases Updated monthly [259] 
  
 
HIPPIE Secondary Manually curated More than 300 000 experimental PPIs 
retrieved form 7 primary databases 
Scoring system is based on the nr of studies 
reporting an interaction; the nr and quality of 
the experimental techniques used to detect 
the interactions and the nr of non-human 
organism in which the interaction is reported 
July 2017 [260,261]  
PSICQUIC 
View 
Web Service - Search web service that allows retrieval of 
PPIs and protein-molecules interactions from 
36 primary and secondary databases.  
Access to more than 151 million binary 
interactions 
Results are reported in a controlled 
vocabulary in a specific format (PSI-MITAB).  
-  [262] 
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A3.2.3. Gene Expression databases: Where are proteins being expressed?  
PPIs are constantly changing to adapt to the biological context. Furthermore, interactomes are 
unique to cell types, tissues, development stage, etc. Consequently, adding expression data to PPIs 
offers a better understanding of binary interactions in a tissue-specific context. Mapping proteins 
in a given tissue is typically based on measuring its mRNA levels. High-throughput techniques for 
mRNA quantification includes RNA sequencing and expressed sequence tags (ESTs). ESTs are short 
sequence reads generated from 5´and 3´ends of tissue cDNA library (immobilized in a microarray). 
Since these sequences are fluorescently tagged, it is possible to measure the amount of cDNA. So, 
the higher abundance of a gene, the higher abundance of the EST derived from its transcripts and 
consequently the higher the signal [263,264]. RNA sequencing (RNA-seq) is an update of ESTs 
technique. Instead of generating short sequences of RNA only from 5´and 3´end, RNA-seq generates 
random cDNA fragments. This is particularly useful, to distinguish between isoforms [265].There 
are several options of tissue gene expression databases and repositories available. The main freely 
available databases are listed in Table A3.2. 
Table A3.2. Tissue gene expression databases and repositories. Name, gene expression technique, latest update 
reference and some features are described. Data retrieved on 18 of July 2017. 
Database Gene 
expression 
detection 
technique 
Features Last 
Update 
Reference 
Human 
Protein Atlas 
(HPA) 
RNA-seq and 
Cap Analysis of 
Gene 
Expression 
(CAGE)  
 
 
Human protein-coding genes, 
expression and localization of the 
corresponding proteins based on 
both mRNA and protein data. 
Coverage of 100% mRNA data and 
87% of protein data of the 
predictive human genes  
Presents several tissue-specific 
and cancer proteomes.  
January 
2017 
[205,266] 
 
BioGPS Affymetrix 
chips 
(microarray) 
and imported 
data. 
Expression data for Homo 
Sapiens, Mus musculus, Rattus 
novergicus; Sus scrofa and others 
Expression data for cancer tissues 
Based on submission of 
expression datasets by the users 
May 2017 [267,268] 
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PaGenBase Affymetrix 
chips 
(microarray), 
next 
generation 
sequencing 
(NGS) and 
curated data-
mining  
Expression of specific, selective 
and housekeeping genes of 
tissues of Homo Sapiens and 10 
model organisms 
Tissue/cell, time/development 
/differentiation specific data 
May 2013 [269]  
Expression 
Atlas 
RNA-seq and 
Affymetrix 
chips 
(microarray). 
Data results from more than 
manually curated 3.000 
independent studies. 
One third of the data is mRNA 
expression for Homo Sapiens. 
Other species, like chicken, pig 
and 17 plant species are also 
represented. 
May 2017 [270] 
  
 
UniGene ESTs For Homo Sapiens, there are more 
than 130.000 mRNA expression 
data 
Data for more than 100 other 
organisms (plants, fungi, bacteria, 
virus, etc.) 
Tissue/pathology/development 
specific data. 
Updated 
monthly 
 
[271]  
Human 
Protein 
Reference 
Database 
(HPRD) 
 Data restricted to normal human 
tissues 
 
April 2010 [272] 
 
 
Since different methodologies for gene expression quantification are used by different databases, 
merging and comparing data can be challenging. If the goal is to retrieve data from two or more 
databases, normalization of the expression must be performed. Besides retrieving gene expression 
data, pin-pointing proteins that are specific or enriched into a particular tissue can be of 
importance. Some databases either provide a subset of tissue-specific proteins (such as HPA) or 
classify proteins as tissue-specific. However, there is no uniformed rules to classify a protein as 
tissue-specific. For example, HPA databases considers tissue-specific proteins as requiring an 
expression in one tissue at least five-fold higher than all other tissues [205]. On the other hand, 
UniGene considers a restricted expression when at least 75% of the detected gene expression is 
clustered in a single tissue [271]. 
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A3.2.4. Gene phenotype and disease associated databases 
In medicine, phenotype refers to relevant abnormalities (symptoms, behavioral anomalies, etc) 
that have an impact on quality of life. Typically, genetic abnormalities of multiple genes result in 
protein deregulation at cellular level and consequently a malfunction of the tissue, resulting in a 
phenotype. By analyzing the phenotype produced, we can infer the protein role within a cell [273]. 
Studying gene-phenotype association is based on two approaches: human gene-disease association 
and animal model gene-phenotype association. Although the ultimate goal is to unravel human 
gene-disease association, human sample shortage and ethical issues make it challenging. Using 
animals to create gene-phenotype model, more specifically mice, help complement the human 
based knowledge. In Table A3.3, most human gene-disease association databases and animal model 
gene-phenotype databases are listed. Most databases allow a phenotype based search (e.g male 
infertility) or a gene based search (e.g. PGK2) and data can be retrieved in a singular tabular format. 
Again, the lack of uniformed rules to classify phenotypes is the biggest challenge when unifying and 
comparing data between distinct databases.  
Table A3.3. Gene-disease association and animal model gene-phenotype databases. Name, lasts update, reference 
and type of data presented are described. Data retrieved on 18 of July 2017 
Database Type of data Last Update Reference 
Mouse Genome 
Informatics (MGI) 
Freely available gene-
phenotype data derived 
from knock out mice  
June 2107 [274] 
Online Mendelian 
Inheritance in Man 
(OMIM) 
Human gene-disease 
and gene-phenotype on 
all known mendelian 
disorders and over 
15.000 genes. 
 
Update daily [275] 
 
Phenopedia/Genopedia Human gene-disease 
and gene-phenotype 
data derived from 
manually curated data-
mining. Disease 
(phenopedia) and genes 
(genopedia) query is 
possible.  
July 2017  [276] 
  
 
DisGeNet Human gene/variants-
diseases data curated 
from repositories; 
genome wide 
May 2017 [277,278]  
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associated studies 
catalogs, animal models 
and scientific literature.  
DISEASES Gene-disease data 
obtained from 
automatic text mining, 
manually curated 
literature, cancer 
mutation data and 
genome wide 
associated studies 
catalogs 
No information [279] 
 
 
A3.2.5. Enrichment analysis tools 
So far, the databases presented provide information for individual proteins. However, can we 
analyze PPIs as a group of proteins? Enrichment analysis tools systematically analyze large protein 
lists and assemble a summary of the most enriched and pertinent biological processes [240]. The 
degree of enrichment is only significant when calculated by comparing the PPIs list against a specific 
background. Depending on the purpose of the study, the background is either the complete human 
genome; tissue-specific background; a control condition etc. Currently, more than 60 enrichment 
tools are available [240]. Most of these tools perform Gene Ontology annotations (enrichment of 
molecular function, biological process and cellular component). The Gene Ontology (GO) project is 
a major bioinformatics initiative to develop a computational representation of our evolving 
knowledge of how genes encode biological functions at the molecular, cellular and tissue system 
levels. The project has developed formal ontologies that represent over 40,000 biological concepts, 
and are constantly being revised to reflect new discoveries. To date, these concepts have been used 
to "annotate" gene functions based on experiments reported in over 100,000 peer-reviewed 
scientific papers. 
Nevertheless, there are enrichment tools for signaling pathway, protein feature (e.g. domains, 
secondary structures) and gene expression profiles, among others. Database for Annotation, 
Visualization and Integrated Discovery, best known as DAVID, is a secondary enrichment tool. It 
collects information from multiple annotations sources (e.g. GO, KEGG pathway) and presents a 
broader enrichment analysis (DAVID was updated in 2016 [280]).  
The main reason for such diversity in enrichment analysis tools relates to the statistical methods 
employed to determined enrichment. Consequently, even when analyzing the same set of PPIs, 
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results vary among tools (for a more comprehensive knowledge about enrichment statistical 
methods please consult [281]) [282]. Other differences, reported between tools are: organism 
supported; user friendly interface and results presentation.  
A3.2.6. Visualization tools: building protein-protein networks 
Information visualization tools transform crude data into structured and visually representations to 
simplify the analysis and interpretation of biological data, tipicaly networks [241]. The latter are a 
visual representation of how two or more entities influence each other. The first report of network 
based solution dates to 1735, when Euler used graph theory to solve the seven bridges question 
[283]. In PPIs networks (PPIN), proteins are typically represented as nodes and interactions as edges 
connecting the proteins. More than visually representing PPIs and interactomes, PPIN topology 
(space arrangement of edges and nodes) can uncover crucial biological information [284]. 
Topological properties include connectivity degree, which is the number of interactions for each 
protein and node, betweenness centrality, which is the number of shortest paths that go through 
a protein among all shortest paths between all possible pairs of nodes [285]. Edge properties 
include types of relationships (inhibition; phosphorylation, etc) and edge betweenness centrality, 
which is the number of shortest paths that go through an edge among all possible shortest paths 
between all the pairs of proteins [286]. Analysis of such properties allows to identify, among other, 
hub proteins, bottleneck proteins and clustering sub-networks [287].  
Cytoscape is the most widely used tool to create and analyze PPINs. Its popularity is reflected in the 
almost 1 million downloads and more than 300 plug-ins, accessible through the Cytoscape app store 
or directly on the software (information from 16 July of 2017) [288]. Also, numerous biological 
databases and repositories (e.g PSIQUIC VIEW; DisGeNet; String; Reactome) can be directly 
accessed using Cytoscape and enabling integration of PPIs; gene expression; gene phenotype and 
disease association; enrichment and many others. Nevertheless, all these data can be imported by 
the user as attributes given to each protein/node. After building a network, the user can visually 
represent biological information by using nodes an edges characteristics, such color, shape, name, 
etc; choose the best layout to stress a topological feature, among many other features (consult 
[289]). Although a bit rough, Cytoscape can analyze the PPIN topological features and find clusters 
(groups of highly connected nodes). Clusters are of particular important, since is expected that 
highly connected proteins share the same biological role [290]. Nevertheless, there are several apps 
that can perform an intense topological analysis [291]. 
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A3.3. Concluding remarks 
In silico analysis of interactomes is key to pinpoint crucial interactions and it is a starting point to 
narrow vast lists to a promising set of interactions. However, keep in mind that in bioinformatics 
approaches have its setbacks. Conclusion cannot be drawn without further experimental evidence; 
the rate of false positives reported in databases are still an issue and the fact that proteins 
exhaustive studied are overrepresented in databases, while other proteins are underrepresented.  
  
A4. Available techniques for sperm internalization of exogenous material 
A4. Available techniques for sperm internalization of 
exogenous material  
Sperm is a unique cell which besides being the only haploid cell in the male body and fulfil its goal 
in the female reproductive system, it does not have the necessary machinery to produce new 
proteins, new lipids and other molecules, and its plasma membrane constitution is one of a kind 
[31]. Sperm plasma membrane is stable and metabolically inert [31]. Consequently, working with 
this type of cell can be challenging. Also, contrary to other type of cells, in which upon a few genetic 
alterations, can be grown and cultured in vitro (cell culture), full mature sperm cannot. In 2011, 
Sato et all reported producing spermatids and sperm using primitive spermatogonia from neonatal 
mouse testis. However, the process is long and intricate [292]. Moreover, human sperm samples 
are typically obtained in fertility clinics, resulting in a bias towards samples with fertility issues. Even 
more difficult is to obtain human epididymal sperm, which results in most motility acquisition 
studies to be performed in animal models.  
Studying signaling mechanisms in somatic cells, is based on overexpression or deletion of a protein 
and evaluation of the phenotype produced. This is accomplished by either, transfection of foreign 
DNA into cultured cells or producing knock out (KO) or knock in (KI) mice. Testis-specific KO or KI 
has been successfully accomplished for several proteins [293,294]. This allows the study of the role 
of such protein in testis and spermatozoa. Yet, transgenic mice are an expensive, laborious and 
time-consuming technique. Regarding overexpression (transfection of gene copy) or deletion 
(siRNA) of proteins using foreign DNA, in sperm these techniques are useless, since sperm does not 
transcribe and translate DNA into proteins [10]. Another approach to studying signaling proteins is 
the use of inhibitor or activation drugs/molecules. However, some of these drugs cannot penetrate 
sperm plasma membrane [295,296]. 
Considering all the sperm peculiarities, working with this type of cell can be frustrating. Yet, in the 
past decades, several alternative methodologies have been developed and applied on studying 
signaling proteins, interactions and pathways in sperm. Most studies aimed to incorporate 
exogenous DNA material into spermatozoa for oocyte deliver (sperm-mediated gene transfer) 
[297]. Little effort has been put towards incorporating other molecules, such as proteins, into 
human sperm. In the next section, we will describe and discuss some methodologies to study sperm 
pathophysiology. 
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A4.1. Streptolysin-O 
One of the first approaches to translocate impermeable molecules into mammalian cells involved 
using non-ionic detergents such as Triton-X (normally in immunocytochemistry studies) [298]. 
Although these reagents successfully expose the intracellular environment, since lipids and 
membrane proteins are removed, signaling pathways that depend on extracellular factors to be 
triggered are impaired. To circumvent these problem, in 1996, Dominguez used a bacterial toxin, 
streptolysin-O, to form large pores (26nm) that allowed entry of large molecules into mouse 
spermatozoa [299]. The use of streptolysin-O did not affect acrosomal reaction but only when pre-
incubated with Ca2+sperm motility was kept. Yet, the pattern of sperm motility changes when 
permeabilized with streptolysin-O. Since most plasma membrane is kept intact, signal transduction 
events initiated with cell surface components are kept intact. Nevertheless, since sperm cannot 
synthetize new lipids, disrupting the plasma membrane can cause sperm physiological alterations, 
for example motility and membrane dynamics [299,300]. Streptolysin-O has been used in human 
spermatozoa to transfer proteins [301], antibodies [302] and ions [303], among others.  
 
A4.2. Lipossomes 
Another strategy employed to transfer exogenous impermeant molecules into mammalian cells is 
the use pf liposomes. Liposomes are small vesicles that can occur naturally or are artificially 
produced from cholesterol and phospholipids. Due to the nature of these molecules (both 
hydrophobic and hydrophilic) they form spherical macromolecules, in which aqueous units ate 
enclosed and isolated from the outside. Depending on the lipid composition, liposomes differ 
considerable in surface charge, size, fluidity and rigidity [304]. Considering all properties, liposomes 
were developed as delivery system, by enclosing impermeant material into liposomes. They work 
by fusing with the plasma membrane and introduction of the enclosed material into the 
intracellular environment of mammalian cells [305]. Liposomes present low toxicity and high 
efficiency.  
Specifically, in the male reproductive system, they occur naturally as epididymosomes and 
prostasomes (see section A1). Artificial liposomes already have been used in sperm, for  protection 
after cryopreservation; incorporation of foreign material; trigger capacitation, acrosome reaction 
and gamete interaction by lipid membrane alteration [306,307]. Most of the material introduced 
into mammalian sperm was foreign DNA with the goal of being delivered to the oocyte [308,309]. 
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Although the incorporation of DNA into the sperm is successful, no transgenic animals were 
obtained [310,311]. The first report of offspring obtained from liposome-transfected sperm are in 
silver sear bream [312]. Regarding, the usage of liposomes to modulate signaling events in sperm, 
the effect of inositol 1,5,5-triphosphate and bindin on sperm activation was assessed by deliver of 
both molecules into sperm [305,313].  
A common laboratory reagent used for transfection of cultured cells, lipofectamine, is based on 
creating liposomes that incorporated foreign DNA and translocated into the cultured cells. 
Lipofectamine was already used in sperm (bovine) and did not improve either the transfection rate 
compared with detergent based permeabilization and in some cases sperm motility was affected 
after lipofectamine usage [314,315]. This may reflect the lack of compatibility between a general 
liposome composition (more suitable for somatic cells) and the uniqueness of sperm plasma 
membrane composition (see section A1). Moreover, this general liposome-delivery approach was 
mainly performed in poultry and cattle sperm to delivery exogenous DNA [314,315]  
 
A4.3. Nanoparticles 
Nanomaterials have been applied in several fields, from medical devices, food products, cosmetic 
and drug delivery systems [316]. Specifically, nanoparticles are advantageous to medical 
application since their surface to mass ratio is high and their ability to adsorb and carry several 
molecules, such proteins, drugs and DNA. Typically, nanoparticles present a dimension below 
100nm, although in drug delivery larger particles may be needed to ensure sufficient amount of 
drug [317]. The nature of the nanoparticle can vary greatly, from metallic to magnetic nanoparticles 
[318]. From a biomedical point of view, the ability to customize nanoparticles is particularly 
advantageous. This allows large loading capacity, stability and specificity towards a selected cell 
population [319,320]. 
In sperm, most reports focus on using nanoparticle to deliver DNA into the spermatozoa or in the 
effects of nanoparticles used in medical applications on testis and sperm [319]. In 2008, Makhluf et 
al, successfully used nanoparticles to deliver anti-protein kinase C alpha antibody into bovine sperm 
cells [321]. In 2012, Feugang labeled sperm by fusing the protein Renilla luciferase with 
nanoparticles [322]. These reports proved that is possible to use nanoparticles as a delivery system 
for molecular research tools into sperm. However, a great concern is the fact that most 
nanoparticles tested for safety in spermatozoa are non-biodegradable which raises the question 
about reversibility and in a medical perspective their potential long-term effect [319].  
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A4.4. Cell penetrating peptides  
Cell penetrating peptides (CPPs) are short peptide sequences (less than 40 aminoacids) that have 
the ability to rapid translocate into most mammalian cells [323]. The discovery of CPPs arouse from 
the observation that certain proteins could cross the plasma membrane. Tat transactivator of HIV 
virus type 1 could enter cells and target the nucleus. This observation resulted in Tat, and several 
structural variants of this protein, to originate the first CPP. Moreover, further studies identified 
the specific sequence of Tat necessary for translocation across the plasma membrane [324]. Since 
Tat, dozens of CPPs were either identified in proteins or designed and have been successfully used 
to transport proteins, peptides, oligonucleotides, plasmids and large particles, like liposomes, into 
cells [325–334].  
Typically, CPPs are polybasic and/or amphipatic molecules and their cell-penetrating properties 
arise from positively charged aminoacids [335,336]. Besides, the importance of positively charged 
aminoacids, there is still much debate on how CPPs are uptake into cells. Several models for CPPs 
internalization, from energy-depended endocytosis mechanisms to direct plasma translocation 
(e.g. carpet and pore formation model) have been suggested and proved [337,338]. Moreover, 
distinct CPPs may have different uptake methods [336]. Also, within the cell, CPPs target specific 
intracellular organelles or compartments [339]. 
The CPPs were first developed to exclusively deliver bioactive cargo to cells, by covalent binding 
cargo and CPPs (message-address hypothesis). Consequently, they were required to be relatively 
inert. Yet, the report of adverse effects such as toxicity or inhibition of key signaling pathways, 
proved that CPPs with favorable bioactive properties could be a useful strategy in both research 
tools and diagnostic agents. So recently the term bioportide was introduced. Bioportides are 
peptides that can translocate the mammalian plasma membrane and at the same time have a 
biological role within the cell (bioactive) [340,341]. Bioportides designed to mimic proteins domains 
appear to be more efficient, as they are able to directly modulate cellular events, such as protein-
protein interactions. One of the first examples of a bioportide is int-H1-S6A, F8A. This bioportide 
results from a variation of 14 aminoacid sequence of c-Myc extended with CPP penetratin and 
demonstrated anti-proliferative and apoptogenic properties towards cancer cell lines [342]. Since 
int-H1-S6A, F8A many others were developed, from bioportides with anti-apoptotic effects; cAMP 
modulation; promotion of blood vessel contraction; anti-adrenergic to stimulation of inflammatory 
mediators secretion [340,343–347]. 
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The use of CPPs or bioportides in the male reproductive system is still a new field. Due to the 
reduced cytoplasm and lack of energy dependent endocytosis mechanism, sperm cells are a 
suitable model for the study of CPP or bioportide translocation and accretion [339]. The preference 
accumulation of several CPPs was evaluated in bovine sperm. Tat accumulates in the head; MitP in 
midpiece and C105Y is absent from interior head and acrosome. Also, since bovine sperm is 
incapable of clathrin-mediated endocytosis and micropinocytosis, neither CPP tested were 
internalized using these routes. The advantages of using CPPs and bioportide in sperm are clear: 
targeted delivery of bioactive cargos into subcellular compartments; any CPP effect in gene 
expression is irrelevant in sperm; CPP can be altered to the unique plasma membrane sperm 
composition and certain CPPs do not alter sperm physiology (viability and motility) [348]. Even 
more, since sperm rely on protein-protein interactions to mature in the epididymis and to adapt to 
new environments, the use of bioportides targeting such protein-proteins is a promising field. 
 
A4.5. Concluding remarks 
The singularity of the sperm cell make it also unique to work with. The distinct plasma membrane 
composition, the fact that it is a transcriptional silent cell and highly compartmentalization rises 
problems on using common molecular research tools. Over several decades, alternative methods 
to work with spermatozoa have been developed, from reagents to demembrane sperm cells to 
using cell penetrating peptides to target sperm proteins. Regardless, we believe that much is still 
to be overcome. The biggest obstacle is the lack of sperm samples, particularly testicular and 
epididymal sperm. Although animal models are of great value, transposing knowledge acquired in 
animal models to human physiology has its setbacks. A great example is the role of glucose in 
capacitation. In hamster [349] and macaque [350] sperm, glucose is essential for capacitation, while 
in bovine [351] and dog sperm [352] glucose inhibits capacitation.  
Studying human sperm motility is of great value, since poorly motility samples account for 15% of 
male related infertile phenotypes. 
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Sperm motility is a crucial event for oocyte fertilization by the sperm. Thus, modulation of sperm 
motility, specifically inhibition represents a perfect target for a reversible male contraceptive. 
Moreover, since sperm motility it is a post-testicular process, targeting does not affect sperm 
production. To achieve such goal, we need to understand how sperm motility is acquired during 
sperm epididymis transit. This work aimed to enrich the knowledge on the signaling events involved 
in human sperm motility with the final goal of identify potential targets for male contraception. We 
approached this general goal by focusing on the characterization and modulation of the signaling 
pathway GSK3/PPP1R2/PPP1 in human sperm.  
 
To this end the following aims were proposed: 
 
Aim 1: Modulate protein-protein interactions in human spermatozoa involved in human 
spermatozoa motility 
Results: Sperm motility modulation by using a bioportide based on PPP1/PPP1R2 
interaction interface (Chapter B1) 
Aim 2: Identify and characterize protein-protein interactions involved in human sperm motility as 
potential targets for male contraceptives  
Results: Identification and characterization of GSK3 human testis and spermatozoa 
interactome 
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B1.1. Abstract 
The limited options available for male contraception reflect the necessity of a new group of male 
contraceptives. The sperm motility acquisition mechanism is an optimal target for a new male 
contraceptive since is essential for fertilization and a post-testicular sperm maturation process. 
Sperm motility relies on phosphorylation of key proteins. Phosphoprotein phosphatase 1 catalytic 
subunit gamma 2 (PPP1CC2) is a central player on controlling the phosphorylation state of proteins 
and consequently sperm motility. On human sperm, PPP1CC2 activity is partially controlled by PPP1 
regulatory subunit 2 (PPP1R2). We hypothesized that disruption of PPP1R2/PPP1CC2 interaction 
would have a deleterious effect on sperm motility. In order to modulate sperm motility, we 
designed peptides sequences capable of disrupting PPP1R2/PPP1CC2 interactions based on 
PPP1R2/PPP1CC2 interaction interference. To insure sperm intracellular delivery, the peptides 
were coupled with cell penetrating peptides (CPPs) originating bioportides. We demonstrated that 
the disruptive bioportide was able to interfere with PPP1R2/PPP1CC2 interaction, translocate to 
human sperm and significantly reduced sperm motility. In conclusion, we proved that rationally 
designed peptides can target protein-protein interactions in spermatozoa and development of a 
new type of male contraceptive based on sperm motility modulations is possible.  
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B1.2. Introduction 
Currently, contraception is mainly limited to female contraceptives. Condom and vasectomy are 
the foremost methods used by males [1,2]. Although research on hormonal male contraceptives 
has been reported, severe secondary side effects have discouraged further investment. [3]. Since 
sperm motility is a post-testicular acquisition process and it appears to be hormonal independent, 
we consider that targeting the mechanism of sperm motility acquisition may be the future on male 
contraceptives. 
Sperm motility is acquired in the epidydimis and relies mostly on intracellular signaling events, since 
sperm cells are transcriptionally silent. Reversible phosphorylation is essential to motility 
acquisition and Phosphoprotein phosphatase 1 (PPP1) is a key player in this process [4]. In 
mammalian sperm PPP1CC2, a testis-enriched PPP1 isoform, appears to be the sole responsible for 
PPP1 activity [5,6]. Furthermore, PPP1CC2 is distributed along the entire flagellum [7,8] and 
inhibition of PPP1 by phosphatase inhibitors (calyculin A and okadaic acid) induces caput sperm 
motility [5]. Smith et al showed that in epidydimis caput, bovine immotile sperm present a two-fold 
higher activity of PPP1 compared with fully mature sperm [5,9]. Control of PPP1 catalytic activity is 
achieved through binding to regulatory subunits, the PPP1 interacting proteins. In mammalian 
sperm, Phosphoprotein phosphatase 1 regulatory subunit 2 (PPP1R2), a PPP1 inhibitor, is central in 
controlling PPP1 activity. PPP1R2 is a highly intrinsically disordered protein that only acquires a 
defined structure when associated with PPP1 [7,10,11]. In human sperm, Korrodi-Gregório et al 
demonstrated that part of PPP1 population is bound to PPP1R2 and within these complex PPP1 is 
inactive [10].  
The interaction between PPP1 and PPP1R2 has been solved by crystallography. PPP1R2 interacts 
with PPP1 in 3 regions: between residues 12-17 (site 1); 44-56 (site 2) and 130-169 (site 3) of 
PPP1R2. PPP1R2 contains two degenerated RVxF motifs, the most common motif among PPP1 
interactors. The first RVxF motif, 44KSQKW48 sites on top of PPP1 RVxF pocket, far away from the 
catalytic center, while the 145KLHY148 motif sites on top of PPP1 catalytic center. PPP1R2 site 3 of 
interaction is unique, since it extends on top of the active site of PPP1 resulting in complete 
inhibition of PPP1, by displacement of metal ions (Mn2+ and Fe2+) crucial for phosphatase activity 
[12,14].  
The interface between PPP1 and PPP1R2 present an opportunity for pharmacological interventions, 
specifically to modulate sperm motility. However, target intracellular complexes can be challenging 
due to cells bilayred lipid membrane. Cell penetrating peptides (CPPs) are short peptide sequences 
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that are able to rapid translocate into mammalian cells and deliver biological active molecules [15]. 
In 2015, Jones and colleagues proved that CPPs translocate into human and bovine sperm without 
affecting viability and motility [16].  
The goal of this study was to design and synthetize peptides capable of translocating the sperm 
membrane and disrupting PPP1/PPP1R2 complex, as well as, evaluate their ability to modulate 
sperm motility. 
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B1.3. Methods 
B1.3.1. Bioportide design 
With the goal of disrupting the complex PPP1/PPP1R2 in human sperm, the following bioportides 
were designed (Table B1.1):  
Table B1.1. Peptide sequence, peptide designation and length of the bioportides (BP) used in this study. To enable 
quantitative and qualitative uptake studies, TAMRA fluorophore was added. Underline, C105Y (CPP); Red PPP1 binding 
motif; Bold, PPP1R2 RVxF flanking sequence. 
Peptide Designation Sequence Length 
BP-PPP1R2 RVxF H-36VDEELSK44KSQKW48DEMNILA54CSIPPEVKFNKPFVYLI-NH2 36 
BP-PPP1R2 RVxF SC H-36VDEELSK44QWKKS48DEMNILA54CSIPPEVKFNKPFVYLI-NH2 36 
 
The BP-PPP1R2 RVxF bioportide was designed by coupling the PPP1R2 RVxF motif- 44KSQKW48-  and 
the adjacent 7 aminoacids with C105Y CPP. The BP-PPP1R2 RVxF SC is similar to the BP-PPP1R2 
RVxF peptide, yet the RVxF was scrambled to QWKKS to prevent disruption of PPP1/PPP1R2 
complex. 
 
B1.3.2. Microwave-assisted solid phase peptide synthesis  
Fmoc-protected aminoacids were purchased from Novabiochem (Beeston, UK). Microwave-
assisted solid phase peptide syntheses were performed using a Discover SPS Microwave Peptide 
Synthsizer (CEM Microwave Technology Ltd, Buckingham, UK) with fibre optic temperature control. 
Peptides were synthesized (0.1 mmol scale) using Rink amide MBHA resins pre-loaded with the first 
amino acid (AnaSpec, Inc., Cambridge Bioscience Ltd, Cam- bridge, UK) and employed an N-a-Fmoc 
protection strategy with HCTU activation. Deprotection with 7 mL of 20% piperidine was performed 
for 3 min at 50 W/75ºC. A majority of AA coupling reactions were accomplished with a 4-fold molar 
excess of Fmoc-protected AA with HCTU and diisopropylethylamine (DIPEA), molar ratio of 1:1:2 
(AA/HCTU/ DIPEA), in 4 mL for 10 min at 25 W/75ºC. Arg coupling was performed in two stages: 30 
min 0W/25ºC followed by 5 min at 17 W/75ºC. To reduce racemization of Cys and His, coupling 
conditions were 5 min at 0 W/25ºC followed by 6 min at 17 W/50ºC with the hindered base 
collidine (TMP) at a molar ratio of 1:1:2 (AA/HCTU/TMP) [17]. Aspartimide formation was reduced 
by the substitution of piperidine for 5% piperazine and 0.1 M 1-hydroxybenztriazole hydrate (HOBt) 
in the deprotection solution [17]. Fluorescent peptides, to be used in cell imaging and quantitative 
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uptake analyses, were synthesized by amino-terminal acylation with 6-carboxy-
tetramethylrhodamine (TAMRA) (Novabiochem, Beeston, UK) as previously described. Peptides 
were purified by semi-preparative scale high-performance liquid chromatography, and the 
predicted masses of all peptides were confirmed by matrix-assisted laser desorption ionization 
(MALDI) time of flight mass spectrometry.  
 
B1.3.3. In vitro effect of Bioportides 
A concentration range of commercial PPP1R2 (New England Biolabs, Herts, UK) was incubated with 
purified PPP1CC2 (1:20; 1:200 and 1:2000) and either BP-PPP1R2 RVxF or BP-PPP1R2 RVxF SC for 
30 min (ratio of 1:200:0.5 of PPP1R2, PPP1CC2 and bioportides). PPP1CC2 activity was measured 
during 30 min, in 5 min breaks, using the SensoLyte® pNPP Protein Phosphatase Assay Kit 
*Colorimetric*(AnaSpec, Inc., Cambridge Bioscience Ltd, Cambridge, UK) and a PPP1 specific assay 
buffer according to manufactures instructions. Negative control (only assay buffer) was included. 
Four replicas were performed. 
 
B1.3.4. Sperm cells preparation 
This study was approved by the Ethics and Internal Review Board of the Hospital Infante D. Pedro 
E.P.E. (Aveiro, Portugal) (Process number: 36/AO) and was conducted in accordance with the ethical 
standards of the Helsinki Declaration. All donors signed an informed consent allowing the samples 
to be used for scientific purposes. Human semen samples were obtained from a randomized group 
of donors and collected by masturbation into a sterile container. Basic semen analysis was 
conducted in accordance with World Health Organization (WHO) guidelines [18] and only 
normospermic samples were further used. Fresh semen from Holstein Friesian bulls was obtained 
from LusoGenes, LDA, Aveiro, Portugal. Semen was collected by artificial vagina and assessed by a 
certified veterinarian. Human and bovine sperm were isolated and washed three times in PBS 1x 
(Fisher Scientific, Loures, Portugal) from seminal plasma by centrifugation (600 g for 10 min at RT) 
using AllGrade Wash medium (LifeGlobal, Brussels, Belgium). Pellet was resuspended in medium to 
a final concentration of 40x106 sperm cells/mL and incubated at 37 ºC with 5% CO2 until further 
treatment. 
 
B1.3.5. Microscopy evaluation of intracellular accumulation of bioportides 
B1. Sperm motility modulation using a bioportide based on PPP1/PPP1R2 interaction interface  
Washed bovine and human sperm cells (40x106) were resuspended and incubated with 10 M 
TAMRA-labeled bioportides for 1 h at 37 ºC in a humidified atmosphere of 5% CO2. After, cells were 
washed 3 times in PBS 1x (800 g for 5 min) in AllGrade Wash medium (LifeGlobal, Brussels, Belgium). 
To confirm that the fluorescently labeled peptides were not merely surface associated, sperm cell 
were treated with trypsin. Briefly, sperm cells were divided into two populations and half of the 
cells were fixed in 4% of paraformaldehyde (PFA) (Fisher Scientific, Loures, Portugal) for 20 min. 
The other half was incubated with 1% of trypsin (wt/vol) (Promega, Madison, Wisconsin, USA) at 
37 ºC, centrifuged at 3000 g, washed in AllGrade Wash medium (LifeGlobal, Brussels, Belgium) and 
resuspended in 4% of PFA for 20min. Fixed cells from both populations were spread into coverslips, 
allowed to air dry and mounted. Negative controls (only cells) were processed in parallel. Slides 
were assessed using an Imager Z1, Axio-Cam HRm camera and AxioVision software (Zeiss, Jena, 
Germany). 
 
B1.3.6. Quantitative evaluation of intracellular accumulation of bioportides 
Quantitative assessment of bioportide translocation into sperm was based on a previously 
described method [19]. Washed bovine and human sperm cells were incubated with 10 M TAMRA-
labeled bioportide for 1 h 37 ºC in a humidified atmosphere of 5% CO2. Cells were then washed 3 
times with PBS 1x, incubated with 1% trypsin (Promega, Madison, Wisconsin, USA) at 37 ºC and 
collected by centrifugation at 3000 g. Next, cells were lysed in 300 L 0.1 M NaOH (Fisher Scientific, 
Loures, Portugal) for 2 h on ice. The lysate (250 L) was placed into a black 96-well plate and 
analyzed using an Infinite® 200 PRO plate reader (Tecan, Switzerland) (λAbs 544 nm/ λEm 590 nm). 
 
B1.3.7. Sperm viability assays  
Bovine sperm was incubated for 1 min in a 1:1 proportion of Trypan Blue (Fisher Scientific, Loures, 
Portugal) and 10 L spread in a slide and left to dry. Dead sperm present a compromised plasma 
membrane, enabling the Trypan Blue to stain the cell. Live sperm have intact plasma membrane 
and appear translucid. Two hundred sperm cells were counted per condition using a Zeiss Primo 
Star microscope (Zeiss, Jena, Germany). Experiments were performed on samples form 3 individual 
bulls. 
 
B1.3.8. Motility assays 
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Bioportides were prepared in AllGrade Wash medium (LifeGlobal, Brussels, Belgium) in individual 
volumes. Washed bovine sperm cells (20x106) were added to the medium to a final volume of 500 
L. Control samples included sperm cells in medium. All samples were incubated at 37 ºC for 1 or 2 
h in a humidified atmosphere of 5%CO2. Sperm motility, was evaluated using the Sperm Class 
Analyzer CASA System (Microptic S L, Barcelona, Spain) with SCA® v5.4 software. Briefly, 2 L of 
samples were loaded into individual chambers of Leja Standart Count 8 chamber slide 20 μm depth 
(Leja Products B. V., The Netherlands) pre-heated to 37 ºC. This temperature was kept while at least 
500 sperm/condition were evaluated. Experiments were performed on samples form 3 individual 
bulls and all the conditions were performed in triplicate.   
 
B1.3.9. Molecular modelling and dynamic studies 
Computer simulation studies of PPP1R2 RVxF and scrambled RVxF and the 7 flanking aminoacids 
were performed by the MD (molecular dynamics) simulation package Amber v14 applying Amber-
ff14SB force field [20]. The two systems were solvated, in a simulation octahedral box of explicit 
water molecules (TIP3P model) [21], counter ions were added to neutralize the system and periodic 
boundary conditions imposed in the three dimensions (12 Aº). After minimizations, systems were 
subjected to an equilibration phase where water molecules position were restrained, then 
unrestrained systems were simulated for a total of 5 microseconds, in a NPT ensemble; Langevin 
equilibration scheme and Berendsen thermostat were used to keep constant temperature (300 K) 
and pressure (1 atm), respectively. Electrostatic forces were evaluated by Particle Mesh Ewald 
method and Lennard-Jones forces by a cutoff of 10 Å. All bonds involving hydrogen atoms were 
constrained using the SHAKE algorithm. Figures were extracted using VMD and prepared in Maestro 
[22]. Simulation was run for 200 ns in each system. 
To perform the trajectory analysis, GROMACS [23], more specifically g_cluster command, was used 
.For each system, a conformational cluster analysis using gromos algorithm was carried out using a 
cut-off of 0.2 nm. Using a threshold, the algorithm finds the neighbouring structure and forms 
clusters with the structure with the largest number of neighbours. The cluster is removed from the 
frames and the process repeated for the remaining frames. Each of the cluster centroids is used as 
a representative structure. Change in binding affinity or stability toward PPP1CC2 caused by 
mutations to alanine or residues within the RVxF motif were calculated using the Residue Scanning 
functionality in BioLuminate [22] which incorporates the Prime MM-GBSA approach [24]. 
The PDB format file of rat PPP1CC complexed with mouse PPP1R2 (ref:2O8A) [12] freely available 
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at protein data bank [25] was modified in MacPymolEdu software to create Figure B1.5. 
 
B1.3.10. Biostatistics analysis 
In vitro effect of the CPP: To characterize the sample statistical measures, line graphs and bars 
graphs were used. For each condition (11 conditions), a Pos Hoc analysis of the Friedman test to 
detect differences over time (pairwise comparisons) was performed. For each time (0 m, 5 m, 15 
m, 20 m, 25 m and 30 m), the Kruskall Wallis test was used to detect differences between the 
conditions (independent groups). Finally, a pairwise comparisons of conditions test was applied to 
identify between differences (Mann-Whitney U test).  
CPPs impact on sperm motility: To summarize the information contained in the sample a descriptive 
analysis was performed (central tendency, dispersion measures and bar graph). To decide between 
parametric or non-parametric methods, a Shapiro-Will test analyzed the existence of outliers. 
Finally, the differences between the means of two independent groups were tested. In the 
parametric case, after the Levene’s test for equality of variances, the Student’s T test was 
performed to assess for equality of means. 
For all tests, the significance level was set at 0.05. Statistical analysis was conducted using IBM SPSS 
Statistics Software 22.
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B1.4. Results 
A bioportide was synthesized by coupling a peptide with the potential of disrupting the 
PPP1/PPP1R2 complex was with a CPPs, with the goal of translocating to sperm cells and affecting 
their motility. The peptide sequence mimics the PPP1 binding motif of human PPP1R2 (44KSQKW48), 
which is conserved among bovine, mouse and rat. A bioportide presenting a scrambled PPP1R2 
RVxF motif (QWKKS) was used as a control in all experiments.  
 
B1.4.1. Bioportides can disrupt PPP1/PPP1R2 complex in vitro 
To assess the disruptive capacity of the bioportides, PPP1 activity was evaluated in the presence of 
the BP--PPP1R2 RVxF and BP--PPP1R2 RVxF SC. The results show that PPP1R2 inhibited PPP1CC2 in 
a concentration dependent manner [increasing amounts of PPP1R2 led to higher PPP1CC2 
inhibition (Supplementary Figure B1.1)]. After 15 min and until 30 min, PPP1R2 inhibited 
significantly around 50% of PPP1CC2 activity (ratio of 1:200) (Figure B1.1 A and D). Upon adding BP-
PPP1R2 RVxF (1:200:0.5), PPP1CC2 activity is restored to original values starting at 15 min (Figure 
B1.1 B and D) showing that the bioportide that mimics the RVxF PPP1R2 motif was able to disrupt, 
in vitro, the PPP1CC2/PPP1R2 complex. Also, when BP-PPP1R2 RVxF SC was added, PPP1CC2 activity 
was also restored (time point 25 min and 30 min) (Figure B1.1 C and D). PPP1R2 alone does not 
present any phosphatase activity (Supplementary Figure B1.1). Descriptive and statistical analysis 
can be consulted in Supplementary Table B1.1 and Supplementary Table B1.2, respectively. 
 
B1.4.2. Bioportides translocate into human and bovine spermatozoa 
Fluorescent cell imaging analysis revealed that fluorescently labeled BP-PPP1R2 RVxF and BP-
PPP1R2 RVxF SC (10 M) were able to translocate and accumulate in human and bovine sperm 
(Figure B1.2 A and B). In human and bovine sperm, both CPPs accumulated preferentially at the 
midpiece (* in Figure B1.2 A and B) and, occasionally, in sperm´s head (+ in Figure B1.2 A and B) and 
along the length of the flagellum. Quantitative uptake comparisons demonstrated that BP-PPP1R2 
presented a higher cellular uptake, when compared with BP-PPP1R2 RVxF SC (human 2.9 times; 
bovine 10.7 times) (Figure B1.2 C). In contrast, bioportides accumulation was similar between 
species. Higher concentrations were also analyzed (20 M and 50 M) and the pattern of 
bioportides distribution was similar (data not showed). 
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Figure B1.1. Effect of bioportides on PPP1 activity. Effect of BP-PPP1R2 RVxF SC and BP-PPP1R2 RVxF SC on PPP1 
activity during 30min A. PPP1CC2 and PPP1R2/PPP1CC2 (1:200) phosphatase activity. B. PPP1CC2 and 
PPP1R2/PPP1CC2/BP-PPP1R2 RVxF (1:200:0.5) phosphatase activity. C. PPP1CC2 and PPP1R2/PPP1CC2/BP-PPP1R2 
RVxF SC (1:200:0.5) phosphatase activity. D. Comparison of phosphatase activity mean of PPP1CC2; PPP1R2/PPP1CC2 
(1:200); PPP1R2/PPP1CC2/BP-PPP1R2 RVxF and PPP1R2/PPP1CC2/BP-PPP1R2 RVxF SC (1:200:0.5). Data is expressed 
as arbitrary units of phosphatase activity (minus negative control). Graph bars and lines represent the mean values 
of 4 replicas. Error bars represent the SEM (standard error of the mean). Statistically significant findings are indicated 
with a (*). * P<0.05. 
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B1.4.3. Bioportides decrease sperm motility  
Bovine sperm were exposed to a range of bioportides concentration (20, 50 and 100 M) and 
motility parameters were evaluated at 1 h and 2 h. Negative controls were performed in the 
absence of bioportides. Sperm viability was evaluated after bioportides exposure (100 M, 1 and 2 
h) and no significant changes were observed for both bioportides (Supplementary Figure B1.2).  
To assess the effect of the bioportides on sperm physiology, bovine sperm were exposed to 20 M, 
50 M and 100 M of both peptides. Exposure of bovine sperm to 20 and 50 M of both bioportides 
did not induce any significant alterations in the motility parameters (data not shown). Yet, exposure 
of bovine sperm to 100 μM BP-PPP1R2 RVxF reduced significantly the percentage of progressive 
fast motile sperm at 1 h and 2 h (mean decrease of 36.3%, p=0.007 for 1 h and 47.6% p=0.001 for 
2 h) compared with the negative control (Figure B1.3 A). In contrast, the percentage of immotile 
sperm increased significantly at 1 h and 2 h (mean increase of 45.5%, p=0.015 and 49.2%, p=0.007) 
(Figure B1.3 B). BP-PPP1R2 RVxF SC also significantly decreased the percentage of progressive fast 
motile sperm at 1 h and 2 h compared with the negative control (mean decrease of 53.2%, p=0.000 
and 49.6%, p=0.000) (Figure B1.3 A) and increased the percentage of immotile sperm (mean 
increase of 73.2%, p=0.000 and 55.7%, p=0.002) (Figure B1.3 B) at both time points tested. No 
significant alterations were observed in slow progressive motility and non-progressive motility 
(Figure B1.3 C and D). Descriptive and statistical analysis can be consulted in Supplementary Table 
B1.3 and Supplementary Table B1.4, respectively. 
Figure B1.2. Bioportides translocation into bovine and human spermatozoa (previous page). BP-PPP1R2 RVxF and 
BP-PPP1R2 RVxF SC were synthesized and complexed TAMRA to assess the delivery of the bioportides. A. Bovine 
spermatozoa. bioportides accumulation in midpiece (*), head of spermatozoa (+) and occasionally along the 
flagellum. B. Human spermatozoa. Both bioportides also accumulate in midpiece (*) and occasionally in the head (+) 
and along the flagellum. Scale bar in is 10 m. Bovine spermatozoa were acquired at 150 ms and human spermatozoa 
were acquired at 50 ms. C. Quantification of CPP translocation into bovine and human spermatozoa. Graph bars 
represent the mean values of four independent replicas. Error bars represent the SEM (standard error of the mean). 
B1. Sperm motility modulation using a bioportide based on PPP1/PPP1R2 interaction interface  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B1.4.4. PPP1R2 RVxF and PPP1R2 RVxF scrambled have different stabilities and affinities 
towards PPP1 RVxF pocket 
Molecular dynamics simulations were performed with the peptide sequence, which comprised the 
PPP1R2 RVxF binding motif and 7 aminoacids flanking at N- and C-termini. Figure B1.4 A shows that 
the RVxF binding motif forms a rigid secondary structure, an -helix, while the remaining sequence 
showed no secondary structure. In the case of PPP1R2 RVxF SC binding motif peptide, the most 
frequent cluster presented a pronounced -helix at the N- term and a tendency to form a -helix 
at the C-term. The middle region, comprising the scrambled RVxF binding motif, showed no evident 
secondary structure with an apparently higher flexibility (Figure B1.4 B).  
Figure B1.3. Impact of the bioportides in bovine spermatozoa motility parameter. A. Impact of bioportides (100µM) 
on the percentage fast progressive motility, B. on the percentage immotile spermatozoa, C. on the percentage slow 
progressive motility, D.  on the percentage of non-progressive spermatozoa. Graph bars represent the mean values 
of three independent experiments performed in triplicate. Error bars +/- SE (standard error). Statistically significant 
findings are indicated with a (*). * P<0.05; ** P<0.01.  
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Next, aminoacid substitution studies using previous crystallography studies (PDB code 2O8G) 
revealed that the peptide with RVxF scrambled may bind more stably and with more affinity with 
the core region of the PPP1 RVxF pocket. The substitution of lysine to a glutamine in the first 
aminoacid of RVxF motif appears to provide more stability to the peptide (Table B1.2) while the 
change in the second aminoacid from a serine to a tryptophan confers more affinity to the PPP1 
RVxF pocket (Table B1.2). 
 
Table B1.2. Aminoacids substitution studies of RVxF motif. The substitutions studies were performed using previous 
experimental data no PPP1/PPP1R2 interaction. The more negative the  affinity and  stability (kcal/mol), the stronger 
the affinity and stability, respectively*. In the scrambled peptide, the lysine present at position 47 was not changed. In 
the substitutions studies this lysine was changed for an alanine. 
PPP1R2 Residue RVxF Original RVxF scrambled   Affinity  Stability
44 LYS GLN 3.59 -6.89 
45 SER TRP -4.33 3.16 
46 GLN LYS 6.54 9.27 
47 LYS ALA* 7.34 -3.84 
48 TRP SER 25.3 0.91 
  
Figure B1.4. Molecular dynamics of PPP1R2 RVxF and PPP1R2 RVxF SC peptide. A. RVxF and the 7 flanking 
aminoacids of the BP-PPP1R2 RVxF bioportide. B. Scrambled RVxF and the 7 flanking aminoacids of the BP-PPP1R2 
RVxF SC bioportide. Note that the number of the aminoacids correspond to their position within the peptide not 
within PPP1R2.  Green: N-terminus; Orange: C-terminus; Blue: RVxF aminoacids side chains.  
A B
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B1.5. Discussion 
PPP1 has a broad activity spectrum, but is restrained in vivo by numerous PPP1 interacting proteins 
(PIPs) [26]. One of the major set-backs for the design of selective inhibitors for PPP1 lies in the 
similarity of the catalytic pocket between PPP1 and other serine/threonine phosphatases [27]. Even 
more challenging is to selective inhibit PPP1 isoforms activity, since the catalytic pocket of all PPP1 
isoforms is identical. A promising approach for development of PPP1 selective inhibitors is targeting 
specific interfaces between PPP1 and PIPs. Around 90% of all PIPs present a PPP1 binding motif, the 
RVxF [28]. In 1997, Egloff and colleagues, used a short peptide based on p53BP2, a PIP, to disrupt 
PPP1/PPP1R2 interaction in vitro [28] and more recently Chatterjee and colleagues proved that a 
peptide based on NIPP1 RVxF can, in vivo, release PPP1 from PPP1R2 (among other interactors) and 
restore PPP1 activity. This resulted in enhanced histone H3 dephosphorylation that leaded to loss 
of centromeric dynamic [27]. 
Targeting intracellular protein-protein interactions is dependent on delivering protein-protein 
interactions disruptor drugs to the intracellular environment. Cell penetrating peptides (CPPs) can 
be employed to carry various cargo molecules across the highly impermeable cellular lipid bilayer. 
CPPs are short peptides sequences (typically less than 40 aminoacids) that are rapidly translocated 
into mammalian cells [15]. In 2015, Jones and colleagues proved that CPPs enter mammalian 
spermatozoa at different rates depending on the CPP [16]. Coupling CPPs with a biological active 
peptide originates a bioportide [29,30]. With the purpose of disrupting the interaction between 
PPP1CC2 and PPP1R2 in human sperm, we designed a disruptive bioportide that mimics the PPP1R2 
RVxF and the flanking 7 aminoacids coupled with a CPP (C105Y). The C105Y peptide was used in this 
study, since it has an enhanced and quick translation efficacy into bovine sperm [16]. Two 
bioportides were synthesized: the BP-PPP1R2 RVxF which is expected to be biological active and 
the BP-PPP1R2 RVxF SC which should be biological inactive (scrambled RVxF) (Table B1.1) 
In vitro studies proved that BP-PPP1R2 RVxF disrupted PPP1CC2/PPP1R2 interaction restoring 
PPP1CC2 activity (Figure B1.1). Also, the fact that half the amount of BP-PPP1R2 RVxF released 
PPP1CC2 from PPP1R2 inhibition suggests that the peptide can have a high affinity towards 
PPP1CC2 RVxF pocket. These results indicate that of BP-PPP1R2 RVxF competitively binds to PPP1, 
displacing PPP1R2 and thereby increasing PPP1CC2 enzymatic activity. Surprisingly, the BP-PPP1R2 
RVxF SC also restored PPP1CC2 activity, upon incubation with PPP1CC2/PPP1R2 (Figure B1.1). BP-
PPP1R2 RVxF SC was designed by scrabbling the RVxF motif (QWKKS instead of KSQKW) with the 
goal of not interfering with PPP1CC2/PPP1R2 interaction and keep the peptide chemical features 
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(Table B1.1). Computationally studies revealed that the peptide sequence alterations that 
characterizes the BP-PPP1R2 RVxF SC may resulted in higher stability and affinity of the bioportide 
towards the PPP1 RVxF pocket and consequently explain the observed biological effect of BP-
PPP1R2 RVxF SC (Figure B1.4 and Table B1.4). Nevertheless, docking studies of PPP1/bioportides 
are pivotal to understand these preliminary results as well to determine optimal peptide sequence 
to achieve higher affinity towards the PPP1 RVxF pocket, translocation across the plasma 
membrane and stability within sperm cells. 
Translocation and intracellular accumulation of BP-PPP1R2 RVxF and BP-PPP1R2 RVxF SC were 
verified by qualitative and quantitative fluorescence detection. Subcellular localization of the 
bioportides was similar in bovine (Figure B1.2 A) and human (Figure B1.2 B) sperm and not 
attributed to surface-associated bioportides. Bioportides accumulated preferentially at the 
midpiece and posterior head, analogous to previously described for C105Y [16] (Figure B1.2. A and 
B). BP-PPP1R2 RVxF presented a higher sperm intracellular accumulation (either bovine or human) 
when compared with BP-PPP1R2 RVxF SC (Figure B1.2 C). This may result from different rates of 
translocation, intracellular stability and/or metabolic cleavage of the bioportides in sperm, as 
described in other studies [31,32]. Further studies using a range of CPPs concentration must be 
performed in order determine the external concentrations necessary to achieve a similar 
intracellular uptake and accumulation.  
The effect of the bioportides on bovine sperm motility was evaluated. Both BP-PPP1R2 RVxF and 
BP-PPP1R2 RVxF SC induced significant alterations in motility parameters without altering cell 
viability. We demonstrated that the BP-PPP1R2 RVxF decreased significantly the percentage of fast 
motile sperm and increased significantly the percentage of immotile sperm (Figure B1.3). Our in 
vitro studies, support the idea that BP-PPP1R2 RVxF, which mimics the PPP1R2 RVxF, competed 
with PPP1R2 for PPP1CC2 and prevented PPP1CC2/PPP1R2 interaction (Figure B1.1). Since it is not 
expected that the CPP interferes with PPP1CC2 catalytic center, in contrary to PPP1R2, PPP1CC2 
becomes active and capable of dephosphorylate key proteins involved in sperm motility (Figure 
B1.5). 
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Consequently, sperm becomes immotile. Similarly to our work, earlier studies targeted PPP1 
interactions successfully. Salubrinal, a small molecule that blocks PPP1/GADD34 interaction 
prevents eIF2α dephosphorylation by PPP1 [33]. Trichostatin A disrupts the interactions between 
PPP1 and HDAC6 in glioblastoma and prostate cancer cells [34]. Nevertheless, since RVxF mediated 
PPP1 interactions are common to most PIPs, the bioportides used in this study may be interfering 
with most PPP1 sperm interactions. Further studies are required to determine the impact of BP-
PPP1R2 RVxF and BP-PPP1R2 RVxF SC in human sperm motility, in PPP1CC2 sperm interactome and 
phosphorylation levels of sperm proteins. Moreover, identify specific PPP1CC2 interactors that are 
expressed uniquely in testis/sperm would be perfect for pharmacologic intervention and overcome 
the issue of ubiquitous expressed PPP1 regulators, such as PPP1R2. In 2017, Silva et al proved that 
disruption of PPP1CC2/AKAP4 interface may be a potential sperm specific pharmacological target 
[35].  
Although in somatic cells the role of PPP1/PPP1R2 complex is well explored, in sperm cells, the role 
of PPP1/PPP1R2 complex is still unclear. Yet, it has been suggested that the PPP1/PPP1R2 is 
essential for regulation of sperm motility [10]. PPP1CC2 activity is inversely associated to human 
sperm motility in human epididymis [5]. In human sperm, it is hypothesized that in caput epididymis 
PPP1CC2 is active due to PPP1R2 inability to interact with PPP1CC2. This results from GSK3 
phosphorylation on threonine 73 of PPP1R2 rendering it unable to interact with PPP1CC2 [36]. 
Throughout epididymis transit, GSK3 activity decreases, resulting in decreased PPP1R2 
phosphorylation. Consequently, PPP1R2 blocks the catalytic center of PPP1CC2 rendering it inactive 
and leading to sperm motility [5,12]. PPP1CC2 inhibition is required for sperm motility and PPP1R2 
Figure B1.5. Schematic representation of the structure of PPP1CC complexed with PPP1R2. PPP1R2 interacts with 
PPP1CC in three regions (orange). The PPP1R2 sequence used in the BP-PPP1R2 RVxF is represented as part of PPP1R2
(green). Unlike PPP1R2, the bioportide BP-PPP1R2 RVxF is expected to only cover the PPP1 RVxF pocket and not 
interfere with PPP1 catalytic center (light blue). Please note that PPP1R2 presents a second RVxF motif (wheat) that 
sites on top of the catalytic center. Light blue: PPP1 catalytic center; Dark blue: PPP1 RVxF pocket; Orange: PPP1R2; 
Wheat: second PPP1 RVxF; Green: PPP1R2 RVxF and flanking aminoacids used on the bioportide BP-PPP1R2 RVxF.  
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is necessary for PPP1CC2 activity inhibition, it is reasonable to assume that loss of PPP1CC2/PPP1R2 
interaction due to the competitive bioportide is associated with immotile sperm. Further studies 
are needed to determine the alterations of PPP1 activity in human sperm upon exposure to 
competitive BP-PPP1R2 RVxF. Additionally, competitive assays will be used to conclusively 
determine that the effect of the BP-PPP1R2 RVxF is due to PPP1CC2/PPP1R2 interaction 
interference.  
Although we observe a decreased sperm motility upon exposure to disruptive peptide, motility is 
not completely abolished (around 18% of sperm still present a fast-progressive motility) (Figure 
B1.3). To completely abolish sperm motility, we believe that instead of targeting one 
PPP1CC2/PPP1R2 interface, a multi interface targeting approach must be undertaken. This will 
increase the percentage of immotile human sperm and decrease the amount of peptide necessary 
to achieve complete immotile sperm. In conclusion, we significantly reduced sperm motility by 
using disruptive bioportides that target PPP1/PIPs interaction interface instead of interfering with 
PPP1 itself. 
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B1.7. Supplementary Material 
B1.7.1. Tables 
Supplementary Table B1.1. Descriptive and statistical measures of the effect of bioportide in PPP1 activity. Mean and 
standard deviation (SD) associated with BP-PPP1R2 RVxF and BP-PPP1R2 RVxF SC peptides in PPP1 activity. 
Condition 0min 5min 10min 15min 20min 25min 30min 
PPP1CC2 
Mean 0.058 0.093 0.127 0.189 0.252 0.298 0.348 
Std. 
Deviation 
0.069 0.076 0.107 0.148 0.186 0.194 0.209 
PPP1R2 and 
PPP1CC2 
(1:200) 
Mean 0.074 0.111 0.079 0.087 0.118 0.155 0.184 
Std. 
Deviation 
0.064 0.111 0.069 0.023 0.030 0.040 0.051 
PPP1R2 and 
PPP1CC2 and 
BP-PPP1R2 
RVxF 
(1:200:0.5) 
Mean 0.072 0.131 0.130 0.188 0.256 0.328 0.392 
Std. 
Deviation 
0.053 0.068 0.072 0.071 0.077 0.085 0.093 
PPP1R2 and 
PPP1CC2 and 
BP-PPP1R2 
RVxF SC 
(1:200:0.5) 
Mean 0.074 0.116 0.113 0.166 0.222 0.284 0.342 
Std. 
Deviation 
0.048 0.063 0.056 0.063 0.071 0.076 0.081 
 
Supplementary Table B1.2. Inferential statistics of the effect of bioportide in PPP1 activity. Mann-Whitney U test 
(grouping variable: condition; exact sig. (2-tailed)) was performed to evaluate the diference between means of two 
idependet grupos associated with BP-PPP1R2 RVxF and BP-PPP1R2 RVxF SC peptides in PPP1 activity 
0m 
PPP1R2 and PPP1CC2 
(1:200) 
PPP1R2 and PPP1CC2 and 
BP-PPP1R2 RVxF 
(1:200:0.5) 
PPP1R2 and PPP1CC2 and 
BP-PPP1R2 RVxF SC 
(1:200:0.5) 
PPP1CC2 0.384 0,772 0.554 
PPP1R2 and PPP1CC2 (1:200) - 0.456 0.101 
PPP1R2 and PPP1CC2 and 
BP-PPP1R2 RVxF (1:200:0.5) 
- - 0.765 
5m 
PPP1R2 and PPP1CC2 
(1:200) 
PPP1R2 and PPP1CC2 and 
BP-PPP1R2 RVxF 
(1:200:0.5) 
PPP1R2 and PPP1CC2 and 
BP-PPP1R2 RVxF SC 
(1:200:0.5) 
PPP1CC2 0.712 0.890 0.890 
PPP1R2 and PPP1CC2 (1:200) - 0.546 0.067 
PPP1R2 and PPP1CC2 and 
BP-PPP1R2 RVxF (1:200:0.5) 
- - 0.109 
10m 
PPP1R2 and PPP1CC2 
(1:200) 
PPP1R2 and PPP1CC2 and 
BP-PPP1R2 RVxF 
(1:200:0.5) 
PPP1R2 and PPP1CC2 and 
BP-PPP1R2 RVxF SC 
(1:200:0.5) 
PPP1CC2 0.234 0.234 0.345 
PPP1R2 and PPP1CC2 (1:200) - 1.00 0.345 
PPP1R2 and PPP1CC2 and 
BP-PPP1R2 RVxF (1:200:0.5) 
- - 0.091 
15m 
PPP1R2 and PPP1CC2 
(1:200) 
PPP1R2 and PPP1CC2 and 
BP-PPP1R2 RVxF 
(1:200:0.5) 
PPP1R2 and PPP1CC2 and 
BP-PPP1R2 RVxF SC 
(1:200:0.5) 
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PPP1CC2 0.234 1.00 1.00 
PPP1R2 and PPP1CC2 (1:200) - 0.029 0.901 
PPP1R2 and PPP1CC2 and 
BP-PPP1R2 RVxF (1:200:0.5) 
- - 0.234 
20m 
PPP1R2 and PPP1CC2 
(1:200) 
PPP1R2 and PPP1CC2 and 
BP-PPP1R2 RVxF 
(1:200:0.5) 
PPP1R2 and PPP1CC2 and 
BP-PPP1R2 RVxF SC 
(1:200:0.5) 
PPP1CC2 0.234 1.00 0.990 
PPP1R2 and PPP1CC2 (1:200) - 0.029 0.101 
PPP1R2 and PPP1CC2 and 
BP-PPP1R2 RVxF (1:200:0.5) 
- - 0.191 
25m 
PPP1R2 and PPP1CC2 
(1:200) 
PPP1R2 and PPP1CC2 and 
BP-PPP1R2 RVxF 
(1:200:0.5) 
PPP1R2 and PPP1CC2 and 
BP-PPP1R2 RVxF SC 
(1:200:0.5) 
PPP1CC2 0.234 1.00 0.125 
PPP1R2 and PPP1CC2 (1:200) - 0.029 0.029 
PPP1R2 and PPP1CC2 and 
BP-PPP1R2 RVxF (1:200:0.5) 
- - 0.121 
30m 
PPP1R2 and PPP1CC2 
(1:200) 
PPP1R2 and PPP1CC2 and 
BP-PPP1R2 RVxF 
(1:200:0.5) 
PPP1R2 and PPP1CC2 and 
BP-PPP1R2 RVxF SC 
(1:200:0.5) 
PPP1CC2 0.101 0.235 0.201 
PPP1R2 and PPP1CC2 (1:200) - 0.029 0.029 
PPP1R2 and PPP1CC2 and 
BP-PPP1R2 RVxF (1:200:0.5) 
- - 0.901 
 
Supplementary Table B1.3. Descriptive and statistical measures of the effect of bioportide in bovine sperm motility at 
1 and 2 hours of incubation. Mean and standard deviation (SD) associated with BP-PPP1R2 RVxF and BP-PPP1R2 RVxF 
SC effect on bovine sperm motility 
Time 1h 
Bioportide 
% Progressive 
Mobility Fast 
% Progressive 
Motility Slow 
% Non-Progressive 
Motility % Immotile 
NC Mean 40.23 7.28 17.70 33.64 
Std. Deviation 10.95 2.96 6.80 10.61 
BP-PPP1R2 
RVxF 
Mean 25.57 6.84 18.66 48.94 
Std. Deviation 8.88 2.21 4.53 13.09 
BP-PPP1R2 
RVxF SC 
Mean 18.76 5.42 18.30 58.19 
Std. Deviation 4.37 1.67 6.56 7.84 
Time 2h 
Bioportide 
% Progressive 
Mobility Fast 
% Progressive 
Motility Slow 
% Non-Progressive 
Motility % Immotile 
NC Mean 36.33 7.48 19.74 36.64 
Std. Deviation 10.97 3.54 2.83 12.59 
BP-PPP1R2 
RVxF 
Mean 19.04 5.13 18.97 54.58 
Std. Deviation 7.23 1.28 3.41 11.88 
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BP-PPP1R2 
RVxF SC 
Mean 18.31 6.13 18.58 56.98 
Std. Deviation 5.58 1.92 5.45 10.28 
 
Supplementary Table B1.4. Inferential statistics of the effect of bioportides on bovine sperm motility at 1 and 2 hours 
of incubation. T-tests of equality of means (grouping variable: condition; exact sig. (2-tailed)) was performed to evaluate 
the diference between means of two independent groups associated with BP-PPP1R2 RVxF and BP-PPP1R2 RVxF SC 
peptides in bovine sperm motility. Bold: statistically significant values at p< 0.05 
Condition Variable Sig (2-tailed) 
% of sperm on variable 
is higer in 
1h 
NC vs BP-PPP1R2 RVxF  
Progressive Mobility Fast 0.007 NC 
Progressive Motility Slow 0.730  
Non-Progressive Motility 0.730  
Immotile 0.015 BP-PPP1R2 RVxF SC 
2h 
NC vs BP-PPP1R2 RVxF  
Progressive Mobility Fast 0.001 NC 
Progressive Motility Slow 0.080  
Non-Progressive Motility 0.606  
Immotile 0.007 BP-PPP1R2 RVxF SC 
 
 
B1.7.2. Figures 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure B1.1. Effect of PPP1R2 on PPP1 activity. To evaluate the effect of on PPP1 activity, PPP1CC2 
was incubated with a range of PPP1R2 concentrations during 30min. A. PPP1CC2 and PPP1R2 phosphatase activity. 
B. PPP1CC2, PPP1R2/PPP1CC2 (1:20), PPP1R2/PPP1CC2 (1:200) and PPP1R2/PPP1CC2 (1:2000) phosphatase activity. 
Graph lines represent the mean values of 4 independent experiments. Error bars represent the SEM (standard error 
of the mean). 
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Supplementary Figure B1.2. Impact of bioportides on bovine spermatozoa viability. Graph bars represent the mean 
values of three independent experiments (at least 200 cells count per experiment). Error bars +/- 2 SE. 
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B2.1. Abstract 
The signaling protein glycogen synthase kinase 3 (GSK3) exists in two isoforms, GSK3 and GSK3. 
In male the male reproduction system, GSK3 is a prominent player on mammalian sperm motility 
signaling pathways. In mouse and bovine sperm, its activity is negatively correlated with motility. 
Moreover, it has been suggested an isoform-specific function of GSK3, since GSK3 KO mice are 
infertile due to reduced sperm motility and metabolism, while GSK3 KO present no fertility 
alterations. With the goal of investigate the role of GSK3 in human sperm, we determine expression 
and activity levels of both GSK3 isoforms in asthenozoospermic and normozoospermic human 
samples in both human testis and sperm. We showed that sperm human sperm motility appears to 
be associated specifically with GSK3 expression and activity. Since this isoform-specific function 
may arise from GSK3 interactors that pay central roles in sperm motility, we unravel the GSK3 
interactome in human testis and sperm. By constructing GSK3-centered motility network, we 
showed 26 GSK3 direct interactors involved in sperm motility annotations, and from those one 
highly expressed in testis/sperm, the PRSS37 (probable inactive serine protease 37). Moreover, 
GSK3 and its interactors appears to be highly associated with protein expression processes 
revealing other possible functions for this protein, in both testis and sperm. Finally, given the 
reported relevance of GSK3 PPIs in sperm motility, we hypothesized that they stand as potential 
targets for  
target for male contraceptive strategy based on sperm motility modulation. 
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B2.2. Introduction  
Glycogen synthase kinase 3 (GSK3), a serine/threonine kinase, has been involved in a wide range of 
cellular processes such as apoptosis, mitosis, and proliferation [1,2]. Moreover, deregulation of 
GSK3 functions has been associated with pathological conditions such as cancer, Alzheimer’s 
disease, and diabetes [3,4]. GSK3 is ubiquitously expressed and is encoded by two genes giving rise 
to two isoforms: GSK3 and GSK3. Both isoforms differ in their N-termini with GSK3 having a 
unique glycine-rich N-terminus which is highly conserved in mammals, suggesting an isoform-
specific function [5].  
GSK3 plays a central role in the male reproductive system. In mouse testis, GSK3 is expressed in 
the seminiferous tubules and its expression increases during the onset of spermatogenesis, peaking 
in adult testis [6]. GSK3 expression is present in cells entering meiosis, spermatids and Sertoli cells 
[7]. Curiously, with target disruption of the gene for GSK3, in testis spermatogenesis is normal, 
but mature sperm present a reduced motility and metabolism, rendering male mice infertile [6]. 
On the other hand, GSK3 testis-specific KO is fertile. In sperm, GSK3 activity is inversely 
proportional to motility; in immotile caput sperm, GSK3 activity is 6 times higher than that of motile 
caudal sperm. GSK3 activity is controlled by its phosphorylation state. When serine phosphorylated, 
GSK3 catalytic activity is low (GSK3 Ser9 and GSK3 Ser21) but when tyrosine phosphorylated, it 
is activated (GSK3 Tyr 279 and GSK3 Tyr 216) [8]. In bovine sperm, GSK3 is present in the 
posterior area of the head and along the entire flagellum [9,10]. In mouse sperm, GSK3 localizes to 
the peri-acrosomal area and tail [11]. 
Knowledge on GSK3 in human sperm is limited. The observation that mouse GSK3 cannot 
substitute for GSK3, it implies that GSK3 is essential for normal sperm physiology. We considered 
that the unique role of GSK3 in sperm motility is reliant on its interactors. With that in mind, we 
performed a GSK3 characterization, by determining its activity levels in asthenozoospermic and 
normozoospermic human samples, subcellular location on human sperm, and identifying the 
GSK3 and GSK3 interactomes in both human testis and sperm.  
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B2.3. Methods 
B2.3.1. Ethical approval 
This study was approved by the Ethics and Internal Review Board of the Hospital Infante D. Pedro 
E.P.E. (Aveiro, Portugal) ((Process number: 36/AO) and was conducted in accordance with the 
ethical standards of the Helsinki Declaration. All donors signed an informed consent forms allowing 
the samples to be used for scientific purposes.  
All procedures using mice used in the present study were performed at the Kent State University 
animal facility and were approved by the National Institute of Environmental Health Sciences 
institutional Animal Care and Use Committee (IACUC) and the Kent State Animal Ethics Committee 
under the IACUC protocol number 362DK 13-11. Immediately after CO2 euthanization, testis and 
epididymis of 3-4-month-old wild type and Gsk3a-/- CD1 mice (mus musculus) were removed.  
 
B2.3.2. Sperm extracts  
Human ejaculate semen samples were obtained from healthy donors by masturbation into a sterile 
container. Basic semen analysis was performed by qualified technicians according to World Health 
Organization (WHO) guidelines [12]. After semen liquefaction, sperm cells were washed three times 
in phosphate buffered saline (PBS, Fisher Scientific, Loures, Portugal) and centrifugation at 
600xG for 5min at 4°C. Mouse epididymis was punctured several times with a 26-G (45-mm) needle 
allowing the sperm to swim out (helped by squeezing with surgical scissors) into PBS1x. Sperm were 
also extruded from the vas deferens by squeezing it along its length. Afterwards, sperm 
concentration was determined by counting in a Neubauer hemocytometer (Fisher Scientific, Loures, 
Portugal). Finally, the sperm cells were washed three times in PBS1x followed by centrifugation at 
600xG, 5 min, 4°C.  
To obtain enriched human motile and immotile sperm fractions, sperm cells were separated 
according to their motility using the density gradient method (ORIGIO, Denmark) according to 
manufacturer instructions. Briefly, 1mL of 55% gradient medium was underlayed with 1mL of 80% 
gradient medium and pre-equilibrated at 5% CO2 at 37ºC. 1mL of homogenized sperm was dispense 
on top of the gradient and centrifuged at 300xG, 20min. Then, the supernatant was removed 
(immotile fraction) and transferred to a clean tube. The pellet was resuspended in 5mL of pre-
equilibrated sperm preparation medium (ORIGIO, Denmark), centrifuged at 300g, 10min and the 
supernatant was removed (the washing step was repeated once more). Sperm preparation medium 
B2. Identification and characterization of GSK3 human testis and spermatozoa interactome 
was added to the pellet then concentration and motility were assessed (motile fraction). The human 
albumin and sodium bicarbonate present in the sperm preparation medium are known inducers of 
sperm capacitation.  
 
B2.3.3. Western blot of human and mouse sperm and testis 
After washing, human sperm was lysed in either Tris buffer (20mM Tris-HCl, pH 7.4, 1mM EDTA, 
1mM EGTA) (Fisher Scientific, Loures, Portugal); 1xRIPA (0.05M Tris-HCl, pH 7.4, 0.150M NaCl, 
0.25% deoxycholic acid, 1% NP-40, 1mM EDTA) (Millipore Iberica, Madrid, Spain); 1xRIPA modified 
(0.05M Tris-HCl, pH 7.4, 0.150M NaCl, 0.25% deoxycholic acid, 2% NP-40, 1mM EDTA); or 1%SDS 
(Fisher Scientific, Loures, Portugal) during 30min on ice and centrifuged at 16,000xG, 15min, 4°C. 
The supernatant was recovered (soluble fraction). For mouse sperm, after washing, cells were 
normalized by sperm cell number and lysed in 1xRIPA and centrifuged at 16,000xG, 15min, 4°C. The 
supernatant was recovered (soluble fraction). Human testis protein extract was acquired from 
Takara, Enzifarma, Lisboa, Portugal (ref: 635309). Testis from wild-type mice were homogenized in 
1xRIPA and centrifuged at 16,000xG, 15min, 4°C. The supernatants were recovered (soluble 
fraction).  
Extracts were either mass normalized using BCA assay (ref: 23225, Pierce, Fisher Scientific, Loures, 
Portugal) or sperm cell number. After, sperm protein extracts were separated by SDS-PAGE and 
electrotransferred to a nitrocellulose membrane. Afterwards, the membrane was incubated with 
primary antibody. The following antibodies were used for western blot: mouse anti-GSK3/ 
(Invitrogen, Fisher Scientific, Loures, Portugal, ref: 44-610, 1:2000, 4ºC, ON); rabbit anti-GSK3 (Cell 
Signaling Technology, Danvers, MA, USA, ref: #9338, 1:1000, 4ºC; ON); rabbit anti-GSK3 (Cell 
Signaling ref: #9315, 1:1000, 4ºC; ON); mouse anti-GSK3 pS21 (Santa Cruz Technologies, 
Heidelberg, Germany, ref: sc-365483, 1:1000, 4ºC, ON), mouse anti-GSK3 pS9 (Santa Cruz 
Technologies ref: sc-373800, 1:1000, 4ºC, ON), rabbit anti-LRP6 (Cell Signaling, ref: #2560, 1:1000) 
and rabbit anti-AKAP11 (Invitrogen, ref: PA5-39868, 1:1000). Finally, the membrane was incubated 
with the appropriate infrared secondary antibodies (1:5000, Li-Cor Biosciences UK Ltd, Cambridge, 
UK). The images were obtained using Odyssey Infrared Imaging Bands System (Li-Cor Biosciences 
UK Ltd, Cambridge, UK). Bands were quantified with the Quantity One 1-D Analysis Software (Bio-
Rad, Amadora, Portugal). Phosphoserine GSK3 levels are calculated by determining the ratio 
between phosphoserine signal and total GSK3 signal. Data is expressed as mean ± SEM (standard 
error of the mean). Statistical analysis was conducted using IBM SPSS Statistics Software 22. A test 
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of normality (Shapiro- Wilk test) was performed to assess normality of samples and the Pearson 
correlation coefficient, r, was determined to assess the relationship between two variables. The 
significance level was set at p<0.05. 
 
 
B2.3.4. Immunocytochemistry of human sperm 
Washed sperm was spread onto a glass coverslip and dried at room temperature in a six well plate. 
Sperm cells were fixed in 4% formaldehyde (Fisher Scientific, Loures, Portugal) for 10 min. After, 
sperm was washed and permeabilized in 0.1% Tween (Fisher Scientific, Loures, Portugal) in 1% goat 
serum (Sigma-Aldrich Química, S.A., Sintra) and 5% BSA (NZYTech, Lisboa,Portugal) was added to 
the sperm and incubated for 20min. Blocking was performed with 1% goat serum and 5% BSA for 
1h30min and then incubated with primary antibodies: rabbit anti-GSK3 (Cell Signaling ref: #9338, 
1:50) and rabbit anti-GSK3 (Cell Signaling ref: #9315, 1:50) overnight at 4°C in a moisture 
environment; rabbit anti-LRP6 (Cell Signaling, ref: #2560, 1:50), rabbit anti-pLRP6 1490 (Cell 
Signaling, ref: #2568, 1:50) and rabbit anti-AKAP11 (Invitrogen, ref: PA5-39868, 1:100) for 1h20min 
in a moisture environment. The sperm cells were incubated with a fluorescently-labeled secondary 
antibody against rabbit (Alexa 594nm 1:800, Life Technologies S.A., Madrid, Spain) for 45min at 
room temperature. Coverslips were washed in PBSx1 + 0.1 Tween three times, followed by one 
wash step in PBS1x. Finally, Hoechst was added and coverslips were mounted with ProLong™ Gold 
Antifade Mountant (Invitrogen, ref: 10144). Negative controls (only secondary antibody) were 
processed in parallel. Fluorescence images were obtained using an Imager.Z1, Axio-Cam HRm 
camera and AxioVision software (Zeiss, Jena, Germany). 
 
B2.3.5. Yeast two-hybrid screen of human testis 
Homo Sapiens GSK3 cDNA (NM_019884.2) was subcloned using EcoRI and BamHI (New England 
Biolabs, Herts, UK) into pAS2-1, and Homo Sapiens GSK3 (NM_002093.3) was subcloned using 
NdeI and SalI (New England Biolabs, Herts, UK) into pAS2-1. Both vectors were sequenced to ensure 
that GSK3 and GSK3 were in frame with Gal-AD. The original vectors were a kind gift from Dr. 
Phiel. The pAS2-1-GSK3 and pAS2-1-GSK3 vectors were transformed into AH109 yeast strain by 
a standard lithium acetate method (Clontech, Takara, Enzifarma, Lisboa, Portugal). GSK3 and 
GSK3 are not cytotoxic to AH109 yeast cells. Expression of GSK3 and GSK3 was confirmed and 
both proteins did not activate per se the reporter genes (Supplementary Figure 1). For library 
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screening, the yeast strain AH109 transformed with either pAS2-1-GSK3 or pAS2-1-GSK3 was 
mated with yeast strain Y187 expressing human testis cDNA library in pGADT7-Rec (Mate&Plate 
Library – Human testis ref. 630470, Clontech, Takara, Enzifarma, Lisboa, Portugal) according to 
manufacture instructions. Half of the mating mixture was plated onto high-stringency medium 
(Quadruple dropout medium: SD/-Ade/-His/-Leu/-Trp) and the other half onto low-stringency 
medium (Triple dropout medium: SD/-His/-Leu/-Trp) and the plates were incubated at 30ºC. 
Colonies obtained in the low stringency plates were replica plated onto medium with X--Gal and 
incubated at 30ºC to check for MEL-1 expression (blue color colonies). Positive clones were 
numbered and kept in culture until identification.  
 
B2.3.6. Identification of yeast two-hybrid positive clones 
Yeast plasmid DNA (pGADT7-Rec) containing the cDNA of the positive clones was analyzed using 
the Matchmaker Insert Check PCR mix 2 (Clontech, Takara, Enzifarma, Lisboa, Portugal, ref:630497) 
and DNA sequence analysis was performed using a specific primer for pGADT7-Rec. The DNA 
sequences obtained were compared to the GeneBank database to identify the corresponding 
protein. Moreover, every DNA sequence was check if it was in frame with SV40-AD CDS.  
 
B2.3.7. Yeast co-transformation 
AH109 yeast cells transformed with either LRP6, AKAP11, PTMA or LRRC37A2 in pGADT7-Rec 
(recovered from the human cDNA testis library) or co-transformed with pAS2-1-GSK3 or pAS2-1-
GSK3 and LRP6, AKAP11, PTMA or LRRC37A2 in pGADT7-Rec using a standard lithium acetate 
method (Clontech, Takara, Enzifarma, Lisboa, Portugal) to reconfirm the interaction. Co-
transformation of pAS2-1 and pGADT7-Rec was used as a negative control and co-transformation 
of pAS2-1-p53 and pACT2-SV40 was used as positive control. The co-transformation were plated in 
either quadruple dropout medium or triple dropout medium.  
 
B2.3.8. Co-immunoprecipitation of GSK3 interactors from human sperm 
After washing, 50x106 sperm cells were lysed in 1xRIPA (Millipore Iberica, Madrid, Spain) 
supplemented with 1mM of Phenylmethylsulfonyl fluoride (PMSF) (Fisher Scientific, Loures, 
Portugal) and 0.2mM of sodium orthovanadate (Na3VO4) (Fisher Scientific, Loures, Portugal) for 
60min on ice and centrifuged at 16.000xG, 4°C, 15min. Sperm extracts were pre-cleared using 
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Dynabeads Protein G (ref: 10003D, Invitrogen, Fisher Scientific, Loures, Portugal) and incubated 
with either rabbit anti-GSK3 (Cell Signaling ref: #9338, 1:50), rabbit anti-GSK3 (Cell Signaling ref: 
#9315, 1:50) or rabbit anti-IgG (ref: sc-2027, Santa Cruz Biotechnology) at 4ºC ON with rotation. 
After incubation, 50µL of Dynabeads Protein G were added and incubated for 2h. After washing 
three times with PBS1x at 4°C, 10min with rotation. The beads were resuspended in 50mM glycine 
(Fisher Scientific, Loures, Portugal) for 5min. Finally, the supernatant was recovered and 1%SDS was 
added to the dynabeads, incubated 5min, boiled and recovered.  
Alternatively, rabbit anti-GSK3 (Cell Signaling ref: #9338, 1:50) or rabbit anti-GSK3 (Cell Signaling 
ref: #9315, 1:50) were crosslinked using BS3 (bis(sulfosuccinimidyl)suberate) (Invitrogen, Fisher 
Scientific, Loures, Portugal ref: 21580) to Dynabeads Protein G, according to manufacturer 
instructions. After, sperm extracts were pre-cleared using Dynabeads Protein G, they were 
incubated with crosslinked beads for 1h. After washing the beads were resuspended in trypsin 
digestion buffer (20 mM Tris-HCl pH 8.0, 2 mM CaCl2) and stored at -20ºC. One quarter of the 
Dynabeads were eluted in 1%SDS (for western blot). 
For both protocols, western blot was performed using a mouse anti-GSK3/ (Invitrogen, ref: 44-
610, 1:2000), ON, 4ºC, with shaking and the corresponding secondary antibodies, 1h RT (1:5000, Li-
Cor Biosciences UK Ltd, Cambridge, UK). The images were obtained using Odyssey Infrared Imaging 
System.  
 
B2.3.9. Mass spectrometry 
Mass spectrometry studies of GSK3 human sperm interactors were performed in two facilities. 
The Lerner Research Institute's Proteomics and Metabolomics Laboratory: The LC-MS system was 
a Dionex Ultimate 3000 nano-flow HPLC interfacing with a Finnigan Orbitrap LTQ Elite hybrid ion 
trap mass spectrometer system. The HPLC system used an Acclaim PepMap 100 precolum (75 μm 
x 2 cm, C18, 3 μm, 100 A) followed by an Acclaim PepMap RSLC analytical column (75 μm x 15 cm, 
C18, 2 μm, 100 A). The data was analyzed by using all CID spectra collected in the experiment to 
search the human UniProtKB protein database with the search programs Sequest and Mascot. Only 
results with mascot score p<0.05 and at least two identifying peptides with mascot ion scores of at 
least 40 were considered. Specifically, GSK3 and GSK3 sequences searches were performed in 
Sequest program.  
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VIB Proteomics Core Facility: The LC-MS/MS system was Ultimate 3000 RSLCnano system (Thermo) 
in-line connected to a Q Exactive mass spectrometer (Thermo, Fisher Scientific, Loures, Portugal).  
Peptides were loaded on a reverse-phase column (made in-house, 75 µm I.D. x 20 mm, 3 µm beads 
C18 Reprosil-Pur, Dr. Maisch). Each sample was injected 3 times and analyzed in triplicate. Data 
analysis was performed with MaxQuant (version 1.5.6.5) [13] using the Andromeda search engine 
with default search settings including a false discovery rate set at 1% on both the peptide and 
protein level. Spectra were searched against the human proteins in the UniProt/Swiss-Prot 
database (database release version of January 2017 containing 20,172 human protein sequences). 
Only proteins with at least one unique or razor peptide were retained. Proteins were quantified by 
the MaxLFQ algorithm integrated in the MaxQuant software [14]. A minimum ratio count of two 
unique or razor peptides was required for quantification. Further data analysis was performed with 
the Perseus software (version 1.5.5.3) [15] after loading the protein groups file from MaxQuant. 
Proteins only identified by site, reverse database hits and contaminants were removed and 
technical replicate samples of GSK3, GSK3, and the negative control were grouped. Proteins with 
less than three valid values in at least one group were removed and missing values were imputed 
from a normal distribution around the detection limit. Then, t-tests were performed (FDR=0.0001 
and S0=5) to compare samples of GSK3 and GSK3 with the negative control. 
 
B2.3.10. In silico analysis of human GSK3 and GSK3 interactors: gene expression; 
phenotype; disease association and Gene Ontology. 
To characterize human GSK3 and GSK3 interactors, either UniProtKB or FASTA sequence was 
retrieved for all interactors and used for subsequent in silico analysis (only Homo sapiens 
information was considered). 
For presence of GSK3 consensus phosphorylation site (xxx[ST]xxx[ST]P) [16] in the identified 
interactors, the following bioinformatics tools were used: Eukaryotic Linear Motif (ELM) resource 
[17]; PhosphoSitePlus [18]; Kinase Net (http://www.kinasenet.ca); NetPhos 3.1 Server [19] ; 
ScanProsite [20] and GPS 3.0 [21]. Only data obtained with high threshold, high conservation scores 
and using the specific GSK3 phosphorylation site were used. Also, we only consider the presence of 
GSK3 phosphorylation site in the interactors if at least 3 of the tools supported this information. All 
tools were consulted in the April 2017. 
To determine if any of the GSK3 and GSK3 interactions identified were new interactions, GSK3 
and GSK3 interactomes were retrieved from IMEx-curated databases (DIP; DIP-IMEx; I2D-IMEx; 
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InnateDB-IMEx; MPIDB; MolCon; MatrixDB, MINT; MBinfo; Uniprot, IntAct; bhf-ucl) [22] and 
Human Integrated Protein-Protein Interaction rEference (HIPPIE) database [23]  and compared with 
the identified GSK3 interactome.  Only interactions for human GSK3 and GSK3 with human 
proteins were considered. The GSK3 interactome retrieved from the databases was used for further 
in silico analysis.  
Gene expression patterns (mRNA) for all interactors (whether identified in this study or obtained 
from databases) were retrieved from: The Human Protein Atlas [24]; Pattern Gene Database 
(PaGenBase) [25] Expression atlas EMBL-EBI (68 FANTOM5 project-adult; 32 Uhlen´s Lab and GTEx) 
[26]; BioGPS [27] and UniGene [28].  Specifically, for the Human Protein Atlas and PaGenBase, since 
these databases have subsets list, only mRNA expression patterns of already classified as testis-
enriched, testis-enhanced and group-enriched (that included testis) were retrieved. Also, only 
human gene expression patterns were considered. mRNA expression values for all databases 
(Transcripts per million or fragments per kilobase of exon model per million mapped reads) were 
retrieved and testis expression values were normalized by calculating the percentage of testis 
expression taking into account the expression of all tissues (Supplementary Table B2.1). Only 
interactors that presented more than 50% of expression in testis in at least 2 of the 5 databases 
used were considered highly expressed in testis. Furthermore, these interactors were classified in 
three categories: 50-75%, 75-90%, and >90%. Differently expressed proteins in asthenozoospermic 
samples were collected from peer reviewed papers and compared with GSK3 interactors [29–41]. 
Phenotypes associated with all interactors (genes) were retrieved form Mouse Genome Informatics 
(MGI) [42] and OMIM [43]. Manually curated genes associated with phenotypes of male infertility 
were retrieved from DisGeNet [44] and Phenopedia [45]. These genes were compared with GSK3 
interactome. Also, the DISEASE database was consulted, specifically the experimental data of 
disease-gene associations [46]. Only phenotypes or diseases related with sperm, testis, epididymis 
and spermatogenesis defects; general defects of the male productive system; infertility (including 
litter size) and ciliary defects were included. Altered accessory glands; genetic disorders, sexual 
behavior and tumor incidence were excluded. Phenotypes were categorized into 10 groups: Male 
infertility; Morphological male reproductive system defects; Germ cell line abnormalities; 
Spermatogenesis abnormalities; Male hormonal abnormalities; Inflammation of male reproductive 
system components; Asthenozoospermia and flagellum, cilium and mitochondrial abnormalities; 
Oligozoospermia and Teratozoospermia (Suplementary Table 2). Also, GSK3 and GSK3 
interactors annotated to testis and sperm physiology on GeneOntology enrichment tool (PANTHER 
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version 12.0, 25 August 2017) [47] were classified according to those annotations (Supplementary 
Table B2.2). All databases were consulted June, July, and August of 2017 
To determine the enrichment of GSK3 and GSK3 testis and sperm interactors, the Gene Ontology 
enrichment analysis was performed (PANTHER version 12.0, 25 August 2017) [47]. All genes 
annotated from Homo sapiens were used as reference list and the GO complete lists as annotation 
data set. Only results with p<0.05 were considered. Analysis tool was used on August 2017  
 
B2.3.11. Construction of GSK3 PPIs network 
GSK3 and GSK3 protein-protein interaction networks were built using Cytoscape v 3.4 [48].  Also, 
the inner connections between those proteins were captured. In order to construct sperm motility 
and testis GSK3 and GSK3 PPI networks, GSK3 and GSK3 interactors associated with motility 
annotations and phenotypes and testis annotations and phenotypes were extracted from GSK3 
and GSK3 interactome network.  
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B2.4. Results 
B2.4.1. GSK3 is present in human testis and sperm and its activity is differently correlated with 
ejaculated and capacitated spermatozoa motility 
First, we evaluated the expression and activation of both GSK3 isoforms in human testis and 
ejaculated and capacitated human sperm.  
 
 
 
 
 
 
 
 
 
In order to demonstrates that both GSK3 and GSK3 are expressed in human testis and sperm, 
these proteins were immunodetected in human testis and sperm, similar to what was previously 
described in mouse and bovine (n=1). Moreover, human sperm, different strength recovered 
different amounts of both GSK3 isoforms (Supplementary Figure B2.2). The levels of inhibited 
GSK3 and GSK3 (serine phosphorylation) were assessed in human testis and sperm. In human 
testis, it appears that no serine phosphorylated GSK3 was detected, while in human sperm both 
phosphorylated GSK3 isoforms were detected (Figure B2.1 C).  
To assess if in human sperm GSK3 activity is correlated with sperm motility, serine phosphorylated 
GSK3 and GSK3 (low activity) were evaluated in ejaculated normospermic and 
asthenozoospermic samples. Total GSK3 and serine phosphorylated GSK3 levels were lower in 
asthenozoospermic samples compared to normospermic (Figure B2.2 A and B). Also, it appears that 
the higher the percentage of immotile sperm the lower are the levels of total GSK3 and 
Figure B2.1. GSK3 in human testis and sperm. Western blot analysis of GSK3 isoforms in human testis and sperm, 
mouse testis and HeLa cells. Human sperm, mouse testis and HeLa cells were homogenized in 1xRIPA. 30µg of protein 
were loaded per sample. A. GSK3⍺ and GSK3β were detected using an anti-GSK3/ antibody (Invitrogen, ref: 44-
610, 1:2000). B. GSK3⍺ was immunodetected using an anti-GSK3 antibody (Cell Signaling ref: #9338, 1:1000) and 
GSK3β was immunodetected using an anti-GSK3 antibody (Cell Signaling ref: #9315, 1:1000). Blots were cropped. 
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phosphorylated GSK3 (r= -0.910, p=0.012 and r= -0.872, p=0.023, respectively) (Figure B2.2 C and 
D and Supplementary Table B2.3). Therefore, these results suggest that in human sperm there is a 
strong negative correlation between the percentage of immotile sperm and the levels of total and 
phosphorylated (low activity) GSK3. Regarding GSK3, it seems that the expression of total and 
phosphorylated levels of GSK3 were similar in both normospermic and asthenozoospermic 
samples (Figure B2.2 A and B). It appears that there is no correlation between total GSK3 and 
sperm motility and between phosphorylated (low activity) GSK3 and the percentage of immotile 
sperm (Supplementary Table B2.3) (Figure B2.2 C and D).  
The correlation between motility and levels of total GSK3 and serine phosphorylated GSK3 (low 
activity) in capacitated sperm was also assessed. Ejaculated sperm was subjected to density 
gradients in capacitating conditions, and enriched motile and immotile fractions were recovered. 
Contrary to the situation in ejaculated sperm, total and phosphorylated GSK3 slightly increased in 
immotile sperm compared to the motile sperm, and the higher the percentage of immotile sperm 
the higher the levels of total GSK3 (Figure B2.2 E, F and G). Similarly to GSK3, there was also an 
increase in total and phosphorylated GSK3 in immotile compared to motile sperm. Here again, 
higher the percentage of immotile sperm higher were the levels of total and phosphorylated GSK3 
(low activity) (r= 0.848, p=0.033) (Figure B2.2 H and Supplementary Table B2.3).  
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B2.4.2. GSK3 and GSK3 have distinct spermatozoa subcellular localizations  
Given the importance of GSK3 in sperm motility and distinct expression patterns in normospermic 
and asthenozoospermic samples, the subcellular location of GSK3 and GSK3 in ejaculated human 
sperm was analyzed. Three normospermic human sperm samples were analyzed and around 300 
cells were assessed (total). Figure B2.3 shows that GSK3 was primarily located in the flagellum 
(100%) and 75.7% of sperm cells also showed immunoreactivity in the head. Curiously, 24.2% of the 
spermatozoa showed a strong immunoreactivity for GSK3 in the equatorial region, particularly at 
the edges. In contrast, GSK3 was mainly located in the sperm head (100%), 23.9% of sperm showed 
GSK3 distributed throughout the entire head and flagellum and in 76.0% of sperm it was present 
only sperm head (Figure B2.3).  
 
*
*
Bright Field Alexa 459 Hoechst 33258 Merge
N
e
g
a
ti
ve
 c
on
tr
o
l
G
S
K
3⍺
G
S
K
3β
ROI
*
*
Figure B2.2. Total and serine phosphorylated GSK3 levels in human sperm (previous page). A. Immunoblot of total 
and serine phosphorylated GSK3 isoforms in human normo and asthenozoospermic ejaculated sperm.  B. GSK3 
isoforms protein levels in human normo and asthenozoospermic ejaculated sperm (n=3). C. Correlation between 
percentage of immotile ejaculated sperm and protein levels of total and serine phosphorylated GSK3⍺. D. Correlation 
between percentage of immotile ejaculated sperm and protein levels of total and serine phosphorylated GSK3β. E. 
Immunoblot of total and serine phosphorylated GSK3 isoforms in motile and immotile capacitated sperm. F. GSK3 
isoforms protein levels in motile and immotile capacitated sperm (n=3). G. Correlation between percentage of 
immotile capacitated sperm and protein levels of total and serine phosphorylated GSK3⍺. D. Correlation between 
percentage of immotile capacitated sperm and protein levels of total and serine phosphorylated GSK3β. 
Phosphoserine GSK3 levels are calculated by determining the ratio between phosphoserine signal and total GSK3 
signal. Error bars represent ±SEM. r= Pearson correlation. * Correlation is significant at the 0.05 level (2-tailed). Blots 
were cropped. 
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B2.4.3. Thirty-five new interactors for GSK3 and fourteen new interactors for GSK3 were 
identified in human testis 
To identify novel GSK3 and GSK3 interactors relevant for fertility, yeast two-hybrid screens were 
performed using a human testis library and full-length Homo sapiens GSK3 and GSK3. For GSK3, 
93 positive clones were obtained from a total 2.64x107 screened clones. For GSK3, 54 positive 
clones were obtained from a total of 2.75x107 screened clones. Nucleotide sequencing of the 
positive clones, revealed forty-six putative interactors for GSK3 and twenty-one for GSK3 (Table 
B2.1 and Table B2.2). 
For GSK3, 76% were new putative interactors while 24% were previously described as GSK3 
interactors. From the latter, 45.5% were described as interacting with GSK3 in PPI databases 
(either exclusively or interaction for GSK3 was not tested) and 54.5% interacted with both GSK3 
isoforms. Moreover, 58.7% of GSK3 interactors identified contained the GSK3 consensus 
phosphorylation site (xxx[ST]xxx[ST]P). Finally, 34.8% of GSK3 interactors were already described 
to be present in either testis and/or sperm of mammals (Table B2.1). For GSK3, 77.8% were 
identified for the first time as GSK3 putative interactors, while 22.2% of the interactors were 
already described as GSK3 interactors in PPI databases, from which 50% interacted with GSK3 
(either exclusively or interaction for GSK3 was not tested) and the other half interacted with both 
GSK3 isoforms. Moreover, around 38% of the GSK3 identified interactors had the GSK3 consensus 
phosphorylation site and 61.1% were previously reported to be present in testis and/or sperm of 
mammals (Table B2.2). 
To validate the yeast two-hybrid approach and to confirm some of the interactions identified, yeast 
co-transformations were performed. GSK3 or GSK3 and AKAP11, LRC37A2, LRP6 and PTMA were 
co-transformed in yeast and plated on highly stringency medium. Also, AKAP11, LRRC37A2, LRP6 
and PTMA were transformed in yeast to check for auto-activation of the reporter genes. Figure B2.4 
shows that none of the interactors tested activated per se the transcription of the reporter genes.  
Regarding the interaction between AKAP11 and LRP6 with GSK3, although it was only identified as 
a GSK3 interactor, they also interacted with GSK3 (Figure B2.4). 
  
Figure B2.3. Subcelular localization of GSK3 and GSK3 in mature human sperm (previous page). GSK3 is located 
in the flagellum and head (arrowhead), more specifically in the equatorial region. GSK3 is located through the entire 
head (star) and occasionally in the flagellum. Scale bar is 5 µm. Nucleus is marked in blue. ROI: region of interest. All
images were obtained with 63X magnification in a Imager.Z1, Axio-Cam HRm camera and AxioVision software (Zeiss, 
Jena, Germany). 
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Table B2.1. GSK3 human testis interactors. Gene name, UniProtKB, nr of clones, GSK3 phosphorylation site, previously described GSK3 interactor, presence on mammal testis and sperm 
and alteration on asthenozoospermic samples of testis GSK3 interactors identified by yeast two-hybrid. 
GSK3 human testis interactors 
Gene Name UniProtKB Name 
Nr of 
clones  
GSK3 
phosphorylation 
site 
Previously known 
GSK3 interactor 
Present in testis and/or sperm 
Asthenozoospermic 
alteration 
AKAP11 Q9UKA4 A-kinase anchor protein 11  1 Yes GSK3β [49–51]  Human testis and human sperm [52] 
 
ALKBH3 Q96Q83 
Alpha-ketoglutarate-dependent 
dioxygenase alkB homolog 3  
1    
 
AP3D1 O14617 AP-3 complex subunit delta-1  1 Yes    
AURKAIP1 Q9NWT8 Aurora kinase A-interacting protein  2 Yes    
AXIN2 Q9Y2T1 Axin-2  1 Yes 
GSK3⍺ and GSK3β 
[50,51,53,54] 
Mouse testis [55] 
 
BCCIP Q9P287 BRCA2 and CDKN1A-interacting protein  7 Yes    
C11orf98 E9PRG8 Uncharacterized protein C11orf98 1     
CCDC174 Q6PII3 
Coiled-coil domain-containing protein 
174 
1 Yes   
 
CHTOP Q9Y3Y2 Chromatin target of PRMT1 protein 1     
CNTROB Q8N137 Centrobin  1 Yes  
Mouse testis (spermatocyte and 
spermatids) [56] 
 
DCAF8 Q5TAQ9 DDB1- and CUL4-associated factor 8 1 Yes    
DCP1B Q8IZD4 mRNA-decapping enzyme 1B  5 Yes    
DDI1 Q8WTU0 Protein DDI1 homolog 1 1 Yes    
DEAF1 O75398 
Deformed epidermal autoregulatory 
factor 1 homolog  
1 Yes 
GSK3⍺ and GSK3β 
[57]  
 
 
DNAJB1 P25685 DnaJ homolog subfamily B member 1  1   
Human sperm (midpiece and principle 
piece) [58]  + [36] 
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GSK3 human testis interactors 
Gene Name UniProtKB Name 
Nr of 
clones  
GSK3 
phosphorylation 
site 
Previously known 
GSK3 interactor 
Present in testis and/or sperm 
Asthenozoospermic 
alteration 
DRC1 Q96MC2 Dynein regulatory complex protein 1 1 Yes    
FBXO42 Q6P3S6 F-box only protein 42  1 Yes    
GOLGA6C A6NDK9 Golgin subfamily A member 6C 1     
H2AFV Q71UI9 Histone H2A.V  1     
HMBS P08397 Porphobilinogen deaminase 1     
HMGN1 P05114 
Non-histone chromosomal protein HMG-
14  
1    
 
HNRNPM P52272 
Heterogeneous nuclear 
ribonucleoprotein M 
1   
Mouse testis [59]  and human sperm 
(mRNA) [60] 
 
HSP90AA1 P07900 Heat shock protein HSP 90-alpha  12 Yes 
GSK3⍺ and GSK3β 
[51,61,62] 
Yes, mouse testis (mRNA) [63] and human 
sperm [64]   
+ [36] 
HSP90AB1 P08238 Heat shock protein HSP 90-beta  4  
GSK3⍺ and GSK3β 
[51,61] 
Rat testis (Sertoli cells) [65] and human 
sperm (equatorial region) note that does 
not distinct AA1 from AB1 [66] 
+ [36]  
  
LDHA P00338 L-lactate dehydrogenase A chain  1   Human sperm (principal piece) [67] 
- [36] 
 
LRP6 O75581 
Low-density lipoprotein receptor-related 
protein 6  
1 Yes 
GSK3⍺ and GSK3β 
[68–70]  
Human sperm (flagellum more intense in 
midpiece) [71] 
 
LRRC37A2 A6NM11 
Leucine-rich repeat-containing protein 
37A2 
1 Yes   
+[36] 
 
MAEA Q7L5Y9 Macrophage erythroblast attacher  1 Yes    
MTCH1 Q9NZJ7 Mitochondrial carrier homolog 1 1 Yes    
MYL12A P19105 Myosin regulatory light chain 12A  1     
NBR1 Q14596 Next to BRCA1 gene 1 protein  1 Yes 
GSK3⍺ and GSK3β 
[57,72]  
Human testis (mRNA) [73] 
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GSK3 human testis interactors 
Gene Name UniProtKB Name 
Nr of 
clones  
GSK3 
phosphorylation 
site 
Previously known 
GSK3 interactor 
Present in testis and/or sperm 
Asthenozoospermic 
alteration 
PSMD8 P48556 
26S proteasome non-ATPase regulatory 
subunit 8  
3   Boar sperm (acrosome) [74] 
 
PTMA P06454 Prothymosin alpha  2   
Rat testis (Leydig cells, panchytene 
spermatocyte and spermatids) [75], human 
sperm (acrosome) [76] 
 
RPL15 P61313 60S ribosomal protein L15 1     
RPL19 P84098 60S ribosomal protein L19 1  GSK3β [51] Yes, human sperm [60]  
RPL29 P47914 60S ribosomal protein L29 1  GSK3β [51] Mouse testis [77] 
 
RPS15 P62841 40S ribosomal protein S15  1     
RPS19 P39019 40S ribosomal protein S19 1  GSK3β [51]   
RUNX1 Q01196 Runt-related transcription factor 1  1 Yes    
SBNO1 A3KN83 Protein strawberry notch homolog 1  2 Yes    
SMARCA5 O60264 
SWI/SNF-related matrix-associated actin-
dependent regulator of chromatin 
subfamily A member 5  
1 Yes GSK3β [51] Mouse testis [78] 
 
SMG7 Q92540 Protein SMG7  1 Yes  
Mouse testis (spermatocytes and 
spermatids) [79] 
 
SUGP2 Q8IX01 
SURP and G-patch domain-containing 
protein 2  
1 Yes   
 
TTC16 Q8NEE8 Tetratricopeptide repeat protein 16  1 Yes    
UBTF P17480 Nucleolar transcription factor 1 1 Yes    
VCPIP1 Q96JH7 Deubiquitinating protein VCIP135  1 Yes    
Homo Sapiens Chromosome 
21 clone CTD-250 3J9 map 
p11-q21.1 
  1    
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GSK3 human testis interactors 
Gene Name UniProtKB Name 
Nr of 
clones  
GSK3 
phosphorylation 
site 
Previously known 
GSK3 interactor 
Present in testis and/or sperm 
Asthenozoospermic 
alteration 
Human Dna sequence from 
clone RP11-543N17 
  1    
 
RefSeqGene on chromosome 
5 Chromosome 5: 
150,401,911-150,402,122 
  2    
 
 
Table B2.2. GSK3 human testis interactors. Gene name, UniProtKB, nr of clones, GSK3 phosphorylation site, previously described GSK3 interactor, presence on mammal testis and sperm 
and alteration on asthenozoospermic samples of testis GSK3 interactors identified by yeast two-hybrid. 
GSK3 human testis interactors 
Gene Name UniProtKB Name 
Nr of 
clones  
GSK3 
phosphorylation 
site 
Previously known 
GSK3 interactor 
Present in testis and/or sperm 
Asthenozoospermic 
alteration 
AXIN2 Q9Y2T1 Axin-2  1 Yes 
GSK3β 
[50,51,53,54]  
Mouse testis [55,71] and mouse sperm 
(mRNA) 
 
BCCIP Q9P287 
BRCA2 and CDKN1A-interacting 
protein 1 Yes  Human testis [80]  
 
C10orf90 Q96M02 Centrosomal protein C10orf90  1 Yes    
C11orf98 E9PRG8 
Uncharacterized protein 
C11orf98 1    
 
CASC4 Q6P4E1 Protein CASC4  1 Yes    
CMTM2 Q8TAZ6 
CKLF-like MARVEL 
transmembrane domain-
containing protein 2  1   
Human testis and sperm (elongating 
spermatids, pachytene spermatocytes, 
posterior head of mature sperm) [81,82] 
 
DCP1B Q8IZD4 mRNA-decapping enzyme 1B 2 Yes    
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GSK3 human testis interactors 
Gene Name UniProtKB Name 
Nr of 
clones  
GSK3 
phosphorylation 
site 
Previously known 
GSK3 interactor 
Present in testis and/or sperm 
Asthenozoospermic 
alteration 
HNRNPM P52272 
Heterogeneous nuclear 
ribonucleoprotein M  2   Mouse testis [59] and human sperm [60] 
 
HSP90AA1 P07900 
Heat shock protein HSP 90-
alpha 2  
GSK3⍺ and GSK3β 
[51,62]  
Mouse testis (mRNA) [63] and human sperm 
[64]  
+[36] 
 
HSP90AB1 P08238 Heat shock protein HSP 90-beta  1  
GSK3⍺ and GSK3β 
[51]  
Rat testis (Sertoli cells) [65] and human sperm 
[83] 
+ [36] 
  
LYAR Q9NX58 
Cell growth-regulating 
nucleolar protein 1   Mouse testis [84] 
 
MYL6 P60660 Myosin light polypeptide 6 2   
Mouse sperm (manchete of elongating 
spermatids) [85] 
+ [36]  
 
PRKRIP1 Q9H875 PRKR-interacting protein 1 2     
PSMD8 P48556 
26S proteasome non-ATPase 
regulatory subunit 8  2   Boar sperm (acrosome) [74] 
 
RPS15 P62841 40S ribosomal protein S15  2     
SMG7 Q92540 Protein SMG7 1 Yes  
Mouse testis (spermatocytes and spermatids) 
[79]  
 
TEKT5 Q96M29 Tektin-5 1 Yes  
Mouse sperm (flagellum, more intense in 
midpiece) [86] 
 -  [29,36] 
 
 
YBX1 P67809 
Nuclease-sensitive element-
binding protein 1  1  GSK3β [87]  
 
Human DNA sequence from clone 
RP11-543N17 on chromosome 10, 
complete sequence   
1 
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Table B2.3. GSK3  human sperm interactors. Gene name, UniProtKB, mass spectrometry score, GSK3 phosphorylation site, previously described GSK3 interactor, presence on mammal 
testis and sperm and alteration on asthenozoospermic samples of testis GSK3 interactors identified by yeast two-hybrid. 
GSK3 human spermatozoa interactors 
Gene Name UniProtKB Name 
Spectral 
Count 
ra o*† 
Log of 
GSK3/NC 
ratio±† 
GSK3 
phosphorylation 
site 
Previously 
known GSK3 
interactor 
Present in testis and/or sperm 
Asthenozoospermic 
alteration 
ARG1 P05089  Arginase-1 
GSK3 
only  
 
Yes  Human sperm (activity) [88] 
 
GGCT O75223  
Gamma-
glutamylcyclotransferase 
GSK3 
only  
 
Yes  
Human testis (Sertoli and Leydig cells) and 
epididymis [89] 
 
HIST1H2AD P20671 Histone H2A type 1-D 3     + [36] 
TLR9 Q9NR96 Toll-like receptor 9 
GSK3 
only 
 
  
Mouse sperm (acrosome) [90], human testis 
and sperm(mRNA) [91,92] 
 
SBSN Q6UWP8  Suprabasin  
GSK3 
only  
 
   
 
HIST1H4A P62805  Histone H4  3 
 
  
Mouse testis (spermatocyte) [93] human 
sperm [93] 
 
HIST1H2BK A0A024RCL8  Histone H2B  
GSK3 
only  
 
  Human testis (mRNA) and sperm [94] 
 
HSPA5 P11021 
78 kDa glucose-regulated 
protein 
GSK3 
only 
 
Yes GSK3β [51]   
+ and – [31,36]  
ACR 
P10323 Acrosin  8.0  GSK3β [51] 
Human testis [95] and sperm (acrosome) 
[96,97] 
-[36] 
CPZ Q66K79 Carboxypeptidase Z  4.8     
EEF1G P26641 Elongation factor 1-gamma  4.3  GSK3β [51] Human sperm [98] -[36] 
LTF P02788 Lactotransferrin  6.7   Human sperm (acrosome) [99] -[36] 
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GSK3 human spermatozoa interactors 
Gene Name UniProtKB Name 
Spectral 
Count 
ra o*† 
Log of 
GSK3/NC 
ratio±† 
GSK3 
phosphorylation 
site 
Previously 
known GSK3 
interactor 
Present in testis and/or sperm 
Asthenozoospermic 
alteration 
PRSS37 
A4D1T9 
Probable inactive serine 
protease 37  4.8    
 
RPL13 P26373 60S ribosomal protein L13  6.9     
RPL6 Q02878 60S ribosomal protein L6  4.8     
RPS18 P62269 40S ribosomal protein S18  8.1   Human sperm [29]  
RPS8 
P62241 40S ribosomal protein S8  4.4   
Human testis [95] and sperm (acrosome) 
[96,97] 
 
 
Table B2.4. GSK3 human sperm interactors. Gene name, UniProtKB, mass spectrometry score, GSK3 phosphorylation site, previously described GSK3 interactor, presence on mammal 
testis and sperm and alteration on asthenozoospermic samples of testis GSK3 interactors identified by yeast two-hybrid. 
GSK3 human spermatozoa interactors  
Gene Name UniProtKB Name 
Spectral 
counts 
ratio* 
Log of 
GSK3/NC 
ratio±† 
GSK3 
phosphorylation 
site 
Previously 
known GSK3 
interactor 
Present in testis and/or 
sperm 
Asthenozoospermic 
alteration 
ANXA1 P04083  Annexin A1  GSK3 only  
 
   
 
ARG1 P05089  Arginase-1 GSK3 only  
 
Yes  
Human sperm [88] 
(activity) 
 
BPIFB1 Q8TDL5  BPI fold-containing family B member 1 GSK3 only       
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GSK3 human spermatozoa interactors  
Gene Name UniProtKB Name 
Spectral 
counts 
ratio* 
Log of 
GSK3/NC 
ratio±† 
GSK3 
phosphorylation 
site 
Previously 
known GSK3 
interactor 
Present in testis and/or 
sperm 
Asthenozoospermic 
alteration 
CASP14 P31944 Caspase 14  GSK3 only       
CAT P04040  Catalase  GSK3 only  
 
  
Human sperm (catalase 
activity) [100]  
 
CTSG P08311  Cathepsin G  GSK3 only       
LYZ B2R4C5  C-type lysozyme GSK3 only       
DMBT1 Q9UGM3  Deleted in malignant brain tumors 1 protein  GSK3 only   Yes    
GGCT O75223  Gamma-glutamylcyclotransferase GSK3 only 
 
Yes  
Human testis (Sertoli and 
Leydig cells) and 
epididymis [89] 
 
GSN P06396 Gelsolin  GSK3 only       
GAPDH P04406  Glyceraldehyde-3-phosphate dehydrogenase 2 
 
 GSK3β [101] 
Boar sperm (fibrous 
sheat of the flagellum) 
[102] 
 
HP P00738  Haptoglobin  GSK3 only  
 
 GSK3β [51] Rat testis (mRNA) [103] 
 
HSP90AB1 P08238 Heat shock protein HSP 90-beta GSK3 only  
 
 
GSK3⍺ and 
GSK3β [51]  
Rat testis (Sertoli cells) 
[65] and human sperm 
[83]  
 
HSPA2 P54652  Heat shock-related 70 kDa protein 2 3     +[29]  
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GSK3 human spermatozoa interactors  
Gene Name UniProtKB Name 
Spectral 
counts 
ratio* 
Log of 
GSK3/NC 
ratio±† 
GSK3 
phosphorylation 
site 
Previously 
known GSK3 
interactor 
Present in testis and/or 
sperm 
Asthenozoospermic 
alteration 
 
HIST1H2AD P20671 Histone H2A  4     + [36] 
HIST1H2BK A0A024RCL8  Histone H2B  GSK3 only       
H3F3B P84243 Histone 3.3 GSK3 only  
 
  
Mouse testis 
(spermatogonia, 
leptotene spermatocytes, 
pachytene 
spermatocytes and 
elongating spermatids) 
[104] 
 
HIST1H4A P62805  Histone H4  13 
 
  
Mouse testis 
(spermatocyte) [93] and 
human sperm [105]  
 
HIST1H3A P68431 Histone H3 GSK3 only 
 
  
Human sperm (nuclear) 
[106] 
 
MUC5AC A7Y9J9  Mucin 5AC, oligomeric mucus/gel-formin GSK3 only      
MPO P05164 Myeloperoxidase  GSK3 only  Yes  In seminal plasma [107] - [36]  
PFN1 P07737 Profilin-1 GSK3 only 
 
  
Rat testis (Leydig and 
Sertoli cells) [108] 
+ [36] 
S100A8 P05109 Protein S100-A8 3    Human sperm [109] -[36] 
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GSK3 human spermatozoa interactors  
Gene Name UniProtKB Name 
Spectral 
counts 
ratio* 
Log of 
GSK3/NC 
ratio±† 
GSK3 
phosphorylation 
site 
Previously 
known GSK3 
interactor 
Present in testis and/or 
sperm 
Asthenozoospermic 
alteration 
DKFZp686J11235 Q6MZW0  
Putative uncharacterized protein 
DKFZp686J11235 GSK3 only 
 
Yes   
 
SERPINB4 P48594 Serpin B4 (Fragment) GSK3 only      
TLR9 Q9NR96 Toll-like receptor 9 GSK3 only 
 
  
Mouse sperm (acrosome) 
[90] human testis and 
sperm (mRNA) [91,92] 
 
n/a Q6GMV8  Uncharacterized protein  GSk3 only      
ZG16B Q96DA0 Zymogen granule protein 16 homolog B  GSK3 only      
ACR P10323 Acrosin  7.70   
Yes, human testis [95] 
and sperm (acrosome) 
[96,97] 
 
LTF P02788 Lactotransferrin  6.45  GSK3β [51] 
Human sperm (mRNA) 
[110] 
-[36] 
PRSS37 A4D1T9 Probable inactive serine protease 37  4.40   Human sperm [98]  
RPL13 P26373 60S ribosomal protein L13  4.79  GSK3β [51]   
RPL6 Q02878 60S ribosomal protein L6  4.75     
RPS18 P62269 
40S ribosomal 
protein S18  7.31   Human sperm (acrosome) [99] 
 
B2. Identification and characterization of GSK3 human testis and spermatozoa interactome 
  
* Spectral counts ratios: total number of spectral counts for each protein in GSK3 condition divided by the number of total number of spectral counts for each protein in negative control. 
Only rations higher than 2 were considered relevant (increase of 100% of number of spectral counts in the condition GSK3). Please note that “GSK3 only” means that spectral counts 
were only detected in GSK3 condition.  
±†Logarithm of GSK3/Negative control:  
† Mass spectrometry results present dis nct scoring methods, since the technique was performed in two different facili es, VIB Proteomics Expertise Center 
and Proteomic Core Lab, Lerner Research Institute. 
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As for LRC37A2 and PTMA, both proteins were unable to activate the transcription of the reporter 
genes in the most stringent medium, which suggests that the interactions between GSK3 isoforms 
and LRRPC37A2 and PTMA are weaker or more transient (Figure B2.4).  
 
 
 
 
 
B2.4.4. Fourteen new interactors for GSK3 and twenty-nine new interactors for GSK3 were 
identified in human spermatozoa 
To identify novel GSK3 and GSK3 interactors essential for sperm physiology, GSK3 and GSK3 
interactors were isolated from mature human sperm by co-immunoprecipitation using isoform-
specific GSK3 antibodies in two independent experiments (pool of two different samples in each 
experiment) followed by mass spectrometry analysis. Three different elution methods were used: 
1%SDS, 50mM Glycine pH2.5 and no elution (in beads trypsinization was performed). Endogenous 
GSK3 and GSK3 were successfully immunoprecipitated in all experiments, as seen in Figure B2.5. 
Additionally, five peptides were identified that matched GSK3 and four that matched GSK3 
(Table B2.5). Note that neither GSK3 and GSK3 were detected in the negative control either by 
western blot or identified by mass spectrometry (Figure B2.5 and Table B2.5).  
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Figure B2.4. Yeast co-transformation of GSK3 and GSK3 interactors. pAS2-1- GSK3 and pAS2-1-GSK3 were co-
transformed with the either pGADT7-Rec-AKAP11, pGADT7-Rec-LRP6, pGADT7-Rec-LRRC37A2 or pGADT7-Rec-PTMA 
recovered from the human testis cDNA library. All proteins interact with both GSK3 isoforms but only AKAP11 and 
LRP6 maintain the interaction in a more stringency medium. Also, none of the proteins activate per se the reporter 
genes. Negative (NC) and positive controls (PC) were included. 
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Seventeen and thirty-four interactors were identified as sperm GSK3 and for GSK3 interactors, 
respectively (Table B2.3 and B4). Regarding GSK3 interactors, 82.4% were potentially novel 
interactors while 17.6% were previously identified as GSK3 interactors in PPI databases. From 
those, all were described as interacting with GSK3 (either exclusively or interaction for GSK3 was 
not tested). Also, 58.8% of GSK3 identified interactors were described as expressed in either 
mammalian testis and/or sperm by previous studies. Lastly, 17.6% of GSK3 identified interactors 
contained the GSK3 consensus phosphorylation site (Table B2.3).  
Table B2.5. GSK3 isoforms peptides detected on mass spectrometry. Peptide sequence, first and last aminoacid of the 
peptide, peptide % of coverage for the complete protein and peptide spectral count. 
Sequence Start End Coverage Spectral Count 
Mass spectrometry eluted with 50mM glycine and 1% SDS 
GSK3 (UniProtKB: P49840) 
TSSFAEPGGGGGGGGGGPGGSASGPGGTGGGK 19 50 
10% 5 
VTTVVATLGQGPER 100 113 
GSK3 (UniProtKB: P49841) 
TPPEAIALCSR 309 319 3% 1 
Mass spectrometry on-bead trypsin digestion 
GSK3 (UniProtKB: P49840) 
VTTVVATLGQGPER 100 113 
8% 13 SQEVAYTDIK 114 123 
DIKPQNLLVDPDTAVLK 244 260 
GSK3 (UniProtKB: P49841) 
VTTVVATPGQGPDRPQEVSYTDTK 37 60 
17% 32 DTPALFNFTTQELSSNPPLATILIPPHAR 355 383 
IQAAASTPTNATAASDANTGDR 384 405 
Figure B2.5.Co-Immunoprecipitation of GSK3 from normospermic human sperm sample. Both co-
immunoprecipitations were also used for identification of GSK3 interactors by mass spectrometry. GSK3⍺ and GSK3β
were detected using a anti-GSK3/ (Invitrogen, ref: 44-610, 1:2000). A After co-immunoprecipitation with either a 
GSK3⍺ or GSK3β specific antibody, proteins were eluted with 1% SDS or 50mM glycine. Prior to GSK3 
immunodetection, APP presence was evaluated by probing with 6E10 antibody. Although the reason is unknown, 
upon incubation with the 6E10 antibody, two unspecific bands appear on the negative control eluted with 50mM of 
glycine (Supplementary Figure 3). B After co-immunoprecipitation with crosslink of GSK3⍺ or GSK3β antibodies to 
dynabeads beads, ¼ of the beads were eluted with 1%SDS and GSK3⍺ or GSK3β presence was evaluated. Blots were 
cropped 
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For GSK3 interactors, 85.3% were new putative interactors and 14.7% were already described as 
GSK3 interactors. From the latter, one interaction was reported with both GSK3 isoforms while the 
remaining were described as interacting with GSK3. Moreover, 47.1% of GSK3 identified 
interactors are expressed in either mammalian testis and/or sperm. Finally, the GSK3 consensus 
phosphorylation site is present in 14.7% of GSK3 interactors (Table B2.3). 
 
B2.4.5. GSK3 testis and spermatozoa interactomes are enriched in gene and protein 
expression processes  
In this study, four distinct GSK3 interactomes were characterized: GSK3 and GSK3 in human testis 
and human sperm. The Venn diagrams in Figure B2.6 represent the overlap between GSK3⍺ and 
GSK3β interactomes in human testis, sperm and databases.  
  
 
 
 
 
With the goal of identifying key GSK3 interactors for sperm and testis physiology, gene expression 
for GSK3 interactors was retrieved from 5 different databases (Supplementary Table B2.1). For 
GSK3 four proteins were considered testis-enriched, with more than 90% of their expression 
restricted to testis: DDI1, GOLGA6C (testis interactors), ACR and PRSS37 (sperm interactors). 
Although not testis-enriched, 50-75% expression of TTC16 is limited to testis. For GSK3 interactors, 
besides ACR and PRSS37 similarly to GSK3, TEKT5, CMTM2 (testis interactors), HIST1H1T, PRKACG, 
TSKS (databases interactors) were classified as highly enriched in testis (>90% expression). CABYR 
presented 75%-90% of expression in testis while RGS22 only 50-75%. To further characterize GSK3 
Figure B2. 6. Venn diagram showing the overlap of GSK3⍺ and GSK3β interactomes. The data retrieved from testis, 
sperm and databases GSK3 interactors was compared and the number of common proteins between two or three 
categories is shown A. Overlap of GSK3⍺ and GSK3β interactomes between interactors reported in databases and 
identified in testis and sperm. B. Overlap of testis and sperm GSK3 interactors. Green: Sperm interactors; Orange: 
Testis interactors; Yellow: Databases interactors; Blue: GSK3⍺ interactors and Pink: GSK3β interactors. 
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interactome, differently expressed proteins in asthenozoospermic samples were retrieved from 
proteomics studies (Tables B2.1-B2.4).  
To better understand the role of GSK3 isoforms and their interactors in testis and sperm, an 
enrichment analysis was performed. Testis GSK3 interactome appears to be highly associated with 
RNA metabolic processing and located mainly in the nucleus (Supplementary Table B2.4). On the 
other hand, the GSK3 sperm interactome is enriched in proteins involved in ribosomal function, 
particularly protein production (Supplementary Table B2.5)  
The GSK3 testis interactome it appears to be associated with maintenance of gene quality, 
particularly telomerase length (Supplementary Table B2.6). The GSK3 sperm interactome is 
enriched in proteins reported to be involved in immune response (Supplementary Table B2.7).  
 
B2.4.6. The GSK3 interactomes are associated with sperm motility and testis functions  
To further characterize the GSK3 interactome, protein-protein interaction networks were 
constructed using data obtained from this study and GSK3 PPIs retrieved from databases. The 
GSK3 interactome network (Supplementary Figure B2.4) presents 130 proteins,  
Figure B2.7. GSK3α sperm motility network. GSK3⍺-centered subnetwork for sperm motility extracted from GSK3⍺
interactome network. All GSK3⍺ interactors associated with motility-related annotations were used to build the 
network. Solid lines: testis or sperm GSK3⍺ interactions; Dashed lines: Databased retrieved GSK3⍺ interactions. Node 
size: according to testis expression. Node colors: represent motility-related phenotypes, biological processes (BP) or 
cellular components (CC). 
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including GSK3. Between these GSK3 interactors 257 interactions were formed. The average 
number of neighbor of a node was 3.9 (ranging from 1 to 130). Around 40% of GSK3 interactors 
only formed one interaction (with GSK3). 96% of all GSK3 interactors had five or less interactions. 
As expected, GSK3 was the protein that presents more interactions, since it is a protein-centered 
network. The mean clustering coefficient for GSK3 interactome network is 0.462. The GSK3 
interactome is composed by 456 proteins that form 1813 interactions among them (Supplementary 
Figure B2.5). The average number of neighbor of a node was 7.815 (ranging from 1 to 455). Seventy-
six proteins interacted exclusively with GSK3 and 24% of GSK3 interactors had ten or more 
interactors. GSK3 network presents a mean clustering coefficient of 0.448 (Supplementary Figure 
B2.6).  
GSK3 subnetworks associated with sperm-motility and testis were extracted from GSK3 isoforms 
protein-protein networks (Figure B2.7 and B2.8). Twenty-six GSK3 interactors have been 
associated with motility-related functions, phenotypes and/or subcellular locations (Figure B2.7). 
From those, five (PRSS37; DRC1; RPS19; HSPA5 and AP3D1) were identified in this study as either 
testis or sperm GSK3 interactors and only one was classified as testis-enriched protein (PRSS37). 
Figure B2.8. GSK3α testis network. GSK3⍺-centered subnetwork for testis-related annotations extracted from GSK3⍺
interactome network. All GSK3⍺ interactors associated with testis annotations were used to build the network. Solid 
lines: testis or sperm GSK3⍺ interactions; Dashed lines: Databased retrieved GSK3⍺ interactions. Node size: according 
to testis expression. Node colors: represent testis related phenotypes, biological processes (BP) or cellular 
components (CC).  
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PRKACA and DRC1 stand out by presenting five motility-related functions, phenotypes and/or 
subcellular locations, followed by GLI3 with four. Note that GSK3 itself has been associated with 
locomotion and cell motility processes (Figure B2.7). Ten GSK3 interactors were associated with 
testis-related functions or phenotypes/diseases and two of those were identified in this study 
(PRSS37 and HSP90AA1) (Figure B2.8). Only PRSS37 was described as highly expressed in testis and 
associated with testis-related annotations (PRSS37) (Figure B2.8). With five testis-related functions 
and/or subcellular locations, we highlight AKAP9 and AR. PRSS37 is also the single GSK3 interactor 
that is with associated with sperm motility, testis annotations, and categorized as enriched in testis 
(Figure B2.7 and Figure B2.8). For GSK3, 100 interactors are annotated to motility-related 
categories, and from those six are highly expressed in testis (CABYR, TEKT5, PRKACG, PRSS37, TSKS, 
CMTM2) (Figure B2.9). For testis-related categories, GSK3 presents forty-five interactors (Figure 
B2.10). 
Although not directly related to sperm motility and testis function, several GSK3 interactors are 
related to more general phenotypes or functions related to the male reproductive system 
(Supplementary Figure B2.6 and B2.7).  
Figure B2.9. GSK3β sperm motility network. GSK3β-centered subnetwork for sperm motility extracted from GSK3β
interactome network. All GSK3βinteractors associated with motility-related annotations were used to build the 
network. Solid lines: testis or sperm GSK3β interactions; Dashed lines: Databased retrieved GSK3β interactions. Node 
size: according to testis expression. Node colors: represent motility-related phenotypes, biological processes (BP) or 
cellular components (CC). 
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B2.4.7. AKAP11 and LRP6 subcellular localization in human sperm 
Two GSK3 interactors identified in this study, LRP6 and AKAP11, were chosen for further 
characterization. Both these proteins were chosen due to their potential involvement in male 
reproduction. LRP6 was already described as involved in sperm motility and testis physiology and 
AKAP11 in mouse spermatogenesis. AKAP11 and LRP6 expression in human testis and ejaculated 
sperm and the subcellular localization in human sperm were assessed. Figure B2.11 A shows that 
LRP6 is expressed in human testis and in human sperm. Although the expected molecular weight 
of LRP6 was around 180kDa, in human testis immunoreactivity was detected at around 210kDa. 
Several studies reported LRP6 at a higher molecular weight possible due to post-translational 
modification such as glycosylation and phosphorylation [111,112]. In human sperm, LRP6 was also 
detected at around 180kDa, although the immunoreactivity is weak. No immunoreactivity was 
detected for p1490LRP6 using Western blot. Regarding AKAP11, no signal was detected. We believe 
this is due to limitations of the antibody. All commercially available AKAP11 antibodies are  
 
  
 
 
 
 
 
 
 
 
recommended for immunocytochemistry and immunohistochemistry studies and not for Western 
blot, suggesting that only non-denatured AKAP11 is recognized by the antibodies.  
Figure B2.10. GSK3β testis network. GSK3β-centered subnetwork for testis-related annotations extracted from 
GSK3β interactome network. All GSK3β interactors associated with testis annotations were used to build the network. 
Solid lines: testis or sperm GSK3β interactions; Dashed lines: Databased retrieved GSK3β interactions. Node size: 
according to testis expression. Node colors: represent testis related phenotypes, biological processes (BP) or cellular 
components (CC). 
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Immunocytochemistry studies (Figure B2.11 B), revealed that total LRP6 is localized to the entire 
length of the flagellum and occasionally at the post-acrosomal area. However, p1490LRP6 is 
restricted to the midpiece. Moreover, a closer analysis showed that not all sperm cells present 
immunoreactivity towards LRP6 and LRP6p1490. Only 18% and 29% of sperm cells present 
immunoreactivity for LRP6 and p1490LRP6 respectively (Figure B2.11 B). Regarding AKAP11, this 
protein is localized on the anterior portion of the head and the equatorial area of ejaculated human 
sperm (Figure B2.11 B). 
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Figure B2.11. LRP6 and AKAP11 in human testis and sperm. A. LRP6 in testis and mature human sperm. Western blot 
analysis of LRP6 in human testis and mature sperm, mouse testis and HeLa cells. For human testis, mouse testis and 
HeLa cells 30µg of protein were loaded per sample. For mature human sperm 100µg of proteins were loaded. B.
subcellular localization of LRP6, p1490LRP6 and AKAP11 in mature human sperm. Total LRP6 is located in the entire 
flagellum and occasionally in the post-acrosomal area (arrowhead). The phosphorylated form of LRP6 at serine 1490 
is restricted to the midpiece (star). AKAP11 is located to the head, specifically to the anterior and equatorial area (plus 
sign). Scale bar is 10µm. Nucleus is marked in blue. ROI: region of interest. All images were obtained with 63X 
magnification in a Imager.Z1, Axio-Cam HRm camera and AxioVision software Zeiss, Jena, Germany). 
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B2.5. Discussion 
GSK3 has been long associated with sperm motility acquisition and maintenance in mammals 
[9,10,113]. In mice sperm, GSK3 seems key for primary motility acquisition since mice testis 
lacking this protein present low-motility sperm. However, the characterization of both GSK3 
isoforms (GSK3 and GSK3) in human sperm and testis physiology has been sparse. This work 
aimed to characterize GSK3 isoforms in human sperm as well as identify and analyze GSK3 and 
GSK3 interactome in human sperm and testis. Ultimately, this can help depict new GSK3 isoform-
specific interactions essential for human sperm function. 
Similar to other mammals, both GSK3 isoforms are present in human testis and sperm (Figure B2.1) 
[7,9,10,113,114]. We believe that the observed molecular weight differences between mouse and 
human GSK3 isoforms arise from protein sequence differences (Homo sapiens and Mus musculus 
share 95% identity for GSK3 and 99% identity for GSK3). Intraspecies differences may be 
explained by differences in phosphorylation status since this kinase presents multiple 
phosphorylation sites. Besides, it appears that in human testis, GSK3 and GSK3 are mainly active 
while in human sperm part of the GSK3 population is inhibited (Figure B2.1).  
To evaluate the importance of GSK3 in motility we assessed GSK3 activity in human sperm samples 
with distinct motility levels. We showed that in ejaculated human sperm, GSK3 activity presents 
a strong negative correlation with sperm motility, but GSK3 activity does not appear to influence 
motile sperm (Figure B2.2). Moreover, the fact that 100% of the sperm analyzed presented GSK3 
in the flagellum but only around 24% presented GSK3 on the same subcellular location reinforces 
the possible GSK3 isoforms-specific role in sperm motility (Figure B2.3). Contrary to previously 
described [115], we showed that in capacitated sperm GSK3 presents a strong positive correlation 
with sperm motility, while GSK3 has no correlation with motility (Figure B2.3). These findings 
suggest that human sperm motility acquisition can be a GSK3 isoform-specific function and GSK3 
isoforms may have other functions on sperm physiology. In 2015, Koch et al suggested that besides 
sperm motility, GSK3 may be involved in sperm protein stability and subcellular 
compartmentalization [71].  
Given the reported relevance of GSK3 isoforms in sperm function, specifically GSK3 in motility, 
the GSK3 and GSK3 interactomes in testis and sperm were identified and characterized (Tables 
B2. 1-4). The fact that several GSK3 sperm and testis interactions identified in this study were 
previously described, strengthens the validity of the GSK3 testis interactome. Furthermore, the 
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known interaction between GSK3 isoforms and AXIN2 was also detected in testis. The interaction 
between Axin and GSK3 is extensively described in the literature on somatic cells (see Table 1 and 
[116–119]) and has been target for drug pharmacological approach [120]. Yet to our knowledge, 
this is the first time the interaction was described in testis. 
An enrichment analysis of GSK3 interactome revealed that GSK3 and its testis interactors are 
mainly involved in gene expression (transcription) (Supplementary Table B2.4). Testis require high 
and specialized levels of gene expression mainly due to meiosis and the high level of cell 
differentiation [121,122]. The involvement of GSK3 interactors on these processes suggests that 
GSK3 may play a role in testis gene expression. This is further supported by the fact that both LRP6 
and AXIN2 were identified as GSK3 testis interactors (Table B2.1). LRP6, AXIN2 and GSK3 are 
involved in the gene expression control by Wnt/-catenin signaling pathway [116–119]. In mouse 
testis, Wnt/-catenin signaling participates in undifferentiated spermatogonia proliferation and 
regulation [55] and in idiopathic azoospermic cases, -catenin clusters in Sertoli cells [123]. We 
further investigated the potential role of LRP6 in human fertility. Bioinformatics analysis revealed 
that when LRP6 is absent from mice testis, they became infertile due to morphological defects of 
the reproductive system (Supplementary Figure B2.6 and Supplementary Table B2.2). Expression 
studies showed that LRP6 is present in human testis and sperm and is localized along the entire 
flagellum (Figure B2.11). Furthermore, when LRP6 is phosphorylated on S1490 (in somatic cells a 
GSK3 substrate [124,125]) its subcellular location is restricted to the human sperm midpiece (Figure 
B2.11). This is in accordance to earlier studies in mice and bovine sperm [71]. In 2015, Koch et al 
explored the non-genetic effects of -catenin signaling on human sperm and suggested that the 
interaction between LRP6 and GSK3 is required for protein stabilization and consequently sperm 
motility [71]. Therefore, despite the fact that in somatic cells GSK3/LRP6 interaction is involved in 
gene expression, in human sperm this interaction can have other roles which might deserve further 
studies.  
In sperm, the fact that the GSK3 interactome was involved in protein expression processes 
(Supplementary Table B2.5) and several ribosomal proteins were identified in this study as sperm 
GSK3 and GSK3 interactors (Table B2.3 and B2.4) was surprising. Sperm is typically described as 
a transcriptionally silent cell and being unable to produce proteins due to lack of ribosomes [126]. 
Yet, several cytoplasmic and mitochondrial ribosomal proteins have been previously described in 
human sperm (head and flagellum) [127–130]. Moreover, Gur and colleagues demonstrate the 
translation of mRNA by mitochondrial-type ribosomes [127] in human sperm and inhibition of such 
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translation leads to reduced levels of several proteins and, consequently, a significantly reduction 
of sperm motility, capacitation and in vitro fertilization [127,131]. These findings further strengthen 
the idea that GSK3 is a multi-task protein involved in processes other than motility. 
With the purpose of constructing the most complete GSK3 interactome, GSK3 interactions 
annotated on PPIs databases were retrieved. Interestingly, the overlap between testis/sperm 
interactomes and databases is very small (Figure B2.6). This may be a result of the understudy of 
GSK3 and its interactors in the male reproductive system. Also, the discrepancy between the 
number of GSK3 and GSK3-described interactions in databases may rise from more intense study 
of GSK3 than of GSK3, and not from a biological difference in the number of interactors of both 
isoforms. In both testis and sperm, several proteins were identified exclusively in GSK3 or GSK3 
interactomes (Figure B2.6). This may reflect specific GSK3 isoform interactions but further protein-
protein interaction validation is necessary. The fact that both GSK3 and GSK3 networks 
(Supplementary Figure B2.4 and B2.5) presented a clustering coefficient (how nearest neighboring 
nodes of node are connected to each other) higher than 0.02 suggests a motif-like structure [132]. 
Network motifs are network patterns that appear more frequently than expected and typically 
proteins belonging to the same motif share the same function [133,134].  
To achieve functional and tissue-specific relationships, tissue-expression, phenotypes and 
annotations were integrated into the GSK3 networks (Figure B2.7-10). It may be noted that the 
knowledge of protein tissue expression is still limited and typically does not take into account tissue-
specific alternative splicing products. This is particularly relevant for testis, since testis is the tissue 
with a higher number of alternative transcripts splice variants [135] [24]. None of GSK3 interactors 
listed on databases showed a testis-specific or enriched expression. However, we identified DDI1, 
GOLGA6C (testis interactors), ACR and PRSS37 (sperm interactors) that showed a testis-enriched 
expression pattern (Supplementary Table B2.1). Besides being involved in sperm motility functions 
(Figure B2.7), our in silico analysis revealed that PRSS37 may play a role in spermatogenesis (Figure 
B2.8). PRSS37 when absent in mice testis compromises spermatogenesis, sperm oviduct-migrating 
ability, and sperm-zona binding resulting in low percentage of fertilized eggs [136]. AR, PPP1CC, and 
AKAP9 (identified exclusively in the GSK3 interactome) appear to be highly associated with testis 
functions since germ cells and other types of testicular cells are greatly affected by their absence 
(Figure B2.8). These findings are in accordance to former studies [137–139]. 
AKAP11 was identified as a testis GSK3 interactor (Table B2.1). While the interaction between 
AKAP11 and GSK3 has been previously described [49], to our knowledge this is the first description 
B2. Identification and characterization of GSK3 human testis and spermatozoa interactome 
of the interaction with GSK3. Opposing to earlier studies in human sperm [52], we showed that 
AKAP11 is localized in the anterior portion of the head and equatorial region (Figure B2.11). In 
somatic cells, AKAP11 has been associated with cell migration [140] and in 2002, Tanji et al showed 
that AKAP11, PPP1, PRKACA, and GSK3 formed a multimeric complex in which PPP1 and PRKACA 
controlled GSK3 activity. Since both PPP1 and PRKACA have been extensively described in 
mammalian testis [137,141], we may assume that in testis a similar multimeric complex may be 
formed to control GSK3 activity. 
TEKT5 and CMTM2 were identified as GSK3 testis interactors (Table B2.2) and categorized as 
testis-enriched (Supplementary Table B2.1). TEKT5 is present in mouse testis and expression 
patterns of this protein suggest a role in flagella formation during spermiogenesis [86]. Further, in 
mouse sperm TEKT5 is enriched in flagellar accessory structures and has been implicated in sperm 
motility [86]. The fact that TEKT5 is highly associated with sperm motility phenotypes (Figure B2.9), 
suggests that the interaction GSK3/TEKT5 may be involved in sperm motility. 
In conclusion, human sperm motility is at least partially regulated by GSK3 activity, particularly the 
GSK3 isoform. This isoform-specific function may arise from GSK3 interactors that pay central 
roles in sperm motility. In brain, RACK1 is a GSK3-specific interactor. Although no GSK3-specific 
interaction was identified in testis and sperm, we have identified GSK3 interactors, such as 
PRSS37, that are potentially involved in sperm motility. Moreover, GSK3 and its interactors appear 
to be highly associated with protein expression suggesting other possible functions for this protein 
in both testis and sperm. Finally, the interactions identified in this study could be promising 
pharmacological targets for a new male contraceptive based on disrupting sperm motility.  
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B2.7.1. Tables 
Supplementary Table B2.1. Testis expression levels of GSK3 interactome. Expression levels of all GSK3 interactors were 
retrieved form the human protein atlas, PaGeneBase, Expression atlas, BioGPS and UniGene were retrieved and testis 
expression values were normalized. Yellow: GSK3 testis interactors; Green: GSK3 sperm interactors; Orange: GSK3 
database interactors. 
https://www.dropbox.com/s/161dwhvy8d2ixvt/Supplementary%20Table%201%20Testis%20ex
pression%20levels%20of%20GSK3%20interactome.xlsx?dl=0  
 
Supplementary Table B2.2. Testis and sperm related phenotypes/diseases/annotations of GSK3 interactome. Testis 
and sperm related phenotypes/diseases/annotations of all GSK3 interactors were retrieved and categorized from MGI, 
OMIM, Phenopedia, DISEASES, DisGeNet and GeneOntology. Also, differently expression levels of protein in 
asthenozoospermic samples in peer reviewed papers was retrieved. Yellow: GSK3 testis interactors; Green: GSK3 sperm 
interactors; Orange: GSK3 database interactors. 
https://www.dropbox.com/s/3qzvvi12us8ihfv/Supplementary%20Table%202%20Testis%20and
%20sperm%20related%20phenotypes%3Adiseases%3Aannotations%20of%20GSK3%20interact
ome.xlsx?dl=0  
 
Supplementary Table B2.3. Correlation coefficient between % of immotile sperm and GSK3 isoform expression and 
activation in human sperm. 
Ejaculated sperm Total GSK3⍺ p21GSK3⍺ Total GSK3β pS9GSK3β 
% of immotile sperm Pearson 
Correlation 
-0.910* -0.872* 0.111 -0.458 
Sig. (2-tailed) 0.012 0.023 0.834 0.361 
N 6 6 6 6 
Capacitated sperm  Total GSK3⍺ pS21 GSK3⍺ Total GSK3β pS9 GSK3β 
% of immotile sperm Pearson 
Correlation 
0.545 0.283 0.578 0.848* 
Sig. (2-tailed) 0.263 0.587 0.230 0.033 
N 6 6 6 6 
 
Supplementary Table B2.4. Top 5 of GeneOntology enrichment of GSK3 testis interactome. The 5 most significant 
categories of biological process, molecular function and cellular component according to p-value are listed. Category, nr 
of protein and p-value is listed. Only results with p>0.005 were considered. 
Testis GSK3 interactome enrichment 
Category nr of proteins p-value 
Biological process 
nuclear-transcribed mRNA catabolic process, nonsense-mediated decay 7 6.06E-05 
mRNA metabolic process  11 1.02E-03 
nuclear-transcribed mRNA catabolic process 7 1.89E-03 
mRNA catabolic process  7 2.88E-03 
protein localization to membrane 8 5.47E-03 
Molecular function 
B2. Identification and characterization of GSK3 human testis and spermatozoa interactome 
Testis GSK3 interactome enrichment 
Category nr of proteins p-value 
RNA binding 14 1.57E-02 
Cellular component 
nuclear lumen 24 2.54E-04 
nuclear part 25 2.89E-04 
intracellular organelle part 36 3.18E-04 
intracellular non-membrane-bounded organelle 24 3.92E-04 
non-membrane-bounded organelle 24 3.92E-04 
   
 
Supplementary Table B2.5. Top 5 of GeneOntology enrichment of GSK3 sperm interactome. The 5 most significant 
categories of biological process, molecular function and cellular component according to p-value are listed. Category, nr 
of protein and p-value is listed. Only results with p>0.005 were considered. 
Sperm GSK3 interactome enrichment 
Category nr of proteins p-value 
Biological process 
cellular amide metabolic process 8 1.27E-04 
amide biosynthetic process 7 2.71E-04 
protein localization to endoplasmic reticulum  5 2.76E-04 
peptide metabolic process 7 5.81E-04 
peptide biosynthetic process 6 3.27E-03 
Molecular function 
structural constituent of ribosome 4 2.25E-02 
Cellular component 
cytosolic ribosome  4 2.37E-03 
ribosomal subunit 4 1.55E-02 
ribosome 4 4.27E-02 
cytosolic part  4 4.34E-02 
extracellular matrix 6 1.96E-03 
   
 
Supplementary Table B2.6. Top 5 of GeneOntology enrichment of GSK3 testis interactome. The 5 most significant 
categories of biological process, molecular function and cellular component according to p-value are listed. Category, nr 
of protein and p-value is listed. Only results with p>0.005 were considered. 
Testis GSK3 interactome enrichment 
Category nr of proteins p-value 
Biological process 
telomere maintenance via telomerase 3 4.38E-03 
telomere maintenance via telomere lengthening 3 1.17E-02 
RNA-dependent DNA biosynthetic process 3 2.67E-02 
telomerase holoenzyme complex assembly 2 4.76E-02 
Molecular function 
RNA binding  4 6.36E-04 
nitric-oxide synthase regulator activity 4 3.88E-02 
TPR domain binding  4 3.88E-02 
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Supplementary Table B2.7. Top 5 of GeneOntology enrichment of GSK3 sperm interactome. The 5 most significant 
categories of biological process, molecular function and cellular component according to p-value are listed. Category, nr 
of protein and p-value is listed. Only results with p>0.005 were considered. 
Sperm GSK3 interactome enrichment 
Category nr of proteins p-value 
Biological process 
multi-organism process 18 5.34E-07 
defense response to fungus 5 1.67E-05 
antimicrobial humoral response 6 3.62E-05 
immune response  14 8.06E-05 
response to fungus 5 9.04E-05 
Molecular function 
disordered domain specific binding 3 3.56E-02 
Celular component 
cytoplasmic vesicle lumen  9 6.86E-07 
secretory granule lumen  9 4.48E-07 
DNA packaging complex  4 5.87E-03 
nucleosome 4 4.08E-03 
nuclear nucleosome 3 2.12E-03 
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Supplementary Figure B2. 1. Expression and auto-activation of the reporter genes tests of pAS2-1-GSK3 and pAS2-
1-GSK3 in AH190 yeasts. A. Yeast protein extracts previously transformed with pAS2-1-GSK3 or pAS2-1-GSK3
were probed with an anti-GSK3 antibody (Cell Signaling ref: #9338, 1:1000) and an anti-GSK3 antibody (Cell 
Signaling ref: #9315, 1:1000). The calculated molecular weight of hybrid protein is presented. Blots were cropped B. 
Yeast transformed with pAS2-1-GSK3 or pAS2-1-GSK3 were plated in different levels of stringency mediums. 
Supplementary Figure B2.2. Solubilizing effect of different lysis buffers for GSK3 and GSK3. A. 1% SDS is very 
effective on solubilizing GSK3. For GSK3, 1XRIPA and 1XRIPA modified solubilized approximately half of the protein 
and 20mM Tris-HCl only 30%, when compared with 1%SDS. For GSK3, 1xRIPA and 1XRIPA modified solubilized 
around 70% of GSK3  and 20mM of Tris-HCl only 30%, when compared with 1% SDS. GSK3⍺ and GSK3β were detected 
using a anti-GSK3/ (Invitrogen, ref: 44-610, 1:2000). B. GSK3⍺ was immunodetected using a anti-GSK3 (Cell 
Signaling ref: #9338, 1:1000) and GSK3β was immunodetected using a anti-GSK3 (Cell Signaling ref: #9315, 1:1000). 
Experience done once. 
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Supplementary Figure B2.3. Co-Immunoprecipitation of GSK3 from normospermic human sperm sample (previous 
page). Prior to GSK3 immunodetection, APP presence was evaluated by probing with 6E10 antibody. Although the 
reason is unknown, upon incubation with the 6E10 antibody (Sigma-Aldrich, ref: A-1474), two unspecific bands appear 
on the negative control eluted with 50mM of glycine. 
Supplementary Figure B2.4. The GSK3 interactome network. GSK3α-centered protein-protein interactome 
network. All GSK3⍺ interactors (testis, sperm and databased) were used to build the network. Node size: degree 
(number of neighbors of a protein). 
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Supplementary Figure B2.5. The GSK3 interactome network (previous page). GSK3β-centered protein-protein 
interactome network. All GSK3 interactors (testis, sperm and databased) were used to build the network. Due to the 
density of the network, the name of the proteins was not possible to present Node size: degree (number of neighbors 
of a protein). 
Supplementary Figure B2.6. The GSK3 general male infertility network. GSK3-centered subnetwork for male 
infertility annotations extracted from GSK3 interactome network. GSK3 interactors associated with male infertility 
annotations were used to build the network. Solid lines: testis or sperm GSK3 interactions; Dashed lines: Databased 
retrieved GSK3 interactions. Node size: according to testis expression. Node colors: represent male infertility related 
phenotypes, biological processes (BP). 
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Supplementary Figure B2.7. The GSK3 general male infertility network (previous page). GSK3-centered 
subnetwork for male infertility annotations extracted from GSK3 interactome network. GSK3 interactors associated 
with male infertility annotations were used to build the network. Solid lines: testis or sperm GSK3 interactions; 
Dashed lines: Databased retrieved GSK3 interactions. Node size: according to testis expression. Node colors: 
represent male infertility related phenotypes, biological processes (BP) 

  
 
 
 
 
 
 
 
 
 
 
C. General Discussion  
 

C1. Main conclusions and future perspectives 
C1. Main conclusions and future perspectives 
The signaling events that culminate in sperm motility acquisition and maintenance have been 
studied for decades [1]. Yet, many questions are still unanswered. The main goal of this thesis was 
to deepen the knowledge on the signaling events involved in human sperm motility by focusing on 
the characterization and modulation of the signaling pathway GSK3/PPP1R2/PPP1 in human sperm. 
Ultimately, the data generated by this work can be further applied to the development of a new 
group of reversible male contraceptives based sperm motility modulation. 
To achieve this goal, we first developed a molecular biology tool that is capable of specifically 
interfere with protein-protein interactions (PPIs) in mammalian sperm (Section B1.). Although this 
approach has been previously applied in another cell type [2], in mammalian sperm this work is one 
of the first reports [3] . We chose to target phosphoprotein phosphatase 1 catalytic subunit gamma 
2 (PPP1CC2) interactions in human sperm, since former work showed that the PPP1CC2 activity is 
associated with sperm motility control [4,5] and inhibition of PPP1 activity in sperm throughout the 
epididymis transit is partially responsible for highly motile sperm. Our previous work showed that 
PPP1 regulatory subunit 2 (PPP1R2), a PPP1 inhibitor, is involved in regulating PPP1CC2 activity in 
human sperm [6]. Therefore, blocking motility-related PPP1CC2 interactions, such as 
PPP1CC2/PPP1R2, will prevent motility acquisition. In order to disrupt PPP1CC2/PPP1R2 
interaction, we undertook a PPIs disruption peptide approach based on the PPP1CC2/PPP1R2 
interaction interface. With increased affinity towards PPP1CC/PPP1R2 interactions, the disruptive 
peptide competes and displaces PPP1RR2 from PPP1CC2, rendering active PPP1CC2 and 
consequently immotile mammalian sperm. To insure sperm intracellular delivery, the peptide was 
coupled with a cell penetrating peptide (CPP) originating a bioportide. We designed, synthetized 
and evaluated the effect of the disruptive PPP1CC2/PPP1R2 peptide on sperm motility. We 
successfully modulated PPP1CC2/PPP1R2 complex and restored PPP1CC2 activity, in vitro. When 
applied to mammalian sperm, the disruptive peptide was delivered to sperm cells and reduced 
sperm motility without affecting sperm viability. These results demonstrated that it is possible to 
target protein-protein interactions and modulate sperm complexes involved in motility using 
rationally-designed bioportides. We also demonstrated that the development of new type of male 
contraceptive based on inhibiting sperm motility is now achievable.  
The disruptive peptide approach reported in this work can be applied in other key processes for 
reproduction. Although sperm motility acquisition is an ideal target for male contraceptive since it 
is a post-spermatogenesis process and hormone independent, using protein-protein interactions 
C1. Main conclusions and future perspectives 
disruptive peptides to interfere with sperm acrosome reaction and/or sperm-oocyte interaction 
can also be explored to prevent oocyte fertilization. Inhibiting sperm motility can be useful not only 
as a reversible male contraceptive, but also as preservative technique in assisted reproductive 
techniques. Sperm motility maintenance requires a high-energy turnover. Consequently, sperm 
energy resources are consumed and high levels of reactive oxidative species are produced [7]. 
Blocking sperm motility, reversibly, can help preserve the quality of sperm samples prior to, for 
example sperm sample storage. 
Although the PPP1CC2/PPP1R2 interaction is involved in sperm motility acquisition, the fact that is 
not restricted to sperm, particularly due to a ubiquitous expression of PPP1R2, is an obstacle to 
achieve sperm-specific phenotypes. To overcome this problem, we aimed to identify testis/sperm-
specific interactors of glycogen synthase kinase 3 (GSK3), a modulator of PPP1R2/PPP1 interaction 
in human somatic and sperm cells and a key protein in sperm motility acquisition. In sperm, PPP1R2 
phosphorylation by GSK3 results in detachment of PPP1R2 from PPP1, rendering the latter active 
[8]. With the goal of unravel key GSK3 interactions for sperm motility, in section B2 we identified 
and characterized the GSK3 testis and sperm interactome. First, we showed that human sperm 
motility appears to be correlated specifically with GSK3 expression and activity. Then, we 
constructed a GSK3-centered motility network that revealed 26 direct interactors involved in 
sperm motility annotations, and from those one highly expressed in testis/sperm, the PRSS37 
(probable inactive serine protease 37). Besides being related with sperm motility, PRSS37 has been 
associated to a successful acrosome reaction [9]. Developing a male contraceptive by targeting 
GSK3/PRSS37 interaction would culminate in both sperm motility and acrosome reaction 
disruption. An in depth PRSS37 characterization in human sperm is necessary to confirm if 
GSK3/PRSS37 interaction is a viable pharmacological target. Given the reported relevance of GSK3 
PPIs in sperm motility, we hypothesized that interfering with such interactions may affect motility 
acquisition and represent a suitable target for male contraceptive strategy. A similar strategy is 
currently being pursued for PPP1CC2 sperm motility related interactions [10] In figure C1.1 is an 
overview of the aims, results accomplished in this work as well as future perspectives. 
   
 
 
 
C1. Main conclusions and future perspectives 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
We demonstrated that disruptive bioportides based on sperm protein-protein interactions can 
modulate sperm motility. Molecular modelling and dynamic studies will be used to determine the 
interaction interfaces between bioportides and their target in order to identify and refine 
Figure C1.1. Overview of the aims, results accomplished in this work and future perspectives. Orange circle: GSK3 
testis/sperm specific interactor; HP, homing peptide. 
C1. Main conclusions and future perspectives 
bioportides with higher stability, affinity, specificity, activity and uptake to human sperm. A multi 
interface targeting approach will be considered to achieve a more efficient result. The most 
promising bioportides will be further selected for synthesis and in vitro and in vivo studies in 
normospermic human sperm samples. Future efforts will focus on delivering bioportides exclusively 
to fully mature sperm cells using a specific tissue/cells targeting system. Please note that targeting 
fully mature sperm requires transposing the blood epididymal barrier. A homing peptides strategy 
can be used to exclusively deliver bioportides to the epididymal epithelium and sperm cells.  
The association between GSK3 activity and sperm motility has been described extensively [5]. Yet, 
we reported for the first time an isoform-specific association between GSK3 and sperm motility 
in human samples. A population profile concerning GSK3 activity in heterogeneous sperm samples 
will allow to further validate the correlation between GSK3 and human sperm motility and 
indisputably confirm GSK3 as suitable target for sperm motility modulation. Fully characterization 
of GSK3 isoforms in human sperm is required. Approaches such as inhibitory compounds and 
subcellular localization in morphological and motility distinct sperm samples must be undertaken. 
Although no testis/sperm-specific protein-protein complex involved exclusively in sperm motility 
was identified, the knowledge acquired in this work represents the starting point to identify 
potential male contraceptive targets. We believe that GSK3 motility function relies on unique 
interactors of this isoform in human sperm. Future work will center on identification of exclusively 
GSK3 interactors by a proteomic and in silico approach. Characterization of GSK3 and GSK3 
human sperm interactome in normospermic and asthenozoospermic samples will allow to pin-point 
GSK3 interactions key for sperm motility. Additionally, integrating the data in publicly available 
databases and literature concerning testis/sperm-specific and motility-related proteins will allow 
to construct a sperm motility protein-protein network and, consequently, identify interactions 
optimal for pharmacological intervention. 
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